

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 07:55:03 ; Search time 1615 Seconds
(without alignments)
436.427 Million cell updates/sec

Title: US-09-310-844c-24
Perfect score: 29
Sequence: 1 uaugaucuuuuuagagccuagggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 12152238056 residues

Total number of hits satisfying chosen parameters: 243536

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*

```

1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pin:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_pug:*
27: em_gss_vri:*
28: gb_gsa1:*
29: gb_gsa2:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	16.2	55.9	57	9	AI561770 vv65b08.x
C 2	15.4	53.1	66	29	AL463084 T. Brucei
C 3	15.2	52.4	41	14	CB210991 OML01271
4	15.2	52.4	44	9	AL892747 AL892747

5	15.2	52.4	63	29	BX533881
C 6	14.8	51.0	25	28	AZ93079
7	14.8	51.0	60	10	BE871815
C 8	14.8	51.0	64	29	EX003595
9	14.8	51.0	68	9	AL960604
10	14.8	51.0	69	12	EM128463
11	14.6	50.3	49	29	EX287070
12	14.6	50.3	52	10	BG236504
C 13	14.6	50.3	62	28	BH911891
C 14	14.6	50.3	64	9	AI139668
15	14.6	50.3	66	28	AZ808107
16	14.6	50.3	66	28	AZ440181
C 17	14.4	49.7	31	28	BH910631
C 18	14.4	49.7	43	28	AZ597048
19	14.4	49.7	44	29	AL771575
20	14.4	49.7	54	12	BI865449
21	14.4	49.7	60	9	AL595218
C 22	14.4	49.7	63	10	BG362434
C 23	14.4	49.7	67	9	AI584052
C 24	14.4	49.7	67	10	BE027305
25	14.4	49.7	67	29	BZ289657
C 26	14.4	49.7	69	10	BE647308
27	14.2	49.0	52	9	AM686481
C 28	14.2	49.0	59	28	B00509
29	14.2	49.0	61	9	AI318033
30	14.2	49.0	67	29	EX004510
31	14.2	49.0	70	13	BU063954
C 32	14	48.3	52	10	BF637245
C 33	14	48.3	65	12	BI094834
C 34	14	48.3	67	9	AN936041
35	14	48.3	67	28	BH855810
36	13.8	47.6	37	29	AL951243
37	13.8	47.6	39	28	BH909815
38	13.8	47.6	40	28	BH857340
39	13.8	47.6	40	28	BH857342
40	13.8	47.6	43	28	AZ484548
41	13.8	47.6	55	9	AT005996
C 42	13.8	47.6	55	9	AA276988
43	13.8	47.6	64	29	AL770628
C 44	13.8	47.6	65	29	AL763793
C 45	13.8	47.6	66	29	AL767936

ALIGNMENTS

RESULT 1
AI561770
LOCUS
DEFINITION
IMAGE:1227255 3', mRNA sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS

AI561770 57 bp mRNA linear EST 25-MAR-1999
vv65b08.x1 Stratagene mouse skin (#937313) Mus musculus CDNA clone
IMAGE:1227255 3', mRNA sequence.

AI561770.1 GI:4513115

EST.

Mus musculus (house mouse)

Mus musculus

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Musinae; Mus.

1 (bases 1 to 57)

Marra,M., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T.,

Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers,Y., Person

,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurk,R., Ritter

E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R.,

Waterston,R. and Wilson,R.

The WashU-NCI Mouse EST Project 1999

Unpublished

JOURNAL

COMMENT

Contact: Marra M/WashU-NCI Mouse EST Project 1999

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: mouseest@watson.wustl.edu

This clone is available royalty-free through LNL ; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.
 MGI:652847
 This clone was previously sequenced on the 5' end only, this new
 data is from the 3' end
 High quality sequence stop: 51.
 Location/Qualifiers

FEATURES

source
 1..57
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="C57BL/6"
 /db_xref="taxon:10090"
 /clone="IMAGE:1227255"
 /sex="females"
 /tissue_type="whole skin"
 /dev_stage="11 weeks old"
 /lab_host="SOLR (kanamycin resistant)"
 /clone_lib="Stratagene mouse skin (#937313)"
 /note="Organ: skin; Vector: pBluescript SK-; Site 1: EcoRI
 ; Site 2: XhoI; Cloned unidirectionally. Primer: Oligo
 dt. Whole skin from 11 week old C57BL/6 female mice.
 Average insert size: 1.0 kb; Uni-ZAP XR vector; -5'
 adaptor sequence: 5' GAATTCGCACGAG 3' -3' adaptor
 sequence: 5' CTCGAGTTTTTTTTTTTTTT 3'"
 17 a 9 c 12 g 19 t
 BASE COUNT
 ORIGIN

Query Match 55.9%; Score 16.2; DB 9; Length 57;
 Best Local Similarity 37.9%; Pred. No. 6.7e+04;
 Matches 11; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 1 UAUGAUUCUUUUGUAGCCCUAGGGCGU 29
 Db 25 TTGAATCCTTTTCTATCCATGGGGGT 53

RESULT 2

TA123H02P/c
 LOCUS TA123H02P 66 bp DNA linear GSS 13-DEC-2000
 DEFINITION T. brucei sheared genomic DNA clone 123h02, forward sequence,
 genomic survey sequence.
 ACCESSION AL463084
 VERSION AL463084.1 GI:11833690
 KEYWORDS GSS.
 SOURCE Trypanosoma brucei
 ORGANISM Trypanosoma brucei
 Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
 Trypanosoma.
 1 (bases 1 to 66)
 REFERENCE Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
 Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
 Melville,S.E., Rajandream,M.A. and Barrell,B.G.
 TITLE Direct Submission
 JOURNAL Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
 project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
 Cambridge CB10 1SA, E-mail: barrel@sanger.ac.uk and
 nh@sanger.ac.uk
 COMMENT Constructed at the Institute for Genomic Research (TIGR),
 Rockville, MD. Genomic DNA isolated from a cloned population of
 Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
 to give a tight size distribution (
 4 kb). The v + i method used for the library construction is
 described in detail in Smith, H. and Venter, J.C. (Making small
 insert libraries for whole genome shotgun sequencing projects. In
 Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
 Barrell, Oxford University Press, 1999).
 Email: nelsaved@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available
 at http://www.sanger.ac.uk/Projects/T_brucei/.
 Location/Qualifiers

FEATURES

source
 1..66
 /organism="Trypanosoma brucei"
 /mol_type="genomic DNA"
 /strain="TREU927"

/db_xref="taxon:5691"
 /clone="123h02"
 29 a 8 c 9 g 20 t
 BASE COUNT
 ORIGIN

Query Match 53.1%; Score 15.4; DB 29; Length 66;
 Best Local Similarity 36.0%; Pred. No. 1.3e+05;
 Matches 9; Conservative 10; Mismatches -6; Indels 0; Gaps 0;

QY 1 UAUGAUUCUUUUGUAGCCCUAGG 25
 Db 30 TATGATTTTTCAGAACCCCTAG 6

RESULT 3

CB210991/c
 LOCUS CB210991 41 bp mRNA linear EST 05-FEB-2003
 DEFINITION OML01271 Oryza minuta HybridZAP-2.1 XR library Oryza minuta cDNA 5',
 mRNA sequence.
 ACCESSION CB210991
 VERSION CB210991.1 GI:28257082
 KEYWORDS EST.
 SOURCE Oryza minuta
 ORGANISM Oryza minuta
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzeae; Oryza.
 1 (bases 1 to 41)
 REFERENCE Shin,J.S.
 AUTHORS Oryza minuta HybridZAP-2.1 XR library
 JOURNAL Unpublished
 COMMENT Contact: Jeong Sheop Shin
 Plant Molecular Genetics
 Graduate School of Biotechnology, University of Korea
 136-701 Anam-dong 5/I Seoul, Korea
 Tel: 00 82 2 3290 3430
 Fax: 00 82 2 927 9028
 Email: jsshin@kucn.korea.ac.kr.
 Location/Qualifiers

FEATURES

source
 1..41
 /organism="Oryza minuta"
 /mol_type="mRNA"
 /db_xref="taxon:63629"
 /dev_stage="4-weeks after germination"
 /clone_lib="Oryza minuta HybridZAP-2.1 XR library"
 /note="Organ: immature leaf"
 18 a 10 c 11 g 2 t
 BASE COUNT
 ORIGIN

Query Match 52.4%; Score 15.2; DB 14; Length 41;
 Best Local Similarity 39.3%; Pred. No. 1.6e+05;
 Matches 11; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

QY 1 UAUGAUUCUUUUGUAGCCCUAGGGC 28
 Db 28 TATGCTTCTGTGCTTAGCCCTGTGCC 1

RESULT 4

AL892747
 LOCUS AL892747 XGC-egg Silurana tropicalis cDNA clone TEG904m06 5', mRNA
 DEFINITION AL892747 XGC-egg Silurana tropicalis cDNA clone TEG904m06 5', mRNA
 sequence.
 ACCESSION AL892747
 VERSION AL892747.1 GI:22943298
 KEYWORDS EST.
 SOURCE Silurana tropicalis (western clawed frog)
 ORGANISM Silurana tropicalis
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;
 Xenopodinae; Silurana.
 1 (bases 1 to 44)
 REFERENCE Taylor,R., Ashurst,J.L., Croning,M.D.R., Zorn,A.M. and Rogers,J.
 AUTHORS

insertions. The DNA fragment(s) resulting from the PCR were directly sequenced to determine the genomic sequence flanking the insertion. Sequences displaying significant similarity to the *A. thaliana* nuclear genome sequence were processed for submission. T-DNA derived sequences were removed.

BASE COUNT	18 a	15 c	12 g	18 f
ORIGIN				

2 AUGAUCUUUUUGUAAGCCCUAGGGCU 29
| : | : : : | : | : | : | :
21 AATAATATTTTTTCAAAACCTATGGAT 48

RESULT 6

clone UUGC2M0277P20 R, genomic survey sequence.

KEYWORDS GSS, GSS,

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS
Dunn, D., Aoyagi, A., Barber, M., Beacorn, I., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly

M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.

and Wright, D., Weiss, R.
Measure whole genome conformation with paired end reads from 10kb

TITLE Mouse whole genome scaffolding with paired end reads from long plasmid inserts

COMMENT	Contact: Robert B. Weiss	University of Utah	Comments

University of Utah Genome Center
University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA
W23 001 505 5606

Email: adam@engr.cba
Insert Length: 1000 Std Error: 0.00

Plate: 0277 row: P column: 20

Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends

Class: plasma class
High quality sequence stop: 25.

FEATURES	Location/Qualifiers
1. <i>the</i>	the
2. <i>the</i>	the
3. <i>the</i>	the
4. <i>the</i>	the
5. <i>the</i>	the
6. <i>the</i>	the
7. <i>the</i>	the
8. <i>the</i>	the
9. <i>the</i>	the
10. <i>the</i>	the
11. <i>the</i>	the
12. <i>the</i>	the
13. <i>the</i>	the
14. <i>the</i>	the
15. <i>the</i>	the
16. <i>the</i>	the
17. <i>the</i>	the
18. <i>the</i>	the
19. <i>the</i>	the
20. <i>the</i>	the
21. <i>the</i>	the
22. <i>the</i>	the
23. <i>the</i>	the
24. <i>the</i>	the
25. <i>the</i>	the
26. <i>the</i>	the
27. <i>the</i>	the
28. <i>the</i>	the
29. <i>the</i>	the
30. <i>the</i>	the
31. <i>the</i>	the
32. <i>the</i>	the
33. <i>the</i>	the
34. <i>the</i>	the
35. <i>the</i>	the
36. <i>the</i>	the
37. <i>the</i>	the
38. <i>the</i>	the
39. <i>the</i>	the
40. <i>the</i>	the
41. <i>the</i>	the
42. <i>the</i>	the
43. <i>the</i>	the
44. <i>the</i>	the
45. <i>the</i>	the
46. <i>the</i>	the
47. <i>the</i>	the
48. <i>the</i>	the
49. <i>the</i>	the
50. <i>the</i>	the
51. <i>the</i>	the
52. <i>the</i>	the
53. <i>the</i>	the
54. <i>the</i>	the
55. <i>the</i>	the
56. <i>the</i>	the
57. <i>the</i>	the
58. <i>the</i>	the
59. <i>the</i>	the
60. <i>the</i>	the
61. <i>the</i>	the
62. <i>the</i>	the
63. <i>the</i>	the
64. <i>the</i>	the
65. <i>the</i>	the
66. <i>the</i>	the
67. <i>the</i>	the
68. <i>the</i>	the
69. <i>the</i>	the
70. <i>the</i>	the
71. <i>the</i>	the
72. <i>the</i>	the
73. <i>the</i>	the
74. <i>the</i>	the
75. <i>the</i>	the
76. <i>the</i>	the
77. <i>the</i>	the
78. <i>the</i>	the
79. <i>the</i>	the
80. <i>the</i>	the
81. <i>the</i>	the
82. <i>the</i>	the
83. <i>the</i>	the
84. <i>the</i>	the
85. <i>the</i>	the
86. <i>the</i>	the
87. <i>the</i>	the
88. <i>the</i>	the
89. <i>the</i>	the
90. <i>the</i>	the
91. <i>the</i>	the
92. <i>the</i>	the
93. <i>the</i>	the
94. <i>the</i>	the
95. <i>the</i>	the
96. <i>the</i>	the
97. <i>the</i>	the
98. <i>the</i>	the
99. <i>the</i>	the
100. <i>the</i>	the

```
/organism="Mus musculus"
/mol type="genomic DNA"
```

```
/strain="C57BL/6J"
```

```
/db_xref="taxon:10090"
/cj_cpe="ITIGCM0277P20"
```

```

/sex="Female"

```

```
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
```

```

/clone_lib="Mouse 10Kb plasmid UUC2M library"
/notes="Vector: pWD42ny: Purified genomic DNA from M."

```

[illegible]

musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (g14732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 4 a 8 c 6 g 7 t

ORIGIN

Query Match 51.0%; Score 14.8; DB 28; Length 25;
Best Local Similarity 72.2%; Pred. No. 2.3e+05;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 11 UUUGAAGCCCUAGGGC 28

Db 21 TTTCGAAGCCCAAGGGC 4

RESULT 7
B8871815
LOCUS 60147803F1 NIH_MGC_65 Homo sapiens cDNA clone IMAGE:3851880 5',
DEFINITION mRNA sequence.
ACCESSION B8871815
VERSION B8871815.1 GI:10320591
KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

TITLE NIH-MGC http://mgc.nci.nih.gov/

JOURNAL National Institutes of Health, Mammalian Gene Collection (MGC)

COMMENT Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cgabbs-remail.nih.gov

Tissue Procurement: ATCC

CDNA Library Preparation: Life Technologies, Inc.

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

<http://image.llnl.gov>

Plate: L14M573 row: e column: 01

High quality sequence stop: 60.

Location/Qualifiers

1..60

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:3851880"

/tissue_type="adenocarcinoma"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH_MGC_65"

/note="Organ: colon; Vector: pCMV-SPORT6; Site:1: NotI;

Site:2: SalI; Cloned unidirectionally. Primer: Oligo dr.

Average insert size 1.8 kb. Library constructed by Life

Technologies."

BASE COUNT 16 a 11 c 10 g 23 t

ORIGIN

Query Match 51.0%; Score 14.8; DB 10; Length 60;
Best Local Similarity 38.9%; Pred. No. 2.2e+05;
Matches 7; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 2 AUGAUUUUUUUUAAGC 19

Db 10 ATGATTATTTTCTAAGC 27

RESULT 8

BX003595/c

LOCUS

DEFINITION

genomic survey sequence.

ACCESSION BX003595

VERSION BX003595.1 GI:26188555

KEYWORDS GSS:

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana

REFERENCE Arabidopsis thaliana

AUTHORS Arabidopsis thaliana

TITLE Arabidopsis thaliana

JOURNAL Arabidopsis thaliana


```

RESULT 9
AL960604
LOCUS
DEFINITION
AL960604 XGC-gastrula Silurana tropicalis cDNA clone TGas120b03 5',
mRNA sequence.
ACCESSION
AL960604
VERSION
AL960604.1 GI:25784199
SOURCE
EST.
Silurana tropicalis (western clawed frog)
Silurana tropicalis
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
Xenopodinae; Silurana.
1 (bases 1 to 68)
Taylor,R., Ashurst,J.L., Croning,M.D.R., Zorn,A.M. and Rogers,J.
Sanger Xenopus tropicalis EST project 2002
Unpublished
Contact: Taylor R
Sanger Centre
Hinxton, Cambridgeshire, CB10 1SA, UK
Email: trop@sanger.ac.uk
TROPICALIS_SEQUENCE_ID: TGas120b03.pikSP6
Sequencing primer: SP6
This sequence is from a Xenopus Gene Collection (XGC) library
constructed by Aaron M. Zorn.
FEATURES
    source
        1..68
            /organism="Silurana tropicalis"
            /mol_type="mRNA"
            /db_xref="taxon:8364"
            /clone="TGas120b03"
            /rev_stage="gastrula (stages 10.5-13 mixed)"
            /lab_host="Escherichia coli XL1-blue"
            /notes="Vector: pCSI107; Site 1: EcoRI; Site 2: NotI; cDNA
            was oligo dT primed from Sug of poly A+ RNA from stages
            10-13 gastrulae. EcoRI-NotI cut cDNA was then ligated
            into pCSI107 with EcoRI at the 5' end and NotI at the 3'
            end."
BASE COUNT      8 a   25 c   16 g   19 t
ORIGIN
    Query Match      51.0%; Score 14.8; DB 9; Length 68;
    Best Local Similarity 34.8%; Pred. No. 2.2e+05;
    Matches 9; Conservative 10; Mismatches 7; Indels 0; Gaps 0;
QY      4 GAUUCUUUUUUAAGCCUAGGGGCU 29
|      ::::: |||::|
Db      11 GGTGTTTTTTTAAACCCCTGGGCT 36

RESULT 10
BM128463
LOCUS
DEFINITION
BM128463 Melton Normalized Human Islet 4 N4-HIS 1 Homo sapiens
cDNA clone IMAGE:5676297 3', mRNA sequence.
ACCESSION
BM128463
VERSION
BM128463.1 GI:17123015
KEYWORDS
EST.
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 69)
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
Lenisika,I., Scarce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
Hillier,L., Marra,M., Paps,D., Wyllie,T., Martin,J., Blistain,A.,
Schmitt,A., Theising,B., Ritter,B., Ronko,I., Bennett,J., Cardenas
M., Gibbons,M., McCann,R., Cole,R., Tsagarishvili,R., Williams,T.,
Jackson,Y. and Bowers,Y.
REFERENCE
    AUTHORS
        Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
        Lenisika,I., Scarce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
        Hillier,L., Marra,M., Paps,D., Wyllie,T., Martin,J., Blistain,A.,
        Schmitt,A., Theising,B., Ritter,B., Ronko,I., Bennett,J., Cardenas
        M., Gibbons,M., McCann,R., Cole,R., Tsagarishvili,R., Williams,T.,
        Jackson,Y. and Bowers,Y.

```

```

TITLE
JOURNAL
COMMENT
Endocrine Pancreas Consortium
Unpublished
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8857
Email: dmelton@biohp.harvard.edu
Library was constructed by Dr. Douglas Melton DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Juliana Brown
(brown@fas.harvard.edu) This sequence now available from the IMAGE
consortium, for clone orders contact: info@image.llnl.gov.
FEATURES
    Location/Qualifiers
        1..69
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /clone="IMAGE:5676297"
            /sex="Both"
            /tissue_type="Islets of Langerhans"
            /dev_stage="Adult"
            /lab_host="DH10B"
            /clone_lib="Melton Normalized Human Islet 4 N4-HIS 1"
            /note="Organ: Pancreas; Vector: pSPOR1; Site1: Not 1;
            Site 2: Sal 1; Starting library constructed using
            SuperScript Plasmid Library kit (Life Technologies). cDNA
            made by oligo-dT priming. Size-selected by column
            fractionation; average insert size 1.08 kb. Library was
            amplified once on solid support and plasmid DNA from
            library was prepared. The library DNA was normalized by
            method #4 from Bonaldo, Lennon, and Soares 1996 genome
            Research 6:791-806; 0.5 microgram single-stranded library
            plasmid DNA was mixed with 5 micrograms PCR product
            representing library inserts and hybridized to an EcoI of
            20. Single-stranded (unhybridized) plasmids were isolated
            by hydroxyapatite chromatography and used to make this
            library."
BASE COUNT      8 a   10 c   19 g   32 t
ORIGIN
    Query Match      51.0%; Score 14.8; DB 12; Length 69;
    Best Local Similarity 30.8%; Pred. No. 2.2e+05;
    Matches 8; Conservative 11; Mismatches 7; Indels 0; Gaps 0;
QY      1 UAUGAUUCUUUUUUAAGCCUAGGG 26
|      ::::: |||::|
Db      8 TTTTITTTTTTTCTGGGCGCTAGGG 33

RESULT 11
BM287070
LOCUS
DEFINITION
BM287070 Arabidopsis thaliana T-DNA flanking sequence GK-396f11-018295,
genomic survey sequence.
ACCESSION
BM287070
VERSION
BM287070.1 GI:28886066
KEYWORDS
GSS.
Arabidopsis thaliana (thale cress)
ORGANISM
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
Strizhov,N., Li,Y., Rosso,M., Viehoever,P., Dekker,K., Siedler,H.
and Weissenhaar,B.
A pipeline for automated high-throughput generation of FRTs
(flanking sequence tags) from Arabidopsis thaliana T-DNA
transformed lines
Unpublished
REFERENCE
    JOURNAL
        Unpublished

```


Search completed: January 30, 2004, 10:12:36
Job time : 1623 secs

Search completed: January 30, 2004, 10:12:36
Job time : 1623 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 06:57:47 ; Search time 575.333 Seconds
(without alignments)
2062.073 Million cell updates/sec

Title: US-09-310-844c-25

Perfect score: 29
Sequence: 1 aaagaucuuuuuugaagccccaaggccu 29

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 20454813366 residues

Total number of hits satisfying chosen parameters: 1427288

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl :

- 1: gb.ba.*
- 2: gb.btg.*
- 3: gb.in.*
- 4: gb.ov.*
- 5: gb.pat.*
- 6: gb.ph.*
- 7: gb.pl.*
- 8: gb.pr.*
- 9: gb.ro.*
- 10: gb.sts.*
- 11: gb.sy.*
- 12: gb.un.*
- 13: gb.vi.*
- 14: gb.fun.*
- 15: em.fun.*
- 16: em.in.*
- 17: em.in.*
- 18: em.mu.*
- 19: em.mu.*
- 20: em.or.*
- 21: em.or.*
- 22: em.ov.*
- 23: em.pat.*
- 24: em.ph.*
- 25: em.pl.*
- 26: em.ro.*
- 27: em.sts.*
- 28: em.un.*
- 29: em.vi.*
- 30: em.htg.hum.*
- 31: em.htg.inv.*
- 32: em.htg.other.*
- 33: em.htg.mus.*
- 34: em.htg.pln.*
- 35: em.htg.rod.*
- 36: em.htg.mam.*
- 37: em.htg.vrt.*
- 38: em.sy.*
- 39: em.htgo.hum.*
- 40: em.htgo.mus.*
- 41: em.htgo.other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	18.4	63.4	43	8	ATH553793 Arabidops
C 2	16.4	56.6	31	6	AX425989 Sequence
C 3	16.2	55.9	48	6	AX018731 Sequence
C 4	15.2	52.4	33	6	AR020509 Sequence
C 5	15.2	52.4	47	6	AR289362 Sequence
C 6	15	51.7	23	6	E09974 Primer for
C 7	15	51.7	23	6	E0118 PCR primer
C 8	15	51.7	33	6	BD094291 A prepara
C 9	15	51.7	33	6	BD179370 A novel p
C 10	15	51.7	41	6	AX514720 Sequence
C 11	15	51.7	41	6	AX520728 Sequence
C 12	14.8	51.0	29	6	AR019319 Sequence
C 13	14.8	51.0	29	6	AR061847 Sequence
C 14	14.8	51.0	29	6	AR147578 Sequence
C 15	14.8	51.0	29	6	AR252838 Sequence
C 16	14.8	51.0	29	6	AR252838 Sequence
C 17	14.8	51.0	29	6	I34733 Sequence 25
C 18	14.8	51.0	29	6	I67987 Sequence 25
C 19	14.8	51.0	32	6	AR061867 Sequence
C 20	14.6	50.3	32	6	AR252858 Sequence
C 21	14.6	50.3	25	6	AR206010 Sequence
C 22	14.6	50.3	53	6	AX043294 Sequence
C 23	14.4	49.7	25	6	AR061021 Sequence
C 24	14.4	49.7	31	6	AX043671 Sequence
C 25	14.4	49.7	31	6	AX425978 Sequence
C 26	14.4	49.7	51	6	AX117185 Sequence
C 27	14.4	49.7	59	11	AL772710 Arabidops
C 28	14.2	49.0	31	11	AL773099 Arabidops
C 29	14.2	49.0	44	6	AX582577 Sequence
C 30	14.2	49.0	47	6	AX601758 Sequence
C 31	14.2	49.0	65	6	AR288361 Sequence
C 32	14.2	49.0	69	6	AX483200 Sequence
C 33	14.2	49.0	69	6	AR052906 Sequence
C 34	14.2	49.0	69	6	AR054269 Sequence
C 35	14.2	49.0	69	8	AR054471 Sequence
C 36	14	48.3	25	6	ATH527686 Arabidops
C 37	14	48.3	29	11	AX043055 Sequence
C 38	14	48.3	29	11	AL806194 Arabidops
C 39	14	48.3	29	11	AL824524 Arabidops
C 40	14	48.3	33	11	AL824524 Arabidops
C 41	14	48.3	34	11	AL806370 Arabidops
C 42	14	48.3	35	11	AL824530 Arabidops
C 43	14	48.3	35	11	AL806140 Arabidops
C 44	14	48.3	40	11	AL806354 Arabidops
C 45	14	48.3	40	11	AL824626 Arabidops
			41	6	AL824634 Arabidops
			41	6	AR253879 Sequence

ALIGNMENTS

RESULT 1	ATH553793	Arabidopsis thaliana	43 bp	DNA	linear	PLN 29-MAR-2003
LOCUS	Arabidopsis thaliana	T-DNA flanking sequence, left border, clone				
DEFINITION	383B09.					
ACCESSION	AJ553793					
VERSION	AJ553793.1	GI:29370260				
KEYWORDS	left border; T-DNA flanking sequence.					
SOURCE	Arabidopsis thaliana (thale cress)					
ORGANISM	Arabidopsis thaliana					
REFERENCE	1	Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.				
AUTHORS	1	Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,				

Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
MEDLINE
PUBMED
12446565
2 (bases 1 to 43)
Balzergue, S.
Direct Submission
Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment (9) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
source
1..43
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassilewskija"
/db_xref="taxon:3702"
/clone="383B09"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..43
/note="T-DNA flanking sequence
left border"
BASE COUNT 15 a 7 c 4 g 17 t
ORIGIN
Query Match 63.4%; Score 18.4; DB 8; Length 43;
Best Local Similarity 50.0%; Pred. No. 1e+03;
Matches 14; Conservative 8; Mismatches 6; Indels 0; Gaps 0;

QY 1 AAGAUUUUUUUAAGCCCAAGGCG 28
||| : : : : : |||
Db 2 AAAATCTTTTGTAGCATCAATGC 29
||| : : : : : |||

RESULT 2
AX425989/c 31 bp DNA linear PAT 18-JUN-2002
LOCUS
DEFINITION Sequence 4325 from Patent WO0188124.
ACCESSION AX425989
VERSION AX425989.1 GI:21529375
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and Randi, A.M.
TITLE Method and reagent for the inhibition of erg
PATENT: WO 0188124-A 4325 22-NOV-2001;
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1..31
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Enzymatic Nucleic Acid"
BASE COUNT 6 a 10 c 8 g 7 t
ORIGIN
Query Match 56.6%; Score 16.4; DB 6; Length 31;
Best Local Similarity 61.5%; Pred. No. 9.4e+03;

Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
MEDLINE
PUBMED
12446565
2 (bases 1 to 43)
Balzergue, S.
Direct Submission
Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment (9) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
source
1..43
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassilewskija"
/db_xref="taxon:3702"
/clone="383B09"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..43
/note="T-DNA flanking sequence
left border"
BASE COUNT 15 a 7 c 4 g 17 t
ORIGIN
Query Match 63.4%; Score 18.4; DB 8; Length 43;
Best Local Similarity 50.0%; Pred. No. 1e+03;
Matches 14; Conservative 8; Mismatches 6; Indels 0; Gaps 0;

QY 1 AAGAUUUUUUUAAGCCCAAGGCG 28
||| : : : : : |||
Db 2 AAAATCTTTTGTAGCATCAATGC 29
||| : : : : : |||

RESULT 2
AX425989/c 31 bp DNA linear PAT 18-JUN-2002
LOCUS
DEFINITION Sequence 4325 from Patent WO0188124.
ACCESSION AX425989
VERSION AX425989.1 GI:21529375
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and Randi, A.M.
TITLE Method and reagent for the inhibition of erg
PATENT: WO 0188124-A 4325 22-NOV-2001;
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1..31
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Enzymatic Nucleic Acid"
BASE COUNT 6 a 10 c 8 g 7 t
ORIGIN
Query Match 56.6%; Score 16.4; DB 6; Length 31;
Best Local Similarity 61.5%; Pred. No. 9.4e+03;

Matches 16; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 3 AGAUUUUUUUAAGCCCAAGGCG 28
||| : : : : : |||
Db 26 AGATCGTTGTAGCTAGCCCAAGGCG 1
||| : : : : : |||

RESULT 3
AX018731/c 48 bp DNA linear PAT 07-SEP-2000
LOCUS
DEFINITION Sequence 20 from Patent WO9944633.
ACCESSION AX018731
VERSION AX018731.1 GI:10042853
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Minke, J.M. and Audonnet, J.C.
TITLE Live recombined vaccines injected with adjuvant
PATENT: WO 9944633-A 20 10-SEP-1999;
JOURNAL MINKE JULES MAARTEN (FR); MERIAL SAS (FR); AUDONNET JEAN CHRISTOPHE FRANC (FR)
FEATURES
Location/Qualifiers
source
1..48
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="oligonucleotide"
BASE COUNT 17 a 9 c 9 g 13 t
ORIGIN
Query Match 55.9%; Score 16.2; DB 6; Length 48;
Best Local Similarity 44.8%; Pred. No. 1.2e+04;
Matches 13; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 1 AAGAUUUUUUUAAGCCCAAGGCG 29
||| : : : : : |||
Db 37 AAATCTTAATTTTGTAGCTTCCCGGCT 9
||| : : : : : |||

RESULT 4
AR020509/c 33 bp DNA linear PAT 05-DEC-1998
LOCUS
DEFINITION Sequence 5 from patent US 5789171.
ACCESSION AR020509
VERSION AR020509.1 GI:3975124
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 33)
AUTHORS Smeltzer, M.S.
TITLE Use of cna, fnba, fnbb, and hlb, gene probes for the strain-specific identification of Staphylococcus aureus
JOURNAL Patent: US 5789171-A 5 04-AUG-1998;
FEATURES
Location/Qualifiers
source
1..33
/organism="unknown"
BASE COUNT 12 a 8 c 7 g 6 t
ORIGIN
Query Match 52.4%; Score 15.2; DB 6; Length 33;
Best Local Similarity 42.9%; Pred. No. 3.5e+04;
Matches 12; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 AAGAUUUUUUUAAGCCCAAGGCG 29
||| : : : : : |||
Db 32 ATGATTGTTTGTAGTAATTTCCCGGCT 5
||| : : : : : |||

RESULT 5
AR289362

```

LOCUS       AR289362               47 bp    DNA             linear     PAT 12-JUN-2003
DEFINITION   Sequence 1097 from patent US 6537751.
ACCESSION    AR289362
VERSION      AR289362.1   GI:31676646
KEYWORDS     Unknown.
SOURCE       Unclassified.
ORGANISM     1 (bases 1 to 47)
REFERENCE    Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE        Biallelic markers for use in constructing a high density
JOURNAL      dis-equilibrium map of the human genome
FEATURES     Patent: US 6537751-A 1097 25-MAR-2003;
              Location/Qualifiers
              1..47
              /organism="unknown"
BASE COUNT   13 a      9 c      10 g      14 t      1 others
ORIGIN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Query Match      52.4%; Score 15.2; DB 6; Length 47;
Best Local Similarity 50.0%; Pred. No. 3.5e+04;
Matches 11; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY      3 AGAUCUUUUUUAAGCCCAAA 24
      |||:|:|:|:|:|:|:|:|:|
Db      15 AGACTCTTTTGTAACTCCCA 36

RESULT 6
E09974
LOCUS       E09974               23 bp    DNA             linear     PAT 29-SEP-1997
DEFINITION   Primer for amplifying human herpes virus.
ACCESSION    E09974
VERSION      E09974.1   GI:22026598
KEYWORDS     JP 1995250699-A/20.
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 23)
AUTHORS      Yamanishi,K., Mukai,T., Aono,T., Kondo,M. and Takarada,Y.
TITLE        METHOD FOR DISCRIMINATORY DETECTION OF HUMAN HERPES VIRUS AND
JOURNAL      REAGENT THEREFOR
PATENT       Patent: JP 1995250699-A 20 03-OCT-1995;
              TOYOBO CO LTD
COMMENT      OS None
              OC Artificial sequences.
              PN JP 1995250699-A/20
              PD 03-OCT-1995
              PF 11-MAR-1994 JP 1994041101
              PI YAMANISHI KOICHI, MUKAI TORU, AONO TOSHIYA, KONDO MOTOHIRO, PI
              TAKARADA YUTAKA
              PC C12Q1/68,C12N15/09,C12Q1/70;
              CC strandedness: Single;
              CC topology: Linear;
              CC hypothetical: No;
              FH Key
              FT Location/Qualifiers
              1..23
              /organism='Artificial sequences'
              /note='Common sequences for human herpes virus
              6-type A,
              human herpes virus 6-type B,human herpes FT
              virus-7 and
              cytomegalovirus'.
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"
              5 a      5 c      6 g      7 t

BASE COUNT   5 a      5 c      6 g      7 t
ORIGIN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

```

```

Query Match      51.7%; Score 15; DB 6; Length 23;
Best Local Similarity 52.2%; Pred. No. 4.4e+04;
Matches 12; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

QY      4 GAUCUUUUUUAAGCCCAAGG 26
      |||:|:|:|:|:|:|:|:|:|
Db      1 GATCCTTTTGGAGTGCCCAAGG 23

RESULT 7
E10118
LOCUS       E10118               23 bp    DNA             linear     PAT 29-SEP-1997
DEFINITION   PCR primer to detect human herpes virus-6A,6B and 7.
ACCESSION    E10118
VERSION      E10118.1   GI:22026746
KEYWORDS     JP 1995284391-A/6.
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 23)
AUTHORS      Yamanishi,K., Mukai,T., Aono,T., Kondo,M. and Takarada,Y.
TITLE        CLONONUCLEOTIDE FOR DETECTING HUMAN HERPES VIRUS AND ITS USE
JOURNAL      Patent: JP 1995284391-A 6 31-OCT-1995;
              TOYOBO CO LTD
COMMENT      OS None
              OC Artificial sequences.
              PN JP 1995284391-A/6
              PD 31-OCT-1995
              PF 19-APR-1994 JP 1994080488
              PI YAMANISHI KOICHI, MUKAI TORU, AONO TOSHIYA, KONDO MOTOHIRO, PI
              TAKARADA YUTAKA
              PC C12N15/09,C07H21/04,C12Q1/68,G01N33/567,G01N33/569; CC
              strandedness: Single;
              CC topology: Linear;
              FH Key
              FT Location/Qualifiers
              1..23
              /organism='Artificial sequences'
              /note='unidentified'
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"
              5 a      5 c      6 g      7 t

BASE COUNT   5 a      5 c      6 g      7 t
ORIGIN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Query Match      51.7%; Score 15; DB 6; Length 23;
Best Local Similarity 52.2%; Pred. No. 4.4e+04;
Matches 12; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

QY      4 GAUCUUUUUUAAGCCCAAGG 26
      |||:|:~|:~|:~|:~|:~|
Db      1 GATCCTTTTGGAGTGCCCAAGG 23

RESULT 8
E094291/c
LOCUS       E094291/c           33 bp    DNA             linear     PAT 27-AUG-2002
DEFINITION   A preparation method of adenomedullin precursor.
ACCESSION    E094291
VERSION      E094291.1   GI:22639879
KEYWORDS     WO 0127310-A/41.
SOURCE       synthetic construct
ORGANISM     artificial sequences.
REFERENCE    1 (bases 1 to 33)
AUTHORS      Takimoto,A., Mitsuda,Y., Nakayama,T. and Mitsuhashi,K.
TITLE        A preparation method of adenomedullin precursor
JOURNAL      Patent: WO 0127310-A 41 19-APR-2001;
              SHIONOGI & CO LTD,AKIO TAKIMOTO,YUICHI MITSUDA,TOSHIMASA NAKAYAMA,
              KENJI MITSUSHIMA
              OS Artificial Sequence
              PN WO 0127310-A/41

```

LOCUS	AX514720	41 bp	DNA	linear	PAT 05-OCT-2002
DEFINITION	Sequence 918 from Patent WO02052044.				
ACCESSION	AX514720				
VERSION	AX514720.1	GI:23561343			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
AUTHORS	1 Nakamura,Y., Sekine,A., Iida,A. and Saito,S.				
TITLE	Detection of genetic polymorphisms				
JOURNAL	Patent: WO 02052044-A 918 04-JUL-2002;				
FEATURES	Riken (JP)				
source	Location/Qualifiers				
	1..41				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
BASE COUNT	12 a _ 10 c 10 g	8 t	1	others	
ORIGIN					
Query Match	51.7%;	Score 15;	DB 6;	Length 41;	
Best Local Similarity	52.0%;	Pred. NO. 4.3e+04;			
Matches	13;	Conservative	6;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY	4 GAUUCUUUUUGUAAGCCCAAGGCC 28				
Db	41 GATTCATTGCGAGCCCTCGGGAC 17				
	: : : :				
	: : : :				
RESULT 11					
AX520728/c					
LOCUS	AX520728	41 bp	DNA	linear	PAT 05-OCT-2002
DEFINITION	Sequence 6926 from Patent WO02052044.				
ACCESSION	AX520728				
VERSION	AX520728.1	GI:23571381			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
AUTHORS	1 Nakamura,Y., Sekine,A., Iida,A. and Saito,S.				
TITLE	Detection of genetic polymorphisms				
JOURNAL	Patent: WO 02052044-A 6926 04-JUL-2002;				
FEATURES	Riken (JP)				
source	Location/Qualifiers				
	1..41				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
BASE COUNT	12 a _ 10 c 10 g	8 t	1	others	
ORIGIN					
Query Match	51.7%;	Score 15;	DB 6;	Length 41;	
Best Local Similarity	52.0%;	Pred. NO. 4.3e+04;			
Matches	13;	Conservative	6;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY	4 GAUUCUUUUUGUAAGCCCAAGGCC 28				
Db	41 GATTCATTGCGAGCCCTCGGGAC 17				
	: : : :				
	: : : :				
RESULT 12					
AR019319/c					
LOCUS	AR019319	29 bp	DNA	linear	PAT 05-DEC-1998
DEFINITION	Sequence 25 from patent US 5783406.				
ACCESSION	AR019319				
VERSION	AR019319.1	GI:3974433			
KEYWORDS					
ORGANISM	Unknown.				
	SOURCE				
	Unknown.				


```
Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W. and Puers,C.
TITLE Allelic ladders for short tandem repeat loci
JOURNAL Patent: US 5783406-A 25 21-JUL-1998;
FEATURES
    source
    Location/Qualifiers
        1..29
            /organism="unknown"
BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match
Best Local Similarity 51.0%; Score 14.8; DB 6; Length 29;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUGUAGGCCCAAGGCGU 29
Db 29 GATTATTCCTATCATCCACTAGGGCT 4

RESULT 13
AR061847/c
LOCUS AR061847 29 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 39 from patent US 5843660.
ACCESSION AR061847
VERSION AR061847.1 GI:5989538
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W., Micka,K.A. and Rabbach,D.R.
TITLE Multiplex amplification of short tandem repeat loci
JOURNAL Patent: US 5843660-A 39 01-DEC-1998;
FEATURES
    source
    Location/Qualifiers
        1..29
            /organism="unknown"
BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match
Best Local Similarity 51.0%; Score 14.8; DB 6; Length 29;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUGUAGGCCCAAGGCGU 29
Db 29 GATTATTCCTATCATCCACTAGGGCT 4

RESULT 14
AR147578/c
LOCUS AR147578 29 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 31 from patent US 6221598.
ACCESSION AR147578
VERSION AR147578.1 GI:15111381
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W., Sprecher,C.J. and Lins,A.M.
TITLE Multiplex amplification of short tandem repeat loci
JOURNAL Patent: US 6221598-A 31 24-APR-2001;
FEATURES
    source
    Location/Qualifiers
        1..29
            /organism="unknown"
BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match
Best Local Similarity 51.0%; Score 14.8; DB 6; Length 29;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUGUAGGCCCAAGGCGU 29
Db 29 GATTATTCCTATCATCCACTAGGGCT 4

Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W. and Puers,C.
TITLE Allelic ladders for short tandem repeat loci
JOURNAL Patent: US 5783406-A 25 21-JUL-1998;
FEATURES
    source
    Location/Qualifiers
        1..29
            /organism="unknown"
BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match
Best Local Similarity 51.0%; Score 14.8; DB 6; Length 29;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUGUAGGCCCAAGGCGU 29
Db 29 GATTATTCCTATCATCCACTAGGGCT 4

RESULT 15
AR252838/c
LOCUS AR252838 29 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 39 from patent US 6479235.
ACCESSION AR252838
VERSION AR252838.1 GI:27301187
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W. and Sprecher,C.J.
TITLE Multiplex amplification of short tandem repeat loci
JOURNAL Patent: US 6479235-A 39 12-NOV-2002;
FEATURES
    source
    Location/Qualifiers
        1..29
            /organism="unknown"
BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match
Best Local Similarity 51.0%; Score 14.8; DB 6; Length 29;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUGUAGGCCCAAGGCGU 29
Db 29 GATTATTCCTATCATCCACTAGGGCT 4

Search completed: January 30, 2004, 08:51:26
Job time : 578.333 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 06:19:17 ; Search time 283.333 Seconds
(without alignments)
276.295 Million cell updates/sec

Title: US-09-310-844C-25
Perfect score: 29
Sequence: 1 aaagaucuuuuuuaagccccaagggcu 29

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 2640686

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N Geneseq_19Jun03.*

1: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA2002.DAT.*
25: /SIDSI/gcgdata/geneseg/geneseqn-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	29	100.0	29	21	AAA70829 Molecular interact
2	29	100.0	29	21	AAA70830 Molecular interact
3	29	100.0	42	21	AAA71115 Molecular interact
4	29	100.0	42	21	AAA71116 Molecular interact
5	29	100.0	42	21	AAA71120 Molecular interact
6	29	100.0	42	21	AAA71121 Molecular interact
7	29	100.0	42	21	AAA71128 Molecular interact
8	29	100.0	42	21	AAA71129 Molecular interact

9	28	96.6	45	21	AAA70825 Molecular interact
10	28	96.6	45	21	AAA70826 Molecular interact
11	28	96.6	46	21	AAA71088 Molecular interact
12	28	96.6	46	21	AAA71089 Molecular interact
13	28	96.6	46	21	AAA71090 Molecular interact
14	28	96.6	46	21	AAA71105 Molecular interact
15	28	96.6	46	21	AAA71106 Molecular interact
16	28	96.6	46	21	AAA71107 Molecular interact
17	24.8	85.5	42	21	AAA71113 Molecular interact
18	24.8	85.5	42	21	AAA71118 Molecular interact
19	24.8	85.5	42	21	AAA71126 Molecular interact
20	23.8	82.1	46	21	AAA71085 Molecular interact
21	23.8	82.1	46	21	AAA71103 Molecular interact
22	23.2	80.0	29	21	AAA70828 Molecular interact
23	23.2	80.0	42	21	AAA71123 Molecular interact
24	23.2	80.0	42	21	AAA71131 Molecular interact
25	22.2	76.6	45	21	AAA70824 Molecular interact
26	22.2	76.6	46	21	AAA71087 Molecular interact
27	22.2	76.6	46	21	AAA71096 Molecular interact
28	22.2	76.6	46	21	AAA71099 Molecular interact
29	22.2	76.6	46	21	AAA71100 Molecular interact
30	22.2	76.6	46	21	AAA71104 Molecular interact
31	21.2	73.1	42	21	AAA71114 Molecular interact
32	21.2	73.1	42	21	AAA71119 Molecular interact
33	21.2	73.1	46	21	AAA71094 Molecular interact
34	21.2	73.1	46	21	AAA71110 Molecular interact
35	21.2	73.1	46	21	AAA71084 Molecular interact
36	20	69.0	46	21	AAA71098 Molecular interact
37	20	69.0	46	21	AAA71102 Molecular interact
38	20	69.0	46	21	AAA71134 Molecular interact
39	19.6	67.6	42	21	AAA71132 Molecular interact
40	19.6	67.6	42	21	AAA71093 Molecular interact
41	18.6	64.1	46	21	AAA71095 Molecular interact
42	18.6	64.1	46	21	AAA71109 Molecular interact
43	18.6	64.1	46	21	AAA71111 Molecular interact
44	18.6	64.1	46	21	AAA71117 Molecular interact
45	18.4	63.4	42	21	AAA71117 Molecular interact

ALIGNMENTS

RESULT 1
AAA70829
ID AAA70829 standard; RNA, 29 BP.
XX
AC AAA70829;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #29.
XX
KW Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Mus sp.
XX
PN WO9558947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
PR 12-MAY-1998; 98US-0085092.
XX
(ISIS-) ISIS PHARM INC.
XX
Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
WPI; 2000-086439/07.
XX
Identifying compounds which modulate activity of target biomolecules,
PT

PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

XX
 XX
 PS Claim 235; Page 235; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAUCUGUUAAGAGAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
 Best Local Similarity 100.0%; Pred. No. 0.0015;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AAAGAUUCUUUUUGUUAAGAGCCCAAGGGCU 29
 Db 1 AAAGAUUCUUUUUGUUAAGAGCCCAAGGGCU 29

RESULT 2
 AAA70830
 ID AAA70830 standard; RNA; 29 BP.

XX
 XX
 AC AAA70830;

XX 27-APR-2001 (first entry)

XX Molecular interaction site RNA #30.

XX Modulator; identification; molecular interaction; virtual library; ss.

XX Rattus sp.

XX WO958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

PT agricultural and industrial compounds -
 XX Claim 235; Page 235; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAUCUGUUAAGAGAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
 Best Local Similarity 100.0%; Pred. No. 0.0015;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AAAGAUUCUUUUUGUUAAGAGCCCAAGGGCU 29
 Db 1 AAAGAUUCUUUUUGUUAAGAGCCCAAGGGCU 29

RESULT 3
 AAA71115
 ID AAA71115 standard; RNA; 42 BP.

XX
 XX
 AC AAA71115;

XX 27-APR-2001 (first entry)

XX Molecular interaction site RNA #191.

XX Modulator; identification; molecular interaction; virtual library; ss.

XX Unidentified.

XX WO958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

XX Example 7; Figure 122; 405pp; English.

PS This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUUCUAGUUUACAGAAAUAUC (11). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 100.0%; Pred. No. 0.0016;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAAGAUUUUUUGUAGGCCCAAGGCU 29
 |||||
 DB 4 AAAGAUUUUUUGUAGGCCCAAGGCU 32

RESULT 4
 AAA71116
 ID AAA71116 standard; RNA; 42 BP.

XX AAA71116;
 AC AAA71116;
 XX 27-APR-2001 (first entry)
 DT Molecular interaction site RNA #192.
 DE Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS WO9558947-A2.
 XX WO9558947-A2.
 XX 18-NOV-1999.
 PD 12-MAY-1999; 99WO-US10361.
 XX 12-MAY-1998; 98US-0076404.
 XX 12-MAY-1998; 98US-0085092.
 XX (ISIS-) ISIS PHARM INC.
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 PI WPI; 2000-086439/07.
 DR Identifying compounds which modulate activity of target biomolecules,
 XX used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

PS Example 7; Figure 122; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUUCUAGUUUACAGAAAUAUC (11). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 100.0%; Pred. No. 0.0016;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAAGAUUUUUUGUAGGCCCAAGGCU 29
 |||||
 DB 4 AAAGAUUUUUUGUAGGCCCAAGGCU 32

RESULT 5
 AAA71120
 ID AAA71120 standard; DNA; 42 BP.

XX AAA71120;
 AC AAA71120;
 XX 27-APR-2001 (first entry)
 DT Molecular interaction site DNA #126.
 DE Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS WO9558947-A2.
 XX WO9558947-A2.
 XX 18-NOV-1999.
 PD 12-MAY-1999; 99WO-US10361.
 XX 12-MAY-1998; 98US-0076404.
 XX 12-MAY-1998; 98US-0085092.
 XX (ISIS-) ISIS PHARM INC.
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 PI WPI; 2000-086439/07.
 DR Identifying compounds which modulate activity of target biomolecules,
 XX used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAAUUCUAGUUUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 XX Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 69.0%; Pred. No. 0.0016;
 Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AAAGAUCUUUUUUGUAGCCCCCAAGGGCU 29
 |||||:|||||:|||||:|||||:|||||:
 Db 4 AAAGATCTTTTGTAGCCCCCAAGGGCT 32

RESULT 6
 AAA71121
 ID AAA71121 standard; DNA; 42 BP.
 AC AAA71121;
 XX
 XX 27-APR-2001 (first entry)
 DE Molecular interaction site DNA #127.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS
 XX WO9958947-A2.
 PN
 XX 18-NOV-1999.
 DD
 XX 12-MAY-1999; 99WO-US10361.
 PF
 XX 12-MAY-1998; 98US-0076404.
 PR
 XX 12-MAY-1998; 98US-0085092.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 FI
 XX WPI; 2000-086439/07.
 DR
 XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 XX Example 7; Figure 125; 405pp; English.
 PS
 XX

CC This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAAUUCUAGUUUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 XX Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 69.0%; Pred. No. 0.0016;
 Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AAAGAUCUUUUUUGUAGCCCCCAAGGGCU 29
 |||||:|||||:|||||:|||||:|||||:
 Db 4 AAAGATCTTTTGTAGCCCCCAAGGGCT 32

RESULT 7
 AAA71128
 ID AAA71128 standard; RNA; 42 BP.
 AC AAA71128;
 XX
 XX 27-APR-2001 (first entry)
 DE Molecular interaction site RNA #197.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS
 XX WO9958947-A2.
 PN
 XX 18-NOV-1999.
 DD
 XX 12-MAY-1999; 99WO-US10361.
 PF
 XX 12-MAY-1998; 98US-0076404.
 PR
 XX 12-MAY-1998; 98US-0085092.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 FI
 XX WPI; 2000-086439/07.
 DR
 XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 XX Example 7; Figure 126; 405pp; English.
 PS
 XX This invention describes a novel method for identifying compounds which

CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (i) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming an end loop region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAUCUAGUUUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 100.0%; Pred. No. 0.0016;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAAGAUUUUUUUUUAAGCCCAAGGGCU 29
 |||||
 DB 4 AAAGAUUUUUUUUUAAGCCCAAGGGCU 32

RESULT 8
 AAA71129
 ID AAA71129 standard; RNA; 42 BP.
 AC AAA71129;
 DT 27-APR-2001 (first entry)
 DE Molecular interaction site RNA #198.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 OS Unidentified.
 XX WO958947-A2.
 XX PD 18-NOV-1999.
 XX PF 12-MAY-1999; 99WO-US10361.
 XX PR 12-MAY-1998; 98US-0076404.
 XX PR 12-MAY-1998; 98US-0085092.
 XX PA (ISIS-) ISIS PHARM INC.
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX WPI; 2000-086439/07.
 XX PT Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX Example 7; Figure 126; 405pp; English.
 PS This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses

CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (i) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming an end loop region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAUCUAGUUUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 100.0%; Pred. No. 0.0016;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAAGAUUUUUUUUUAAGCCCAAGGGCU 29
 |||||
 DB 4 AAAGAUUUUUUUUUAAGCCCAAGGGCU 32

RESULT 9
 AAA70825
 ID AAA70825 standard; RNA; 45 BP.
 AC AAA70825;
 DT 27-APR-2001 (first entry)
 DE Molecular interaction site RNA #25.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 OS Mus sp.
 XX WO958947-A2.
 XX PD 18-NOV-1999.
 XX PF 12-MAY-1999; 99WO-US10361.
 XX PR 12-MAY-1998; 98US-0076404.
 XX PR 12-MAY-1998; 98US-0085092.
 XX PA (ISIS-) ISIS PHARM INC.
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX WPI; 2000-086439/07.
 XX PT Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX Claim 221; Page 232; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of

CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming an end loop region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAAUUAUCUUAUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 T; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
 Best Local Similarity 71.4%; Pred. No. 0.0046;
 Matches 20; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAAGAUUUUUUUUAAGCCCCCAAGGC 28
 |||||:||||:|||||
 Db 19 AAAGATTCTTTTGTAAAGCCCCCAAGGC 46

RESULT 12
 AAA71089
 ID AAA71089 standard; DNA; 46 BP.
 AC AAA71089;
 DT 27-APR-2001 (first entry)
 DE Molecular interaction site DNA #112.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS Unidentified.
 PN WO9558947-A2.
 PD 18-NOV-1999.
 XX 12-MAY-1999; 99WO-US10361.
 PF 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX (ISIS-) ISIS PHARM INC.
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX Example 7; Figure 121; 405pp; English.
 XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the

CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming an end loop region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAAUUAUCUUAUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX

SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 T; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
 Best Local Similarity 71.4%; Pred. No. 0.0046;
 Matches 20; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAAGAUUUUUUUUAAGCCCCCAAGGC 28
 |||||:||||:|||||
 Db 19 AAAGATTCTTTTGTAAAGCCCCCAAGGC 46

RESULT 13
 AAA71090
 ID AAA71090 standard; DNA; 46 BP.
 AC AAA71090;
 DT 27-APR-2001 (first entry)
 DE Molecular interaction site DNA #113.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS Unidentified.
 PN WO9558947-A2.
 PD 18-NOV-1999.
 XX 12-MAY-1999; 99WO-US10361.
 PF 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX (ISIS-) ISIS PHARM INC.
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX Example 7; Figure 121; 405pp; English.
 XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)

CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a
CC second side of the second ds region; and (g) 3 nucleotides forming a second
CC side of the internal loop region; and (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUUUCUAGUUUACAGAAAUAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 T; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 71.4%; Pred. No. 0.0046;
Matches 20; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 1 AAAGAUCUUUUUUAAGCCCAAGGCG 28
|||||:|||||:|||||:|||||:|||||
DB 19 AAGATTCCTTTTGTAAAGCCCAAGGCG 46

RESULT 14
AAAT71105
ID AAA71105 standard; RNA; 46 BP.
XX
AC AAA71105;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #181.
XX
KW Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN WO9958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
XX used to provide compounds which can be used as pharmacological,
XX agricultural and industrial compounds -
XX
PS Example 7; Figure 122; 405pp; English.

XX This invention describes a novel method for identifying compounds which
XX modulate the activity of a target biomolecule. The method uses
XX 3-dimensional representations of the biomolecule and a library of
XX compounds and comprises (a) identifying at least one molecular
XX interaction site of the target RNA; (b) generating in silico a virtual
XX library of compounds predicted or calculated to interact with the
XX molecular interaction site; and (c) comparing 3-dimensional (3-D)
XX representations of the target RNA with members of the virtual library of

CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a
CC second side of the second ds region; and (g) 3 nucleotides forming a second
CC side of the internal loop region; and (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUUUCUAGUUUACAGAAAUAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 100.0%; Pred. No. 0.0046;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AAAGAUCUUUUUUAAGCCCAAGGCG 28
|||||:|||||:|||||:|||||:|||||
DB 19 AAAGAUCUUUUUUAAGCCCAAGGCG 46

RESULT 15
AAAT71106
ID AAA71106 standard; RNA; 46 BP.
XX
AC AAA71106;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #182.
XX
KW Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN WO9958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
XX used to provide compounds which can be used as pharmacological,
XX agricultural and industrial compounds -
XX
PS Example 7; Figure 122; 405pp; English.

XX This invention describes a novel method for identifying compounds which
XX modulate the activity of a target biomolecule. The method uses
XX 3-dimensional representations of the biomolecule and a library of
XX compounds and comprises (a) identifying at least one molecular
XX interaction site of the target RNA; (b) generating in silico a virtual
XX library of compounds predicted or calculated to interact with the
XX molecular interaction site; and (c) comparing 3-dimensional (3-D)
XX representations of the target RNA with members of the virtual library of
XX compounds to generate a hierarchy of the compounds ranked in accordance

XX

Query Match 96.6%; Score 28; DB 21; Length 46;

Matches	Conservative	Mismatches	Indels	Gaps
28	0	0	0	0

19 AAAGATTCCTTTTGTGAGCCCCAAGGGC 46

Search completed: January 30, 2004, 08:22:12
Job time : 283.667 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 07:56:58 ; Search time 50 Seconds
(without alignments)
256.002 Million cell updates/sec

Title: US-09-310-844C-25
Perfect score: 29
Sequence: 1 aaagaucuuuuuuaagcccaaggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 569978 seqs, 220691566 residues

Total number of hits satisfying chosen parameters: 792150

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA:*
1: /cgn2_6/prodata/2/ina/5A_COMB.seq.*
2: /cgn2_6/prodata/2/ina/5B_COMB.seq.*
3: /cgn2_6/prodata/2/ina/6A_COMB.seq.*
4: /cgn2_6/prodata/2/ina/6B_COMB.seq.*
5: /cgn2_6/prodata/2/ina/PCTUS_COMB.seq.*
6: /cgn2_6/prodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	15.2	52.4	33	1	US-08-667-079B-5
C 2	15.2	52.4	47	4	US-09-422-978-1097
C 3	14.8	51.0	29	1	US-08-219-633-25
C 4	14.8	51.0	29	1	US-08-515-236-25
C 5	14.8	51.0	29	1	US-08-761-950-25
C 6	14.8	51.0	29	2	US-08-632-575B-39
C 7	14.8	51.0	29	3	US-09-327-229-31
C 8	14.8	51.0	29	4	US-09-199-542B-39
C 9	14.8	51.0	29	5	PCT-US95-12608-31
C 10	14.8	51.0	32	2	US-08-632-575B-59
C 11	14.8	51.0	32	4	US-09-199-542B-59
C 12	14.6	50.3	25	4	US-09-063-733A-18
C 13	14.6	50.3	53	2	US-08-486-969-46
C 14	14.2	49.0	47	4	US-09-422-978-96
C 15	14.2	49.0	59	2	US-08-410-654B-30
C 16	14.2	49.0	69	2	US-08-474-851-30
C 17	14.2	49.0	69	2	US-08-481-560-30
C 18	14	48.3	41	4	US-09-571-774-2
C 19	13.8	47.6	25	3	US-08-943-731-336
C 20	13.8	47.6	33	4	US-09-199-542B-76
C 21	13.8	47.6	47	4	US-09-571-317-663
C 22	13.6	46.9	41	4	US-09-565-156A-2
C 23	13.6	46.9	47	4	US-09-422-978-1843
C 24	13.6	46.9	47	4	US-09-402-266B-10
C 25	13.6	46.9	52	4	US-09-310-463-6
C 26	13.6	46.9	52	4	US-08-842-248A-6
C 27	13.4	46.2	32	3	US-08-718-738-16

28	13.4	46.2	32	3	US-09-221-844-16	Sequence 16, Appl
29	13.4	46.2	32	5	PCT-US95-03323A-16	Sequence 16, Appl
C 30	13.4	46.2	46	1	US-08-171-389-42	Sequence 42, Appl
C 31	13.4	46.2	46	1	US-08-171-389-45	Sequence 45, Appl
C 32	13.4	46.2	46	1	US-08-123-936-42	Sequence 42, Appl
C 33	13.4	46.2	46	1	US-08-123-936-45	Sequence 45, Appl
C 34	13.4	46.2	46	2	US-08-475-228A-42	Sequence 42, Appl
C 35	13.4	46.2	46	2	US-08-475-228A-45	Sequence 45, Appl
C 36	13.4	46.2	46	3	US-08-482-080A-42	Sequence 42, Appl
C 37	13.4	46.2	46	3	US-08-482-080A-45	Sequence 45, Appl
C 38	13.4	46.2	46	4	US-09-354-947-42	Sequence 42, Appl
C 39	13.4	46.2	46	4	US-09-354-947-45	Sequence 45, Appl
C 40	13.4	46.2	46	5	PCT-US93-12388-42	Sequence 42, Appl
C 41	13.4	46.2	46	5	PCT-US93-12388-45	Sequence 45, Appl
C 42	13.4	46.2	50	1	US-08-245-754A-13	Sequence 13, Appl
C 43	13.4	46.2	50	1	US-08-171-389-46	Sequence 46, Appl
C 44	13.4	46.2	50	1	US-08-123-936-46	Sequence 46, Appl
C 45	13.4	46.2	50	2	US-08-475-228A-46	Sequence 46, Appl

ALIGNMENTS

RESULT 1
US-08-667-079B-5/c
; Sequence 5, Application US/08667079B
; Patent No. 5789171
; GENERAL INFORMATION:
; APPLICANT: Mark S. Smeltzer
; TITLE OF INVENTION: Use of cna, fnbA, fnbB, and hlb Gene Probes for the Strain-Sp
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Benjamin Aaron Adler, MCGREGOR & ADLER, P.C.
; STREET: 8011 Candle Lane
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77071
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh
; SOFTWARE: Microsoft Word for Macintosh
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,079B
; FILING DATE: June 20, 1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Adler, Benjamin Aaron
; REGISTRATION NUMBER: 35,423
; REFERENCE/DOCKET NUMBER: D5886
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-777-2321
; TELEFAX: 713-777-6908
; INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
; LENGTH: 33
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: other nucleic acid
; HYPOTHETICAL: No
; ANTI-SENSE: No
; ORIGINAL SOURCE:
; STRAIN:
; INDIVIDUAL ISOLATE:
; DEVELOPMENTAL STAGE:
; TISSUE TYPE:
; CELL TYPE:
; CELL LINE:
US-08-667-079B-5

```
Query Match          52.4%; Score 15.2; DB 1; Length 33;
Best Local Similarity 42.9%; Pred. No. 3.6e+02;
Matches 12; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 AAGAUUUUUUUUAAGCCCAAGGCU 29
    |||:||||:||||:||||:||||:
Db 32 ATGATTGTTTGTATTCCTCCGGCT 5

RESULT 2
US-09-422-978-1097
; Sequence 1097, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilva
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET-020Cp1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11/796
; SEQ ID NO 1097
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-2043-220 : polymorphic base A or T
US-09-422-978-1097

Query Match          52.4%; Score 15.2; DB 4; Length 47;
Best Local Similarity 50.0%; Pred. No. 3.8e+02;
Matches 11; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 3 AGAUUUUUUUUAAGCCCAAA 24
    |||:||||:||||:||||:
Db 15 AGACTTTTGTAACTCCCA 36

RESULT 3
US-08-219-633-25/c
; Sequence 25, Application US/08219633
; Patent No. 559666
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; APPLICANT: Puers, Christoph
; TITLE OF INVENTION: ALLELIC LADDERS FOR SHORT TANDEM REPEAT
; TITLE OF INVENTION: LOCI
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ross & Stevens, S.C.
; STREET: One South Pinckney Street, P.O. Box 2599
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53701-2599
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/219,633
; FILING DATE: 28-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/219,633
; FILING DATE: 28-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.019
; TELEPHONE: (608) 257-5353
; TELEFAX: (608) 257-9175
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-219-633-25
```

```
ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.019
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 257-5353
; TELEFAX: (608) 257-9175
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-219-633-25

Query Match          51.0%; Score 14.8; DB 1; Length 29;
Best Local Similarity 42.3%; Pred. No. 5.3e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUUAAGCCCAAGGCU 29
    |||:||||:||||:||||:
Db 29 GATTATTCTTATCATCCACTAGGCT 4

RESULT 4
US-08-515-236-25/c
; Sequence 25, Application US/08515236
; Patent No. 5674666
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; APPLICANT: Puers, Christoph
; TITLE OF INVENTION: ALLELIC LADDERS FOR SHORT TANDEM REPEAT
; TITLE OF INVENTION: LOCI
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ross & Stevens, S.C.
; STREET: One South Pinckney Street, P.O. Box 2599
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53701-2599
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/515,236
; FILING DATE: 15-AUG-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/219,633
; FILING DATE: 28-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.019
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 257-5353
; TELEFAX: (608) 257-9175
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-515-236-25

Query Match          51.0%; Score 14.8; DB 1; Length 29;
Best Local Similarity 42.3%; Pred. No. 5.3e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUUAAGCCCAAGGCU 29
```

COMPUTER READABLE
MEDIUM TYPE: D:

```

COMPUTER: IBM Compatible PC
OPERATING SYSTEM: DOS, version 6.0
SOFTWARE: WordPerfect 5.1 (DOS text format)
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/632.575B
  FILING DATE: 04/15/96
  CLASSIFICATION: 435
  PRIOR APPLICATION DATA:
    APPLICATION NUMBER: 08/316,544
    FILING DATE: 09/30/94
  INFORMATION FOR SEQ ID NO: 39:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 29
      TYPE: Nucleic Acid
      STRANDEDNESS: Single
      TOPOLOGY: Linear
      POSITION IN GENOME:
        MAP POSITION: HUMWRA31

```

332-575B-39

Match	51.0%;	Score 14.8;	DB 2;	Length 29;
Local Similarity	42.3%;	Pred. NO. 5.3e+02;		
Indels	11;	Conservative	8;	Mismatches 7;

4 GAUUCUUUUUGUAGCCCCAAGGCU 29
||: : : : :
29 GATTATCTTATCATCCACTAGGCT 4

7
127-229-31/c
Application US/09327229
Serial No. 6221598
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
Sprecher, Cynthia
Lins, Ann M.
TITLE OF INVENTION: MULTIPLE
REPEAT LO
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ross & Steven
STREET: P. O. Box 2599
CITY: Madison
STATE: Wisconsin

COUNTRY: U.S.A.
ZIP: 53701-2599
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER:
OPERATING
SOFTWARE:
CURRENT APPLIC

APPLICATION NUMBER: US/09/327,229
FILING DATE: 07-Jun-1999
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/316,544
FILING DATE: 30-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 34506.022
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-257-5353
TELEFAX: 608-257-9175
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 base pairs
TYPE: nucleic acid


```
RESULT 11
US-09-199-542B-59/c
; Sequence 59, Application US/09199542B
; Patent No. 6479235
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; APPLICANT: Sprecher, Cynthia J.
; TITLE OF INVENTION: Multiplex Amplification of Short Tandem Repeat Loci
; FILE REFERENCE: 16026/9212
; CURRENT APPLICATION NUMBER: US/09/199,542B
; CURRENT FILING DATE: 1998-11-25
; PRIOR APPLICATION NUMBER: US 08/316,544
; PRIOR FILING DATE: 1994-09-30
; PRIOR APPLICATION NUMBER: US 08/632,575
; PRIOR FILING DATE: 1996-04-15
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: Word97 (converted to DOS text format)
; SEQ ID NO 59
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Homo sapien
; LOCATION: HUMVFA31
US-09-199-542B-59

Query Match          51.0%; Score 14.8; DB 4; Length 32;
Best Local Similarity 42.3%; Pred. No. 5.4e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 GAUUCUUUUUAAGCCCAAGGCU 29
Db 29 GATTATTCATCATCCACTAGGCT 4

RESULT 12
US-09-063-733A-18
; Sequence 18, Application US/09063733A
; Patent No. 6372211
; GENERAL INFORMATION:
; APPLICANT: Isaac, Barbara G.
; APPLICANT: Greenplate, John T.
; APPLICANT: Furcell, John P.
; APPLICANT: Romano, Charles P.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CONTROLLING
; TITLE OF INVENTION: INSECTS
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold White & Durkee
; STREET: PO Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/063,733A
; FILING DATE: 21-APR-1998
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Patterson, Melinda L.
; REGISTRATION NUMBER: 33,062
; REFERENCE/DOCKET NUMBER: MOBT:022
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-787-1400
; TELEFAX: 713-787-1440
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

Query Match          50.3%; Score 14.6; DB 2; Length 53;
Best Local Similarity 47.6%; Pred. No. 7.2e+02;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 9 UUUUUUAAGCCCAAGGCU 29
Db 29 TTTTGTAGCTTCCGGCT 9

RESULT 13
US-08-486-969-46/c
; Sequence 46, Application US/08486969
; Patent No. 5843456
; GENERAL INFORMATION:
; APPLICANT: Paolletti, Enzo
; APPLICANT: Maki, Joanne
; TITLE OF INVENTION: RECOMBINANT POXVIRUS - RABIES
; TITLE OF INVENTION: COMPOSITIONS AND COMBINATION COMPOSITIONS AND USES
; NUMBER OF SEQUENCES: 55
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford, P.C.
; STREET: 530 Fifth Avenue, 25th Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,969
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2600
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 53 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-486-969-46

Query Match          50.3%; Score 14.6; DB 2; Length 53;
Best Local Similarity 47.6%; Pred. No. 7.2e+02;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 9 UUUUUUAAGCCCAAGGCU 29
Db 29 TTTTGTAGCTTCCGGCT 9

RESULT 14
US-09-422-978-96
; Sequence 96, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
```

```

; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 96
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-12847-37 : polymorphic base A or G
US-09-422-978-96

```

```

Query Match          49.0%; Score 14.2; DB 4; Length 47;
Best Local Similarity 42.9%; Pred No. 1.1e+03;
Matches 9; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

```

```

Qy 9 UUUUUAAGCCCAAGGCU 29
    : : : : :
Db 8 TTTTCTAAGTCCACRGCT 28

```

RESULT 15

```

US-08-410-654B-30
; Sequence 30, Application US/08410654B
; Patent No. 5833976
; GENERAL INFORMATION:
; APPLICANT: Rene de Waal Malefyt
; APPLICANT: Di-Hwei Hsu
; APPLICANT: Anne O'Garra
; APPLICANT: Hergen Spits
; TITLE OF INVENTION: Use of Interleukin-10 to Treat
; TITLE OF INVENTION: Septic Shock
; NUMBER OF SEQUENCES: 61
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: 7.5.3
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,654B
; FILING DATE: 24-MAR-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/229,854
; FILING DATE: 19-APR-1994
; APPLICATION NUMBER: US 07/926,853
; FILING DATE: 06-AUG-1992
; APPLICATION NUMBER: US 07/742,129
; FILING DATE: 06-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: DX0221KQ1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908-298-2987
; TELEFAX: 908-298-5388
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 69 base pairs

```

```

; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
US-08-410-654B-30
Query Match          49.0%; Score 14.2; DB 2; Length 69;
Best Local Similarity 51.9%; Pred No. 1.2e+03;
Matches 14; Conservative 5; Mismatches 8; Indels 0; Gaps 0;
Qy 1 AAAGAUCUUUUUUAAGCCCAAGG 27
    : : : : :
Db 7 AAGAATGCTTTAATAGCTCCAAGAG 33

```

Search completed: January 30, 2004, 10:15:14
Job time : 51 secs

RESULT 2
US-10-349-143-1097

QY
7 UCUUUUUGUAAGCCCAAGG 26

Db
26 TCCTTCTGAAGCCCCCATGG 7

```
Query Match          51.7%; Score 15; DB 13; Length 60;
Best Local Similarity 47.8%; Pred. NO. 4.6e+03;
Matches 11; Conservative 7; Mismatches 5; Indels 0; Gaps 0;
```

```

RESULT 6
US-09-908-975-4580
; Sequence 4580, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4580
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-09-908-975-4580

Query Match          51.7%; Score 15; DB 13; Length 65;
Best Local Similarity 56.5%; Pred. No. 4.7e+03;
Matches 13; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

QY      2  AGAUCUUUUUGUAGGCCCA 24
DB      34  AGATGCTCTTTGAAGCAACA 56

RESULT 7
US-09-839-478-31/c
; Sequence 31, Application US/09839478
; Publication No. US20030180724A1
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; APPLICANT: Sprecher, Cynthia J.
; APPLICANT: Lins, Ann M.
; TITLE OF INVENTION: MULTIPLEX AMPLIFICATION OF SHORT TANDEM
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ross & Stevens, S.C.
; STREET: P. O. Box 2599
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53701-2599
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/839,478
; FILING DATE: 20-Apr-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/316,544
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 34506.022
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 608-257-5353
; TELEFAX: 608-257-9175

```

```

; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-839-478-31

Query Match          51.0%; Score 14.8; DB 13; Length 29;
Best Local Similarity 42.3%; Pred. No. 4.9e+03;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY      4  GAUCUUUUUGUAGGCCCAAGGCCU 29
DB      29  GATTATCTTATCATCCACTAGGCT 4

RESULT 8
US-10-005-530-18
; Sequence 18, Application US/10005530
; Publication No. US20030026795A1
; GENERAL INFORMATION:
; APPLICANT: Isaac, Barbara G.
; APPLICANT: Greenplate, John T.
; APPLICANT: Purcell, John P.
; APPLICANT: Romano, Charles P.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CONTROLLING INSECTS
; FILE REFERENCE: 11899.0022.DVUS01 (MOST:022--2)
; CURRENT APPLICATION NUMBER: US/10/005,530
; CURRENT FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: 09/063,733
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/044,504
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-005-530-18

Query Match          50.3%; Score 14.6; DB 15; Length 25;
Best Local Similarity 47.6%; Pred. No. 5.9e+03;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY      2  AAGAUUUUUUUUUAAGCCCC 22
DB      5  AAGCTTCTCTTTGTAATACCC 25

RESULT 9
US-09-908-975-8435
; Sequence 8435, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607

```

; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8435
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-8435

Query Match 50.3%; Score 14.6; DB 13; Length 60;
Best Local Similarity 51.7%; Pred. No. 7e+03;
Matches 15; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

Qy 1 AAAGAUCUUUUUGUAGCCCAAGGCU 29
Db 12 AACGAACGTATTGTAATCCCAAGATCT 40

RESULT 10

US-09-908-975-18114
; Sequence 18114, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICING
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908.975
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18114
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-18114

Query Match 50.3%; Score 14.6; DB 13; Length 60;
Best Local Similarity 52.4%; Pred. No. 7e+03;
Matches 11; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

Qy 9 UUUUUGUAGCCCAAGGCU 29
Db 7 TATTCTCAGTCCCAAGGCT 27

RESULT 11

US-10-378-094-45
; Sequence 45, Application US/10378094
; Publication No. US20030221201A1
; GENERAL INFORMATION:
; APPLICANT: PRIOR, Christopher P.
; APPLICANT: LAI, Char-Huei
; APPLICANT: SDEGHI, Homayoun
; APPLICANT: TURNER, Andrew
; TITLE OF INVENTION: MODIFIED TRANSFERRIN FUSION PROTEINS
; FILE REFERENCE: 54710-5001-01-US
; CURRENT APPLICATION NUMBER: US/10/378,094
; CURRENT FILING DATE: 2003-03-04
; PRIOR APPLICATION NUMBER: US 10/231,494
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 60/334,059
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 60/315,745
; PRIOR FILING DATE: 2001-08-30

; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide encoding peptide with EPO activity
US-10-378-094-45

Query Match 50.3%; Score 14.6; DB 13; Length 60;
Best Local Similarity 52.4%; Pred. No. 7e+03;
Matches 11; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

Qy 6 UUUUUUUGUAGCCCAAGG 26
Db 36 TTGGTTTGTAGCCCAAGG 56

RESULT 12

US-09-848-754A-6937/c
; Sequence 6937, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6937
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic acid
US-09-848-754A-6937

Query Match 49.7%; Score 14.4; DB 11; Length 31;
Best Local Similarity 58.3%; Pred. No. 7.6e+03;
Matches 14; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 4 GAUCUCUUUUUGUAGCCCAAGG 27
Db 25 GATCGTTGTAGCTAGCCCAAGG 2

RESULT 13

US-09-740-332-5660/c
; Sequence 5660, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5660
; LENGTH: 31
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: DNazyme
US-09-740-332-5660

Query Match 49.7%; Score 14.4; DB 11; Length 31;

Best Local Similarity 58.3%; Pred. No. 7.6e+03;
Matches 14; Conservative 4; Mismatches 6; Indels 0; Gaps 0;
Db 35 AGAGATTCCTTTTGTAAAGCGGTAA 12
Search completed: January 30, 2004, 13:10:26
Job time : 178 secs

QY 2 AAGAUUCUUUGUAGAGCCCAAG 25
Db 27 AGATCGTTGTAGCTAGCCCAAG 4

RESULT 14
US-09-817-879-5660/c
; Sequence 5660, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5660
; LENGTH: 31
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: DNazyme
US-09-817-879-5660

Query Match 49.7%; Score 14.4; DB 13; Length 31;
Best Local Similarity 58.3%; Pred. No. 7.6e+03;
Matches 14; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 2 AAGAUUCUUUGUAGAGCCCAAG 25
Db 27 AGATCGTTGTAGCTAGCCCAAG 4

RESULT 15
US-09-908-975-3924/c
; Sequence 3924, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICING
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR FILING DATE: 2001-05-02
; PRIOR FILING DATE: 2001-05-02
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3924
; LENGTH: 65
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-09-908-975-3924

Query Match 49.7%; Score 14.4; DB 13; Length 65;
Best Local Similarity 50.0%; Pred. No. 8.8e+03;
Matches 12; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

QY 1 AAGAUUCUUUGUAGAGCCCAAG 24

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 07:55:03 ; Search time 1615 Seconds

(without alignments)
436.427 Million cell updates/sec

Title: US-09-310-844c-25

Perfect score: 29
Sequence: 1 aaagaucuuuuuuaagcccccaggcu 29

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 22791392 seqs, 12152238056 residues

Total number of hits satisfying chosen parameters: 243536

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*

1: em_estba:*

2: em_esthum:*

3: em_estlin:*

4: em_estmu:*

5: em_estov:*

6: em_estpl:*

7: em_estro:*

8: em_hic:*

9: gb_estl:*

10: gb_est2:*

11: gb_hic:*

12: gb_est3:*

13: gb_est4:*

14: gb_est5:*

15: em_estfun:*

16: em_estcom:*

17: em_gss_hum:*

18: em_gss_inv:*

19: em_gss_pln:*

20: em_gss_vrt:*

21: em_gss_fun:*

22: em_gss_mam:*

23: em_gss_mus:*

24: em_gss_pro:*

25: em_gss_rod:*

26: em_gss_phg:*

27: em_gss_vrl:*

28: gb_gssl:*

29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	18.4	63.4	70	AA516989	AA516989 vh89d02.r
C 2	17.4	60.0	67	AA708911	AA708911 z164a10.s
C 3	16.6	57.2	70	AI609394	AI609394 tw93b03.x
C 4	16	55.2	51	BG361927	BG361927 gb49d10.y

C 5	15.8	54.5	58	9	AI824019	AI824019 wj29f03.x
C 6	15.6	53.8	37	9	AI802260	AI802260 t336g07.x
C 7	15.6	53.8	58	28	AZ834846	AZ834846 2M0117F18
C 8	15.4	53.4	9	14	U44334	U44334 ENT44334 As
C 9	15.2	52.4	61	9	AI318033	AI318033 ta75g02.x
C 10	15.2	52.4	65	12	BM517546	BM517546 k180g07.y
C 11	15	51.7	58	28	B02943	B02943 CSRL-183G2-
C 12	14.8	51.0	34	28	AZ840876	AZ840876 2M0138C08
C 13	14.8	51.0	35	9	AL801069	AL801069 AL801069
C 14	14.8	51.0	49	28	AZ576537	AZ576537 AST-T11CO
C 15	14.8	51.0	55	9	AI224478	AI224478 qx06d06.x
C 16	14.8	51.0	64	10	BE636255	BE636255 SMOVAMCAQ
C 17	14.8	51.0	65	9	AL895107	AL895107 AL895107
C 18	14.6	50.3	53	29	AL940874	AL940874 Arabidops
C 19	14.6	50.3	59	10	BE970792	BE970792 601680150
C 20	14.6	50.3	61	13	BQ479345	BQ479345 Ku33d12.y
C 21	14.6	50.3	65	29	AL763793	AL763793 Arabidops
C 22	14.6	50.3	69	29	BZ768797	BZ768797 SALK_1407
C 23	14.6	50.3	70	29	BZ768791	BZ768791 SALK_1407
C 24	14.6	50.3	70	29	BZ768795	BZ768795 SALK_1407
C 25	14.4	49.7	35	28	BH856246	BH856246 SALK_0811
C 26	14.4	49.7	35	28	BH856247	BH856247 SALK_0811
C 27	14.4	49.7	37	28	AZ5950243	AZ5950243 2M0214C15
C 28	14.4	49.7	41	28	AZ595857	AZ595857 IM0413A04
C 29	14.4	49.7	51	29	DM545740	AJ545740 Drosophil
C 30	14.4	49.7	56	29	BZ665747	BZ665747 KG10262.D
C 31	14.4	49.7	57	10	BG362057	BG362057 gb47b08.y
C 32	14.4	49.7	58	9	AV953887	AV953887 AV953887
C 33	14.4	49.7	64	9	AI321110	AI321110 d4C09nm.r
C 34	14.4	49.7	65	28	BH908271	BH908271 SALK_0468
C 35	14.4	49.7	66	10	BG361679	BG361679 gb48b04.y
C 36	14.4	49.7	67	28	BH848343	BH848343 SALK_0678
C 37	14.4	49.7	68	10	BG362185	BG362185 gb52f02.y
C 38	14.4	49.7	70	28	BH759592	BH759592 KG05236-3
C 39	14.2	49.0	38	23	BZ355014	BZ355014 SALK_1262
C 40	14.2	49.0	54	28	B05408	B05408 CSRL-62a5-u
C 41	14.2	49.0	56	28	AZ938752	AZ938752 2M0197N19
C 42	14.2	49.0	64	29	EX161966	EX161966 Danio rer
C 43	14.2	49.0	65	9	AI719509	AI719509 as44b06.x
C 44	14.2	49.0	65	13	BQ564818	BQ564818 G124h01.y
C 45	14.2	49.0	69	9	AI211081	AI211081 n0806a1.f

ALIGNMENTS

RESULT 1
AA516989/c
LOCUS
DEFINITION
vh89d02.r1 Knowles Solter mouse embryonic stem cell Mus musculus
cDNA clone IMAGE:894147 5' similar to TR:G187568 G187568 MG44 ;
mRNA sequence.
ACCESSION
AA516989
VERSION
AA516989.1 GI:2256448
KEYWORDS
EST.
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
REFERENCE
Mammalia; Eutheraia; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 (bases 1 to 70)

Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Gessel,S., Kucaba,T., Lacy,M., Le,M., Martin,G., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theisinger,B., Wylie,T., Lenon,G., Soares,B., Wilson,R. and
Waterston,R.
TITLE
The WashU-HMI Mouse EST Project
JOURNAL
Unpublished
COMMENT
Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:522107

Trace considered overall poor quality
Possible reversed clone: similarity on wrong strand
High quality sequence stop: 1.

FEATURES

source Location/Qualifiers

1..70
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J x DBA/2J F1"
/db_xref="taxon:10090"
/clone="IMAGE:894147"
/dev_stage="embryo"
/lab_host="DH10B"
/clone_lib="Knowles Soiter mouse embryonic stem cell"
/note="Vector: pSPORT; Site 1: NotI; Site 2: SalI; Cloned
unidirectionally from mRNA prepared from 800 blastocysts.
Primer: SalI(dT): 5'-CGTGCACGTCGACGTTTTTTTTTTT-3'.
cDNAs were cloned into the NotI/SalI sites of a pSPORT
vector (Life Technologies)."
16 a 14 c 15 g 25 t

BASE COUNT

ORIGIN

Query Match 63.4%; Score 18.4; DB 9; Length 70;
Best Local Similarity 57.1%; Pred. No. 1.4e+04;
Matches 16; Conservative 6; Mismatches 6; Indels 0; Gaps 0;
Qy 1 AAGAUCUUUUUGUAGGCCCAAGGCC 28
|||||: : : : :
Db 47 ACAGATTCTTCTAGAAACACCAAGGCC 20

RESULT 2

AA708911/c
LOCUS AA708911 67 bp mRNA linear EST 24-DEC-1997
DEFINITION z164a10.s1 Soares_pregnant_uterus_NHPU Homo sapiens cDNA clone
IMAGE:506682 3' similar to SW:RB32_HUMAN Q13637 RAS-RELATED PROTEIN
RAB-32 ; mRNA sequence.

ACCESSION

AA708911

VERSION

AA708911.1 GI:2718829

KEYWORDS

EST.

SOURCE

Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 67)

AUTHORS

Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S.,

Krizman,D., Kucaba,T., Lacy,M., Le.N., Lennon,G., Marra,M., Martin

J., Moore,B., Scheinberg,K., Steptoe,M., Tan,F., Theising,B.,

White,Y., Wylie,T., Waterston,R. and Wilson,R.

TITLE

WashU-NCI human EST Project

JOURNAL

Unpublished

COMMENT

Contact: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

This clone is available royalty-free through LLNL; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.

Trace considered overall poor quality

Possible reversed clone: similarity on wrong strand

Seq primer: -40m13 fwd. Et from Amersham

High quality sequence stop: 1.

FEATURES

source Location/Qualifiers

1..67
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3812701"
/db_xref="taxon:9606"
/clone="IMAGE:506682"

/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Soares_pregnant_uterus_NHPU"
/note="Organ: uterus; Vector: pT73-Pac; Site 1: Not I;
Site 2: Eco RI; 1st strand cDNA was primed with a Not I -
oligo(dT) primer [5',
RACGGAGAAATTCGGCGCCCTTTTTTTTTTTT 3'],
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization. Library
constructed by M. Fatima Bonaldo."

BASE COUNT 16 a 16 c 18 g 17 t

ORIGIN

Query Match 60.0%; Score 17.4; DB 9; Length 67;
Best Local Similarity 55.6%; Pred. No. 3.4e+04;
Matches 15; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

Qy 3 AGAUCUUUUUGUAGGCCCAAGGCCU 29

|||||: : : : :
Db 51 AGAGATTCTTGTAAACCCCAAGGCT 25

RESULT 3

AI609394/c

LOCUS

AI609394 70 bp mRNA linear EST 16-DEC-1999

DEFINITION

tw93b03.x1 NCI CGAP HN6 Homo sapiens cDNA clone IMAGE:2267213 3'

similar to SW:TCF_HUMAN Q99832 T-COMPLEX PROTEIN 1, ETA SUBUNIT ;

mRNA sequence.

ACCESSION

AI609394

VERSION

AI609394.1 GI:4618561

KEYWORDS

EST.

SOURCE

Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 70)

AUTHORS

NCI/NIH-NCI

National Cancer Institute / National Institute of Dental Research,

Cancer Genome Anatomy Project (CGAP), Tumor Gene Index

Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cgaps-r@mail.nih.gov

Tissue Procurement: Chong Heon Lee, D.D.S., Mary May, J. Silvio

Gutkind, Ph.D., Myung Hee Park, Ph.D.

cDNA Library Preparation: Stratagene, Inc.

cDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center

Clone distribution: NCI-CGAP clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality

Insert Length: 2028 Std Error: 0.00

Seq primer: -40UP from Gibco

High quality sequence stop: 1

POLYA-No.

FEATURES

source Location/Qualifiers

1..70
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2267213"
/tissue_type="normal gingiva (cell line from immortalized
keratinocytes)"
/lab_host="SOLR (kanamycin resistant)"
/clone_lib="NCI CGAP HN6"
/note="Vector: Bluescript SK-; Site 1: EcoRI; Site 2: XhoI
; Cloned unidirectionally. Primer: Oligo dT. Average
insert size 1.3 kb. 5' adaptor sequence: 5' AATTCGCGACGAG
3' GCCGCGCTC 5' 3' adaptor

sequence: 5' (GA)10ACTAGTCTCGAGTTTTTTTTTTTTTTT 3' EcoRI
 site appears to have been lost in a fraction of the
 clones. Library constructed by Stratagene; available
 through Mary May, PhD (Oxal and Pharyngeal Cancer Branch,
 National Institute of Dental and Craniofacial Research,
 NIH; mmay@yoda.nid.nih.gov)." 3 others
 18 a 23 c 14 g 12 t

BASE COUNT
 ORIGIN

Query Match 57.2%; Score 16.6; DB 9; Length 70;

Best Local Similarity 47.8%; Pred. No. 6.6e+04;

Matches 11; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

QY 6 UCUUUUUUGAAGCCCAAGGCC 28

Db 54 TTTTITTTGTGGCCCAAGGCC 32

RESULT 4

BG361927/c

LOCUS 51 bp mRNA linear EST 08-MAR-2001

DEFINITION 9b49d10.y1 Moss EST library PPG Physcomitrella patens cDNA clone

PEP SOURCE ID: 5', mRNA sequence.

ACCESSION BG361927

VERSION BG361927.1 GI:13251024

KEYWORDS Physcomitrella patens

SOURCE Physcomitrella patens

ORGANISM Eukaryota; Viridiplantae; Streptophyta; Bryophyta;

Physcomitrella patens; Bryopsida; Funariaceae; Funariales; Physcomitrella

1 (bases 1 to 51)

REFERENCE Quatrano, R., Bashirades, S., Cove, D., Cuming, A., Knight, C., Clifton

, S., Marra, M., Hillier, L., Pape, D., Martin, J., Wylie, T., Underwood

, K., Theising, B., Allen, M., Bowers, Y., Person, B., Swaller, J.,

Steptoe, M., Gibbons, M., Harvey, N., Ritter, E., Jackson, Y., McCann, R.,

Waterston, R., and Wilson, R.

Leeds/Wash U Moss EST Project

Unpublished

CONTACT: Ralph Quatrano

Leeds/Wash U Moss EST Project

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

Libraries were constructed by Dr. Stavros Bashirades as part of the

Physcomitrella EST program (PEP) at the Univ. of Leeds (UK) and

Washington Univ. in St. Louis (USA) DNA sequencing by: Washington

University Genome Sequencing Center For information on obtaining a

clone please contact: Celis Knight (c.d.knight@leeds.ac.uk)

Seq primer: -4ORP from Gibco.

Location/Qualifiers

1..51

/organism="Physcomitrella patens"

/mol_type="mRNA"

/db_xref="taxon:3218"

/clone="PEP SOURCE ID:"

/tissue_type="gametophore: 30 day old tissue,

ammonium-grown"

/lab_host="DH103"

/clone_lib="Moss EST library PPG"

/notes="Vector: pAMP1; Construction of the cDNA library was

performed by Dr. W. Gregg Clark using a modification of

the cDNA synthesis protocol developed in the laboratory of

Dr. Michael Lovett by Dr. Yulia Korshunova (personal

communication). First polyA + RNA was isolated from total

gametophore RNA using oligo dT magnetic beads. Following

this, first strand cDNA synthesis was performed on the

bead-bound polyA + RNA, during which an oligonucleotide

anchor sequence was incorporated onto the 5'-ends of the

cDNA. PCR amplification was then used to synthesize the

second strand, to amplify the double stranded DNA, and to

incorporate dUTP containing sequences into the ends of the

double stranded cDNA. This DNA was size selected and
 cloned into pAMP1 using the CloneAMP PAMPI System (Life
 Technologies, GibcoBRL) for cloning amplification products
 by a non-restriction site dependant process. The cloning
 was directional based on sequence asymmetry introduced at
 the ends during PCR amplification. The 3' cDNA ends are
 proximal to the NotI site of the multiple cloning site in
 pAMP1. This annealing mixture was transformed into
 chemically competent DH10B cells and selected for
 ampicillin resistant growth. The resulting clones (about
 330,000) were pooled to make the library."

BASE COUNT 18 a 9 c 8 g 16 t

ORIGIN

Query Match 55.2%; Score 16; DB 10; Length 51;

Best Local Similarity 41.7%; Pred. No. 1.1e+05;

Matches 10; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY 6 UCUUUUUUGAAGCCCAAGGCCU 29

Db 27 TTTTITTTTAAGACCAAGAACT 4

RESULT 5

AI824019/c

LOCUS 58 bp mRNA linear EST 21-DEC-1999

DEFINITION WJ29f03.x1 NCI CGAP Kid12 Homo sapiens cDNA clone IMAGE:2404253

similar to TR:O70278 O70278 MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

CANDIDATE PROTEIN NUMBER 18. ;, mRNA sequence.

ACCESSION AI824019

VERSION AI824019.1 GI:5444690

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

1 (bases 1 to 58)

NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.

National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

Tumor Gene Index

Unpublished

CONTACT: Robert Strausberg, Ph.D.

Email: cgapbs-remail.nih.gov

Tissue Procurement: Christopher Mckaluk, M.D., Ph.D., Michael R.

Emmert-Buck, M.D., Ph.D.

cDNA Library Preparation: M. Bento Soares, Ph.D.

cDNA Sequencing by: Greg Lennon, Ph.D.

Clone distribution: NCI-CGAP clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality

Insert Length: 806 Std Error: 0.00

Seq primer: -400P from Gibco

High quality sequence stop: 1.

Location/Qualifiers

1..58

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:2404253"

/tissue_type="2 pooled tumors (clear cell type)"

/lab_host="DH10B"

/clone_lib="NCI CGAP Kid12"

/notes="Organ: kidney; Vector: pT73D-Pac (Pharmacia) with

a modified polylinker; Site 1: Not I; Site 2: Eco RI;

Plasmid DNA from the normalized library NCI_CGAP_Kid5 was

prepared, and ss circles were made in vitro. Following HAP

purification, this DNA was used as tracer in a subtractive

hybridization reaction. The driver was PCR-amplified cDNAs

from a pool of 5,000 clones made from the same library

(cloneIDs 1323912-1325831, 1471368-1472903 and

```

1492104-1493255). Subtraction by Bento Soares and M.
Fatima Bonaldo. "
BASE COUNT      11 a      14 c      19 g      14 t
ORIGIN
Query Match      54.5%; Score 15.8; DB 9; Length 58;
Best Local Similarity 44.4%; Pred. No. 1.3e+05;
Matches 12; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AGAUCUUUUUUAAGCCCAAGGCU 29
    |||:::|||||:::|||||:::
Db 56 AGCTTTTTCACAGTCCCAAGAGCT 30

RESULT 6
AI802260      37 bp      mRNA      linear      EST 13-DEC-1999
LOCUS      t33607.x1 NCI CGAP Pan1 Homo sapiens cDNA clone IMAGE:2143644 3'
DEFINITION      similar to TR:Q41120 Q41120 HYDROXYPROLINE-RICH GLYCOPROTEIN ;,
mRNA sequence.
ACCESSION      AI802260
VERSION      AI802260.1 GI:5367732
KEYWORDS      EST.
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 37)
AUTHORS      NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITILE      National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL      Unpublished
COMMENT      Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Life Technologies catalog #: 11548-013
DNA Sequencing by: Washington University Genome Sequencing Center
Clone Distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 1470 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1.
Location/Qualifiers
1..37
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2143644"
/tissue_type="adenocarcinoma"
/lab_host="DH10B"
/clone_lib="NCI CGAP Pan1"
/note="Organ: pancreas; Vector: pCMV-SPOBNS; Site 1: SalI;
Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.72 kb. Life technologies catalog #:
11548-013"
BASE COUNT      6 a      17 c      3 g      11 t
ORIGIN
Query Match      53.8%; Score 15.6; DB 9; Length 37;
Best Local Similarity 50.0%; Pred. No. 1.3e+05;
Matches 11; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

Qy 1 AAAGAUCUUUUUUAAGCCGCC 22
    |||:::|||||:::
Db 7 ABAATTTTTTTTGAAGCCCC 28

RESULT 7
AZ834846/c
LOCUS      AZ834846
DEFINITION      2M0117F18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic

```

```

clone UUGC2M0117F18 R, genomic survey sequence.
ACCESSION      AZ834846
VERSION      AZ834846.1 GI:13004754
KEYWORDS      GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (Bases 1 to 58)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,B., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
TITILE
JOURNAL      Unpublished
COMMENT      Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112 USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0117 row: F column: 18
Seg primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 58.
Location/Qualifiers
1..58
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0117F18"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42rv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 [gi|4732114|gb|AF129072.1], a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT      15 a      13 c      16 g      14 t
ORIGIN
Query Match      53.8%; Score 15.6; DB 28; Length 58;
Best Local Similarity 54.5%; Pred. No. 1.5e+05;
Matches 12; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

Qy 4 CAUCUUUUUUAAGCCCAAG 25
    |||:::|||||:::
Db 24 GTTCCCTTTGTAATCCCAAG 3

RESULT 8
U44334
LOCUS      U44334
linear      49 bp      mRNA      EST 03-APR-1996

```

```

DEFINITION ENU44334 Aspergillus nidulans cleistothecium Emericella nidulans
CDNA clone SE0762, mRNA sequence.
ACCESSION U44334
VERSION U44334.1 GI:1244997
KEYWORDS EST.
SOURCE Emericella nidulans (anamorph: Aspergillus nidulans)
ORGANISM Eukaryota; Fungi; Ascomycota; Peizizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; Emericella.
REFERENCE 1 (bases 1 to 49)
AUTHORS Lee,D., Lee,S., Kwang,H., Kim,J. and Chae,K.
TITLE Quantitative analysis of gene expression in sexual structures of
Aspergillus nidulans by sequencing of 3'-directed cDNA clones
JOURNAL FEMS Microbiol. Lett. 138 (1), 71-76 (1996)
MEDLINE 96236220
PUBMED 8674973
COMMENT Contact: Keon-Sang Chae
Chonbuk National University
Chonju, 561-756, S. Korea
Tel: +82-652-70-3340
Fax: +82-652-70-3345
Email: chaeks@chonbuknms.chonbuk.ac.kr.

FEATURES
source
1..49
/organism="Emericella nidulans"
/mol_type="mRNA"
/strain="FGSC4"
/db_xref="taxon:162425"
/clone="SE0762"
/tissue_type="cleistothecium"
/cell_type="Hull cell"
/dev_stage="sexual"
/clone_lib="Aspergillus nidulans cleistothecium"
/note="3'-directed cDNA clones; single-pass sequencing"

BASE COUNT 11 a 13 c 10 g 15 t
ORIGIN

Query Match 53.1%; Score 15.4; DB 14; Length 49;
Best Local Similarity 52.0%; Pred. No. 1.9e+05;
Matches 13; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

QY 3 AGAUUCUUUUUGUAGGCCCAAGGG 27
|||||:|||||
Db 20 AGATCTTTCATTACTCCACGG 44
|||||:|||||

RESULT 9
AI318033
LOCUS ta75g02.x1 NCI CGAP HSC2 Homo sapiens cDNA clone IMAGE:2049938 3'
DEFINITION similar to SW:FL34_HUMAN P49207 60S RIBOSOMAL PROTEIN L34. ;, mRNA
sequence.
ACCESSION AI318033
VERSION AI318033.1 GI:4033793
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 61)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgaps-r@mail.nih.gov
Tissue Procurement: Herbert Morse, M.D., Michael R. Emmert-Buck,
M.D., Ph.D.
cDNA Library Preparation: David B. Krizman, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:

```

www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 384 Std Error: 0.00
Seq Primer: -40UP from Gibco
High quality sequence stop: 1.

FEATURES

source

```

1..61
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2049938"
/tissue_type="stem cell 34+/38+"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="NCI CGAP HSC2"
/note="Organ: bone marrow; Vector: pAMPl; mRNA made from
bone marrow, stem cells 34+/38+, cDNA made by oligo-dT
priming. Directionally cloned. Size-selected on agarose
gel, average insert size 400 bp. Primary library,
non-amplified."

BASE COUNT 20 a 10 c 16 g 15 t
ORIGIN

```

Query Match 52.4%; Score 15.2; DB 9; Length 61;

Best Local Similarity 53.6%; Pred. No. 2.2e+05; Indels 0; Gaps 0;
Matches 15; Conservative 5; Mismatches 8;

QY 1 AAAGAUUCUUUUUGUAGGCCCAAGGGC 28

Db 1 AAGGTTTCGTGCTATGACCTAAGGGC 28

RESULT 10

BM517546

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

COMMENT

JOURNAL

Unpublished

Contact: McCarter JP

The Washington Univ. Nematode EST Project, 1999

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@wustl.edu

The library was constructed by Claire Murphy, Brandi Chiapelli, and

Dr. James McCarter at Washington University, St. Louis. DNA

Sequencing by: Washington University Genome Sequencing Center.

Location/Qualifiers

1..65

/organism="Ascaris suum"

/mol_type="mRNA"

/db_xref="taxon:6253"

/sex="Female"

/tissue_type="Head"

/dev_stage="Adult"

FEATURES

source

1..65

/organism="Ascaris suum"

/mol_type="mRNA"

/db_xref="taxon:6253"

/sex="Female"

/tissue_type="Head"

/dev_stage="Adult"


```

Query Match      51.0%; Score 14.8; DB 28; Length 34;
Best Local Similarity 57.7%; Pred. No. 3.2e+05;
Matches 15; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 3 AGAUCUUUUUGUAGGCCCAAGGCC 28
Db 26 ATATAATCTTCGAAAGCACCAGGCC 1

RESULT 13
AL801069/c
LOCUS
DEFINITION
  AL801069 XGC-neurula Silurana tropicalis cDNA clone TNeu127124 5',
  mRNA sequence.
ACCESSION
  AL801069
VERSION
  AL801069.1 GI:21587437
KEYWORDS
  Silurana tropicalis (western clawed frog)
ORGANISM
  Silurana tropicalis
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
  Xenopodinae; Silurana.
REFERENCE
  1 (bases 1 to 35)
  Taylor R., Ashurst, J.L., Croning, M.D.R., Zorn, A.M. and Rogers, J.
  Sanger Xenopus tropicalis EST project 2002
  Unpublished
  Contact: Taylor R
  Sanger Centre
  Hinxton, Cambridgeshire, CB10 1SA, UK
  Email: trop@sanger.ac.uk
  Sanger Xenopus tropicalis EST project 2001
  TROPICALIS_SEQUENCE_ID: TNeu127124.picSP6
  Sequencing primer: PICSP6
  This sequence is from a Xenopus Gene Collection (XGC) library
  constructed by Aaron M. Zorn.
FEATURES
  source
  1..35
  /organism="Silurana tropicalis"
  /mol_type="mRNA"
  /db_xref="taxon:8364"
  /clone="TNeu127124"
  /dev_stage="neurula"
  /lab_host="Escherichia coli DH108"
  /clone_lib="XGC-neurula"
  /notes="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA
  was oligo dT primed from sug of poly A+ RNA from neurula.
  EcoRI-NotI cut cDNA was then ligated into pCS107 with
  EcoRI at the 5' end and NotI at the 3' end."
BASE COUNT      13 a 7 c 8 g 7 t
ORIGIN
Query Match      51.0%; Score 14.8; DB 9; Length 35;
Best Local Similarity 42.3%; Pred. No. 3.2e+05;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 1 AAGAUCUUUUUGUAGGCCCAAGG 26
Db 31 AAAAAATTTTTTTTGTGCCCCGGGG 6

RESULT 14
AZ576537
LOCUS
DEFINITION
  AZ576537 Genetrapp T47D Human Breast Carcinoma Library Homo
  sapiens genomic 5', genomic survey sequence.
ACCESSION
  AZ576537
VERSION
  AZ576537.1 GI:11562848
KEYWORDS
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Query Match      51.0%; Score 14.8; DB 28; Length 49;
Best Local Similarity 57.7%; Pred. No. 3.1e+05;
Matches 15; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 AAAGAUCUUUUUGUAGGCCCAAGG 26
Db 6 AAAGAGACTTCCTGTAAGGCGCAAG 31

RESULT 15
AI224478/c
LOCUS
DEFINITION
  AI224478
  QX06d06.x1 NCI CGAP Lym12 Homo sapiens cDNA clone IMAGE:2000555 3',
  similar to TR:Q23462 Q23462 HYPOTHETICAL 18.0 KD PROTEIN. 1, mRNA
  sequence.
ACCESSION
  AI224478
VERSION
  AI224478.1 GI:3807191
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 55)
  NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
  National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
  Tumor Gene Index
  Unpublished
  Contact: Robert Strausberg, Ph.D.
  Email: cgapbs-remail.nih.gov
  unknown library type
  Trace considered overall poor quality
  Insert Length: 1214 Std Error: 0.00
  Seq primer: -40UP from Gibco
  High quality sequence stop: 1.
  Location/Qualifiers
FEATURES
  source
  1..49
  /organism="Homo sapiens"
  /mol_type="genomic DNA"
  /db_xref="taxon:9606"
  /tissue_type="Carcinoma"
  /cell_type="Epithelial"
  /cell_line="T47D"
  /clone_lib="Genetrapp T47D Human Breast Carcinoma Library"
  /notes="Organ: Breast; Vector: pAMP-1; 3' RACE of total RNA
  from genetrapp pools; shotgun clone in pAMP-1 and used to
  transform DHS-alpha competent bacteria."
BASE COUNT      18 a 11 c 14 g 6 t
ORIGIN

```

```

REFERENCE
  1 (bases 1 to 49)
  Henkel, G., Liyanage, M., Pratt, E., Huang, D., Riley, M., Bernardino, A.
  , Durick, K. and Pollok, B.
  Exon-trap tags from a T47D GenomesScreen(TM) Library
  Unpublished
  Contact: Greg Henkel
  Gene Expression
  Aurora Biosciences Corp.
  11010 Torreyana Road, San Diego, CA 92121, USA
  Tel: 8584048436
  Fax: 8584046719
  Email: henkelga@aurorabio.com
  Pools of cells were isolated from a GenomesScreen(TM) library. The
  library of cells was generated by retroviral integration of a gene
  tagging element consisting of: 1) A promoterless beta-lactamase
  preceded by a splice acceptor as a reporter for gene expression;
  2) A promoter driving neomycin resistance followed by a splice
  donor to trap downstream exons. 3' RACE from neomycin gene was
  performed using total RNA from isolated pools. Output was shotgun
  cloned in pAMP-1 and used to transform DHS-alpha competent
  bacteria. 5' ends of reported sequences were immediately preceded
  by splice donor from the trapping construct.
  Class: exon-trapped.
  Location/Qualifiers
FEATURES
  source
  1..49
  /organism="Homo sapiens"
  /mol_type="genomic DNA"
  /db_xref="taxon:9606"
  /tissue_type="Carcinoma"
  /cell_type="Epithelial"
  /cell_line="T47D"
  /clone_lib="Genetrapp T47D Human Breast Carcinoma Library"
  /notes="Organ: Breast; Vector: pAMP-1; 3' RACE of total RNA
  from genetrapp pools; shotgun clone in pAMP-1 and used to
  transform DHS-alpha competent bacteria."
BASE COUNT      18 a 11 c 14 g 6 t
ORIGIN
Query Match      51.0%; Score 14.8; DB 28; Length 49;
Best Local Similarity 57.7%; Pred. No. 3.1e+05;
Matches 15; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 AAAGAUCUUUUUGUAGGCCCAAGG 26
Db 6 AAAGAGACTTCCTGTAAGGCGCAAG 31

RESULT 15
AI224478/c
LOCUS
DEFINITION
  AI224478
  QX06d06.x1 NCI CGAP Lym12 Homo sapiens cDNA clone IMAGE:2000555 3',
  similar to TR:Q23462 Q23462 HYPOTHETICAL 18.0 KD PROTEIN. 1, mRNA
  sequence.
ACCESSION
  AI224478
VERSION
  AI224478.1 GI:3807191
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 55)
  NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
  National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
  Tumor Gene Index
  Unpublished
  Contact: Robert Strausberg, Ph.D.
  Email: cgapbs-remail.nih.gov
  unknown library type
  Trace considered overall poor quality
  Insert Length: 1214 Std Error: 0.00
  Seq primer: -40UP from Gibco
  High quality sequence stop: 1.
  Location/Qualifiers
FEATURES
  source
  1..49
  /organism="Homo sapiens"
  /mol_type="genomic DNA"
  /db_xref="taxon:9606"
  /tissue_type="Carcinoma"
  /cell_type="Epithelial"
  /cell_line="T47D"
  /clone_lib="Genetrapp T47D Human Breast Carcinoma Library"
  /notes="Organ: Breast; Vector: pAMP-1; 3' RACE of total RNA
  from genetrapp pools; shotgun clone in pAMP-1 and used to
  transform DHS-alpha competent bacteria."
BASE COUNT      18 a 11 c 14 g 6 t
ORIGIN

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 07:56:58 ; Search time 50 Seconds
(without alignments)
256.002 Million cell updates/sec

Title: US-09-310-844C-24
Perfect score: 29
Sequence: 1 uaugaucuuuuuuagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 569978 seqs, 220691566 residues

Total number of hits satisfying chosen parameters: 792150

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA:
1: /cgn2_6/prodata/2/ina/5A_COMB.seq.*
2: /cgn2_6/prodata/2/ina/5A_COMB.seq.*
3: /cgn2_6/prodata/2/ina/6A_COMB.seq.*
4: /cgn2_6/prodata/2/ina/6B_COMB.seq.*
5: /cgn2_6/prodata/2/ina/6C_COMB.seq.*
6: /cgn2_6/prodata/2/ina/backfile1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	15.2	52.4	25	3	US-08-943-731-336
C 2	15.2	52.4	33	1	Sequence 336, Appl
C 3	14.8	51.0	35	6	Sequence 5, Appl
C 4	14.8	51.0	36	3	Patent No. 5422260
C 5	14.8	51.0	36	3	Sequence 1, Appl
C 6	14.8	51.0	36	4	Sequence 5, Appl
C 7	14.8	51.0	36	4	Sequence 7, Appl
C 8	14.8	51.0	36	4	Sequence 55, Appl
C 9	14.8	51.0	36	1	Sequence 55, Appl
C 10	14.8	51.0	36	1	Sequence 55, Appl
C 11	14.8	51.0	36	5	Sequence 55, Appl
C 12	14.8	51.0	36	1	Sequence 54, Appl
C 13	14.8	51.0	36	4	Sequence 54, Appl
C 14	14.8	51.0	36	4	Sequence 54, Appl
C 15	14.8	51.0	36	4	Sequence 54, Appl
C 16	14.8	51.0	36	4	Sequence 54, Appl
C 17	13.8	47.6	36	3	Sequence 1059, Ap
C 18	13.8	47.6	36	3	Sequence 3, Appl
C 19	13.8	47.6	36	4	Sequence 3, Appl
C 20	13.8	47.6	36	4	Sequence 639, Appl
C 21	13.8	47.6	36	4	Sequence 11, Appl
C 22	13.6	46.9	47	4	Sequence 39, Appl
C 23	13.6	46.9	47	4	Sequence 2286, Ap
C 24	13.6	46.9	47	4	Sequence 37, Appl
C 25	13.4	46.2	35	4	Sequence 32, Appl
C 26	13.4	46.2	41	1	Sequence 28, Appl
C 27	13.4	46.2	41	2	Sequence 28, Appl
C 28	13.4	46.2	41	3	Sequence 28, Appl

28	13.4	46.2	41	5	PCT-US94-01553A-28	Sequence 28, Appl
29	13.4	46.2	41	5	PCT-US95-10426-28	Sequence 28, Appl
30	13.4	46.2	51	1	US-08-328-152A-11	Sequence 11, Appl
31	13.4	46.2	52	4	US-08-310-463-6	Sequence 6, Appl
32	13.4	46.2	52	4	US-08-842-248A-6	Sequence 6, Appl
33	13.4	46.2	60	3	US-08-478-097A-32	Sequence 32, Appl
34	13.4	46.2	60	4	US-09-496-398-32	Sequence 32, Appl
35	13.2	45.5	19	3	US-08-532-896-53	Sequence 53, Appl
36	13.2	45.5	27	3	US-09-106-182-23	Sequence 17, Appl
37	13.2	45.5	27	3	US-09-106-182-23	Sequence 23, Appl
38	13.2	45.5	27	4	US-09-227-357-4	Sequence 7, Appl
39	13.2	45.5	27	4	US-09-280-839-7	Sequence 7, Appl
40	13.2	45.5	27	4	US-09-411-977-19	Sequence 19, Appl
41	13.2	45.5	27	4	US-09-479-728B-24	Sequence 24, Appl
42	13.2	45.5	27	4	US-09-257-179-4	Sequence 4, Appl
43	13.2	45.5	27	4	US-09-149-476-4	Sequence 4, Appl
44	13.2	45.5	27	4	US-09-288-143-4	Sequence 4, Appl
45	13.2	45.5	27	4	US-09-487-792-26	Sequence 26, Appl

ALIGNMENTS

RESULT 1

US-08-943-731-336/c
; Sequence 336, Application US/08943731
; Patent No. 6265157
; GENERAL INFORMATION:
; APPLICANT: PROCKOP, DARWIN J.
; APPLICANT: SPOTILA, LORETTA D.
; APPLICANT: DELTAS, CONSTANTINOS D.
; APPLICANT: SEREDA, LARISA
; APPLICANT: LARSON, ANDREA W.
; APPLICANT: PACK, MICHAEL
; APPLICANT: COLIGE, ALAIN
; APPLICANT: EARLY, JAMES
; APPLICANT: KORKKO, JARMO
; APPLICANT: ALA-KORKKO, LEENA, et al.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING
; TITLE OF INVENTION: ALTERED TYPE I OR TYPE IX COLLAGEN GENE SEQUENCES
; NUMBER OF SEQUENCES: 666
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PANITH SCHWARZE JACOBS & NADEL, P.C.
; STREET: ONE COMMERCE SQUARE, 2005 MARKET STREET, 22ND
; STREET: FLR.
; CITY: PHILADELPHIA
; STATE: PA
; COUNTRY: USA
; ZIP: 19103-7086
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,731
; FILING DATE: 03-OCT-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/212,322
; FILING DATE: 14-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/803,628
; FILING DATE: 03-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DOYLE LEARY Ph.D., KATHRYN
; REGISTRATION NUMBER: 36,317
; REFERENCE/DOCKET NUMBER: 9598-27
; TELEPHONE: 215-965-1284
; TELEFAX: 215-567-2991
; TELEX: 831-494
; INFORMATION FOR SEQ ID NO: 336:

FILE REFERENCE: 09/440.001
 CURRENT APPLICATION NUMBER: US/09/605,685
 CURRENT FILING DATE: 2000-06-26
 PRIOR APPLICATION NUMBER: 60/108,099
 PRIOR FILING DATE: 1998-11-12
 NUMBER OF SEQ ID NOS: 6
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 1
 LENGTH: 36
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence:
 OTHER INFORMATION: Oligonucleotide primer
 US-09-605-685-1

Query Match 51.0%; Score 14.8; DB 4; Length 36;
 Best Local Similarity 38.5%; Pred. No. 4.4e+02;
 Matches 10; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

QY 1 UAUAUUCUUUUAAGCCCUAGGG 26
 DB 33 TATCAAGCTTTTGCCGCATGG 8

RESULT 6
 US-09-690-146A-5
 Sequence 5, Application US/09690146A
 Patent No. 6485937
 GENERAL INFORMATION:
 APPLICANT: Palhan, Vikas
 APPLICANT: Roeder, Robert
 TITLE OF INVENTION: System for Rapid Generation of Recombinant
 TITLE OF INVENTION: Baculovirus-Based Expression Vectors for Silkworm Larvae
 FILE REFERENCE: 7529/1G164-US1
 CURRENT APPLICATION NUMBER: US/09/690,146A
 CURRENT FILING DATE: 2001-06-01
 PRIOR APPLICATION NUMBER: 60/159,707
 PRIOR FILING DATE: 1999-10-15
 NUMBER OF SEQ ID NOS: 9
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO 5
 LENGTH: 30
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: VP28 Reverse Primer
 US-09-690-146A-5

Query Match 48.3%; Score 14; DB 4; Length 30;
 Best Local Similarity 45.5%; Pred. No. 1e+03;
 Matches 10; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

QY 5 AUUCUUUUUAAGCCCUAGGG 26
 DB 2 ATTAATTTGTAATCCTTAGGG 23

RESULT 7
 US-09-690-146A-7/c
 Sequence 7, Application US/09690146A
 Patent No. 6485937
 GENERAL INFORMATION:
 APPLICANT: Palhan, Vikas
 APPLICANT: Roeder, Robert
 TITLE OF INVENTION: System for Rapid Generation of Recombinant
 TITLE OF INVENTION: Baculovirus-Based Expression Vectors for Silkworm Larvae
 FILE REFERENCE: 7529/1G164-US1
 CURRENT APPLICATION NUMBER: US/09/690,146A
 CURRENT FILING DATE: 2001-06-01
 PRIOR APPLICATION NUMBER: 60/159,707
 PRIOR FILING DATE: 1999-10-15
 NUMBER OF SEQ ID NOS: 9

SOFTWARE: PatentIn version 3.0
 SEQ ID NO 7
 LENGTH: 30
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthesized oligonucleotide
 US-09-690-146A-7

Query Match 48.3%; Score 14; DB 4; Length 30;
 Best Local Similarity 45.5%; Pred. No. 1e+03;
 Matches 10; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

QY 5 AUUCUUUUUAAGCCCUAGGG 26
 DB 29 ATTAATTTGTAATCCTTAGGG 8

RESULT 8
 US-08-049-264C-55
 Sequence 55, Application US/08049264C
 Patent No. 5518901
 GENERAL INFORMATION:
 APPLICANT: Murtagh, James J.
 TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
 TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
 NUMBER OF SEQUENCES: 75
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: NEEDLE & ROSENBERG, P.C.
 STREET: Suite 1200, The Candler Bldg., 127
 STREET: Peachtree Street N.E.
 CITY: Atlanta
 STATE: Georgia
 COUNTRY: USA
 ZIP: 30303
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/049,264C
 FILING DATE:
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Pertyman, David G.
 REGISTRATION NUMBER: 33,438
 REFERENCE/DOCKET NUMBER: 1313.001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (404) 688-0770
 TELEFAX: (404) 688-9880
 INFORMATION FOR SEQ ID NO: 55:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 37 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-08-049-264C-55

Query Match 48.3%; Score 14; DB 1; Length 37;
 Best Local Similarity 40.9%; Pred. No. 1e+03;
 Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

QY 6 UUCUUUUUAAGCCCUAGGG 27
 DB 8 TTTTITTTTAAACCCCGGGG 29

RESULT 9
 US-08-476-562-55
 Sequence 55, Application US/08476562
 Patent No. 5688669

GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION.
TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/476,562
FILING DATE: 08/04/99
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/049,264
FILING DATE: April 19, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1313.004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-476-562-55
Query Match 48.3%; Score 14; DB 1; Length 37;
Best Local Similarity 40.9%; Pred. No. 1e+03;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;
QY 6 UUCUUUUGUAGCCCUAGGGG 27
Db 8 TTTTITTTTAAACCCGGGGG 29
RESULT 10
US-08-479-723A-55
Sequence 55, Application US/08479723A
Patent No. 574306
GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION.
TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION.
TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,723A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 05010.0061
FILING DATE: (404) 688-0770
TELEPHONE: (404) 688-9880
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-08-479-723A-55
Query Match 48.3%; Score 14; DB 1; Length 37;
Best Local Similarity 40.9%; Pred. No. 1e+03;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;
QY 6 UUCUUUUGUAGCCCUAGGGG 27
Db 8 TTTTITTTTAAACCCGGGGG 29
RESULT 11
PCT-US94-04310-55
Sequence 55, Application PC/TUS9404310
GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION.
TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
NUMBER OF SEQUENCES: 74
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04310
FILING DATE: 19-APR-1993
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US94-04310-55
Query Match 48.3%; Score 14; DB 5; Length 37;
Best Local Similarity 40.9%; Pred. No. 1e+03;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;
QY 6 UUCUUUUGUAGCCCUAGGGG 27
Db 8 TTTTITTTTAAACCCGGGGG 29
RESULT 12
US-08-049-264C-54/c
Sequence 54, Application US/08049264C
Patent No. 5518901
GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION.
TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
STREET: Peachtree Street N.E.
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/049,264C
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1313.001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ. ID NO.: 54:
SEQUENCE CHARACTERISTICS:
LENGTH: 44 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-049-264C-54

Query Match 48.3%; Score 14; DB 1; Length 44;
Best Local Similarity 40.9%;
Pred. No. 1.1e+03;
Matches 9; Conservative 8; Mismatches 5; Indels

QY
6 UUCUUUUGUAAGCCCUAGGGG 27
:: :: :: ::
Db
42 TTTTITTTTTAAACCCCGGGGG 21

RESULT 13
US-08-476-562-54/c
; Sequence 54, Application US/08476562
; Patent No. 5688669
; GENERAL INFORMATION:
; APPLICANT: Murtagh, James J.
; TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
; TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
; NUMBER OF SEQUENCES: 75
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG, P.C.
; STREET: Suite 1200, The Candler Bldg., 127
; STREET: Peachtree Street N.E.
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/476,562
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/049,264
; FILING DATE: April 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Perryman, David G.

```

; REGISTRATION NUMBER: 33,438
; REFERENCE/DOCKET NUMBER: 1313.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO. 54:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 44 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-476-562-54

Query Match 48.3%; Score 14; DB 1; Length 44;
Best Local Similarity 40.9%; Pred.No. 1.1e+03;
Matches 9; Conservative 8; Mismatches 5; Indels 0

QY 6 UUCUUUUGUAGCCCUAGGGG 27
..:.....:|||||
Db 42 TTTTITTTTAAACCCGGGGG 21

RESULT 14
US-08-479-723A-54/c
; Sequence 54, Application US/08479723A
; Patent No. 5744366
; GENERAL INFORMATION:
; APPLICANT: Murtagh, James J.
; TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
; SEQUENCING AND CLONING USING EXONUCLEASE
; TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE

```

Qy 6 UUCUUUUUGUAAGCCCUAGGG 27
: : : : :
Db 42 TTTT TTTT TTAACCCCGGGG 21

RESULT 15
PCT-US94-04310-54/c
; Sequence 54, Application PC/TUS9404310
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
; TITLE OF INVENTION: SEQUENCING AND CLONING USING EXONUCLEASE
; NUMBER OF SEQUENCES: 74
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04310
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/049,264
; FILING DATE: 19-APR-1993
; INFORMATION FOR SEQ ID NO: 54:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 44 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US94-04310-54

Query Match 48.3%; Score 14; DB 5; Length 44;
Best Local Similarity 40.9%; Pred. No. 1.1e+03;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Oy 6 UUCUUUUUGUAGCCUAGGG 27
Db 42 TTTTITTTTAAACCGGGGG 21

Search completed: January 30, 2004, 10:15:13
Job time : 53 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 06:19:17 ; Search time 283.333 Seconds
(without alignments)
276.295 Million cell updates/sec

Title: US-09-310-844C-24
Perfect score: 29
Sequence: 1 uauaauuuuuuuuagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 2640686

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_19Jun03.*

1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*
25: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	29	21	AAA70828 Molecular interact
2	29	100.0	42	21	AAA71123 Molecular interact
3	29	100.0	42	21	AAA71131 Molecular interact
4	28	96.6	45	21	AAA70824 Molecular interact
5	28	96.6	46	21	AAA71087 Molecular interact
6	28	96.6	46	21	AAA71096 Molecular interact
7	28	96.6	46	21	AAA71099 Molecular interact
8	28	96.6	46	21	AAA71100 Molecular interact

9	28	96.6	46	21	AAA71104	Molecular interact
10	25.8	89.0	42	21	AAA71113	Molecular interact
11	25.8	89.0	42	21	AAA71118	Molecular interact
12	25.8	89.0	42	21	AAA71126	Molecular interact
13	24.8	85.5	46	21	AAA71085	Molecular interact
14	24.8	85.5	46	21	AAA71103	Molecular interact
15	23.8	82.1	42	21	AAA71114	Molecular interact
16	23.8	82.1	42	21	AAA71119	Molecular interact
17	23.8	82.1	42	21	AAA71127	Molecular interact
18	23.8	82.1	46	21	AAA71094	Molecular interact
19	23.8	82.1	46	21	AAA71110	Molecular interact
20	23.2	80.0	29	21	AAA70829	Molecular interact
21	23.2	80.0	29	21	AAA70830	Molecular interact
22	23.2	80.0	42	21	AAA71115	Molecular interact
23	23.2	80.0	42	21	AAA71116	Molecular interact
24	23.2	80.0	42	21	AAA71120	Molecular interact
25	23.2	80.0	42	21	AAA71121	Molecular interact
26	23.2	80.0	42	21	AAA71128	Molecular interact
27	23.2	80.0	42	21	AAA71129	Molecular interact
28	22.6	77.9	42	21	AAA71124	Molecular interact
29	22.6	77.9	42	21	AAA71132	Molecular interact
30	22.2	76.6	45	21	AAA70825	Molecular interact
31	22.2	76.6	45	21	AAA70826	Molecular interact
32	22.2	76.6	46	21	AAA71088	Molecular interact
33	22.2	76.6	46	21	AAA71089	Molecular interact
34	22.2	76.6	46	21	AAA71090	Molecular interact
35	22.2	76.6	46	21	AAA71105	Molecular interact
36	22.2	76.6	46	21	AAA71106	Molecular interact
37	22.2	76.6	46	21	AAA71107	Molecular interact
38	21.6	74.5	46	21	AAA71093	Molecular interact
39	21.6	74.5	46	21	AAA71095	Molecular interact
40	21.6	74.5	46	21	AAA71109	Molecular interact
41	21.6	74.5	46	21	AAA71111	Molecular interact
42	19.4	66.9	46	21	AAA71084	Molecular interact
43	19.4	66.9	46	21	AAA71098	Molecular interact
44	19.4	66.9	46	21	AAA71102	Molecular interact
45	18.4	63.4	42	21	AAA71117	Molecular interact

ALIGNMENTS

RESULT 1
AAA70828
ID AAA70828 standard; RNA; 29 BP.
XX
AC AAA70828;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #28.
XX
KW Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Homo sapiens.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
PR 12-MAY-1998; 98US-0085092.
XX
(ISIS-) ISIS PHARM INC.
PA
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,

PT used to provide compounds which can be used as pharmacological,
 XX agricultural and industrial compounds -
 PS Claim 235; Page 235; 405pp; English.
 XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of a second ds region; (c) 4
 CC nucleotides forming a first side of an internal loop region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAGUUAUACAGAAAAUUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX Sequence 29 BP; 5 A; 5 C; 7 G; 12 U; 0 other;
 SQ Query Match 100.0%; Score 29; DB 21; Length 29;
 Best Local Similarity 100.0%; Pred. No. 0.0015;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 UAUAGUUCUUUUUGUAGCCCUAGGGGCU 29
 DB 1 UAUAGUUCUUUUUGUAGCCCUAGGGGCU 29
 RESULT 2
 ID AAA71123 standard; DNA; 42 BP.
 AC AAA71123;
 XX 27-APR-2001 (first entry)
 DE Molecular interaction site DNA #129.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS WO9958947-A2.
 PN 18-NOV-1999.
 XX 12-MAY-1999; 95WO-US10361.
 PF 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX (ISIS-) ISIS PHARM INC.
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX WPI; 2000-086439/07.
 DR Identifying compounds which modulate activity of target biomolecules,
 XX used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

PT agricultural and industrial compounds -
 XX Example 7; Figure 125; 405pp; English.
 PS This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAGUUAUACAGAAAAUUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX Sequence 42 BP; 9 A; 6 C; 9 G; 18 T; 0 other;
 SQ Query Match 100.0%; Score 29; DB 21; Length 42;
 Best Local Similarity 58.6%; Pred. No. 0.0016;
 Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;
 QY 1 UAUAGUUCUUUUUGUAGCCCUAGGGGCU 29
 DB 4 TATGATCTTTTGTAGCCCTAGGGGCT 32
 RESULT 3
 ID AAA71131 standard; RNA; 42 BP.
 AC AAA71131;
 XX 27-APR-2001 (first entry)
 DE Molecular interaction site RNA #200.
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX Unidentified.
 OS WO9958947-A2.
 PN 18-NOV-1999.
 XX 12-MAY-1999; 95WO-US10361.
 PF 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX (ISIS-) ISIS PHARM INC.
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX WPI; 2000-086439/07.
 DR Identifying compounds which modulate activity of target biomolecules,
 XX used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -

XX Example 7; Figure 126; 405pp; English.

XX This invention describes a novel method for identifying compounds which

CC modulate the activity of a target biomolecule. The method uses

CC 3-dimensional representations of the biomolecule and a library of

CC compounds and comprises (a) identifying at least one molecular

CC interaction site of the target RNA; (b) generating in silico a virtual

CC library of compounds predicted or calculated to interact with the

CC molecular interaction site; and (c) comparing 3-dimensional (3-D)

CC representations of the target RNA with members of the virtual library of

CC compounds to generate a hierarchy of the compounds ranked in accordance

CC with their respective ability to form physical interactions with the

CC molecular interaction site. The method also describes (1) RNA comprising

CC a joined sequence of at least 24 nucleotides but not more than 70

CC nucleotides and having secondary structure defined by: (a) 3 nucleotides

CC forming a first side of a first double stranded (ds) region; (b) 2

CC nucleotides forming a first side of an internal loop region; (c) 4

CC nucleotides forming a first side of a second ds region; (d) 4 or 5

CC nucleotides forming an end loop region; (e) 4 nucleotides forming a

CC second side of the second ds region; (f) 4 nucleotides forming a

CC side of the internal loop region; and (g) 3 nucleotides forming a second

CC side of the first ds region; (2) a purified and isolated RNA fragment

CC comprising the human sequence UUUACAAUAUUCUAGUUUACAGAAAAUC (II). The

CC methods and products can be used for identifying agents which modulate

CC the activity of biomolecules, particularly RNA. Such agents can be used

CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 9 A; 6 C; 9 G; 18 U; 0 other;

SQ Query Match 100.0%; Score 29; DB 21; Length 42;

Best Local Similarity 100.0%; Pred. No. 0.0016;

Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 UATGAUUCUUUUUUGAAGCCUAGGGGCU 29

DB 4 UAUAGUUCUUUUUUGAAGCCUAGGGGCU 32

RESULT 4

AAA70824

ID AAA70824 standard; RNA; 45 BP.

XX AAA70824;

AC AAA70824;

XX 27-APR-2001 (first entry)

DT Molecular interaction site RNA #24.

DE Modulator; identification; molecular interaction; virtual library; ss.

XX Homo sapiens.

OS WO9958947-A2.

XX 18-NOV-1999.

PD 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

PI WPI; 2000-086439/07.

DR Identifying compounds which modulate activity of target biomolecules,

XX used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -

XX Example 7; Figure 121; 405pp; English.

PS Claim 220; Page 232; 405pp; English.

XX This invention describes a novel method for identifying compounds which

CC modulate the activity of a target biomolecule. The method uses

CC 3-dimensional representations of the biomolecule and a library of

CC compounds and comprises (a) identifying at least one molecular

CC interaction site of the target RNA; (b) generating in silico a virtual

CC library of compounds predicted or calculated to interact with the

CC molecular interaction site; and (c) comparing 3-dimensional (3-D)

CC representations of the target RNA with members of the virtual library of

CC compounds to generate a hierarchy of the compounds ranked in accordance

CC with their respective ability to form physical interactions with the

CC molecular interaction site. The method also describes (1) RNA comprising

CC a joined sequence of at least 24 nucleotides but not more than 70

CC nucleotides and having secondary structure defined by: (a) 3 nucleotides

CC forming a first side of a first double stranded (ds) region; (b) 2

CC nucleotides forming a first side of an internal loop region; (c) 4

CC nucleotides forming a first side of a second ds region; (d) 4 or 5

CC nucleotides forming an end loop region; (e) 4 nucleotides forming a

CC second side of the second ds region; (f) 4 nucleotides forming a

CC side of the internal loop region; and (g) 3 nucleotides forming a second

CC side of the first ds region; (2) a purified and isolated RNA fragment

CC comprising the human sequence UUUACAAUAUUCUAGUUUACAGAAAAUC (II). The

CC methods and products can be used for identifying agents which modulate

CC the activity of biomolecules, particularly RNA. Such agents can be used

CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 45 BP; 11 A; 6 C; 9 G; 19 U; 0 other;

SQ Query Match 96.6%; Score 28; DB 21; Length 45;

Best Local Similarity 100.0%; Pred. No. 0.0045;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 UAUAGUUCUUUUUUGAAGCCUAGGGGC 28

DB 18 UAUAGUUCUUUUUUGAAGCCUAGGGGC 45

RESULT 5

AAA71087

ID AAA71087 standard; DNA; 46 BP.

XX AAA71087;

AC AAA71087;

XX 27-APR-2001 (first entry)

DT Molecular interaction site DNA #110.

DE Modulator; identification; molecular interaction; virtual library; ss.

XX Unidentified.

OS WO9958947-A2.

XX 18-NOV-1999.

PD 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

PI WPI; 2000-086439/07.

DR Identifying compounds which modulate activity of target biomolecules,

XX used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -

XX Example 7; Figure 121; 405pp; English.

```

XX CC This invention describes a novel method for identifying compounds which
XX CC modulate the activity of a target biomolecule. The method uses
XX CC 3-dimensional representations of the biomolecule and a library of
XX CC compounds and comprises (a) identifying at least one molecular
XX CC interaction site of the target RNA; (b) generating in silico a virtual
XX CC library of compounds predicted or calculated to interact with the
XX CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
XX CC representations of the target RNA with members of the virtual library of
XX CC compounds to generate a hierarchy of the compounds ranked in accordance
XX CC with their respective ability to form physical interactions with the
XX CC molecular interaction site. The method also describes (1) RNA comprising
XX CC a joined sequence of at least 24 nucleotides but not more than 70
XX CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
XX CC forming a first side of a first double stranded (ds) region; (b) 2
XX CC nucleotides forming a first side of an internal loop region; (c) 4
XX CC nucleotides forming a first side of a second ds region; (d) 4 or 5
XX CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
XX CC second side of the second ds region; (f) 4 nucleotides forming a second
XX CC side of the internal loop region; and (g) 3 nucleotides forming a second
XX CC side of the first ds region; (2) a purified and isolated RNA fragment
XX CC comprising the human sequence UUUACACAAUUAUCUAGUUAUACAGAAAAUUC (II). The
XX CC methods and products can be used for identifying agents which modulate
XX CC the activity of biomolecules, particularly RNA. Such agents can be used
XX CC as pharmaceutical, agricultural or industrial compounds.
XX SQ Sequence 46 BP; 11 A; 7 C; 9 G; 19 T; 0 other;

Query Match          96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 60.7%; Pred.No. 0.0045;
Matches 17; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY 1 UAUGAUUUUUUUUUAAGCCUAGGGGC 28
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 19 TATGATCTTTTGTAGCCCTAGGGGC 46

RESULT 6
AAA71096
ID AAA71096 standard; DNA; 46 BP.
AC AAA71096;
XX
XX 27-APR-2001 (first entry)
XX
XX Molecular interaction site DNA #119.
XX
XX Modulator; identification; molecular interaction; virtual library; ss.
XX
XX Unidentified.
XX
XX WO9558947-A2.
XX
XX 18-NOV-1999.
XX
XX 12-MAY-1999; 99WO-US10361.
XX
XX 12-MAY-1998; 98US-0076404.
XX
XX 12-MAY-1998; 98US-0085092.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX PI Hofstadler S, McNeil J;
XX
XX WPI; 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
XX PT used to provide compounds which can be used as pharmacological,
XX PT agricultural and industrial compounds -
XX
XX Example 7; Figure 121; 405pp; English.
XX
XX This invention describes a novel method for identifying compounds which

```

```

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAAUUAUCUAGUUAUACAGAAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX SQ Sequence 46 BP; 11 A; 7 C; 9 G; 19 T; 0 other;

Query Match          96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 60.7%; Pred.No. 0.0045;
Matches 17; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY 1 UAUGAUUUUUUUUUAAGCCUAGGGGC 28
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 19 TATGATCTTTTGTAGCCCTAGGGGC 46

RESULT 7
AAA71099
ID AAA71099 standard; DNA; 46 BP.
AC AAA71099;
XX
XX 27-APR-2001 (first entry)
XX
XX Molecular interaction site DNA #122.
XX
XX Modulator; identification; molecular interaction; virtual library; ss.
XX
XX Unidentified.
XX
XX WO9558947-A2.
XX
XX 18-NOV-1999.
XX
XX 12-MAY-1999; 99WO-US10361.
XX
XX 12-MAY-1998; 98US-0076404.
XX
XX 12-MAY-1998; 98US-0085092.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX PI Hofstadler S, McNeil J;
XX
XX WPI; 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
XX PT used to provide compounds which can be used as pharmacological,
XX PT agricultural and industrial compounds -
XX
XX Example 7; Figure 121; 405pp; English.
XX
XX This invention describes a novel method for identifying compounds which

```


CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming an end loop region; (d) 4 or 5
 CC nucleotides forming a first side of a second ds region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAUCUUAUACAGAAAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.

XX
 XX
 SQ Sequence 46 BP; 11 A; 7 C; 9 G; 19 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
 Best Local Similarity 100.0%; Pred. No. 0.0045;
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 UAUGAUCUUUUUUAAGCCCUAGGGGC 28
 |||||
 DB 19 UAUGAUCUUUUUUAAGCCCUAGGGGC 46
 |||||

RESULT 10
 AAA71113
 ID AAA71113 standard; RNA; 42 BP.
 XX
 AC AAA71113;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site RNA #189.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX
 DR WPI; 2000-086439/07.
 XX
 PT Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 122; 405pp; English.
 XX
 CC This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular

CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming an end loop region; (d) 4 or 5
 CC nucleotides forming a first side of a second ds region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUAUCUUAUACAGAAAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.

XX
 XX
 SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;

Query Match 89.0%; Score 25.8; DB 21; Length 42;
 Best Local Similarity 93.1%; Pred. No. 0.044;
 Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 UAUGAUCUUUUUUAAGCCCUAGGGGC 29
 |||||
 DB 4 UAAGAUUCUUUUUUAAGCCCUACGGGC 32
 |||||

RESULT 11
 AAA71118
 ID AAA71118 standard; DNA; 42 BP.
 XX
 AC AAA71118;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site DNA #124.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX
 DR WPI; 2000-086439/07.
 XX
 PT Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 125; 405pp; English.
 XX
 CC This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual

CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACAAUAUUCUUAUACAGAAAUC (11). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 46 BP; 12 A; 7 C; 9 G; 18 T; 0 other;

Query Match 85.5%; Score 24.8; DB 21; Length 46;
 Best Local Similarity 57.1%; Pred. No. 0.12;
 Matches 16; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 1 UAUAUUCUUUUUGUAAGCCCUAGGGC 28
 |||||:|||||:|||||:|||||
 DB 19 TAAGATCTTTTGTAGCCCTACGGC 46

RESULT 14
 AAA71103
 ID AAA71103 standard; RNA; 46 BP.
 AC AAA71103;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site RNA #179.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 XX
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 PI WPI; 2000-086439/07.
 DR
 XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 122; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of

CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACAAUAUUCUUAUACAGAAAUC (11). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 46 BP; 12 A; 7 C; 9 G; 18 U; 0 other;

Query Match 85.5%; Score 24.8; DB 21; Length 46;
 Best Local Similarity 92.9%; Pred. No. 0.12;
 Matches 26; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 UAUAUUCUUUUUGUAAGCCCUAGGGC 28
 |||||:|||||:|||||:|||||
 DB 19 UAAGAUCUUUUUGUAAGCCCUAGGGC 46

RESULT 15
 AAA71114
 ID AAA71114 standard; RNA; 42 BP.
 AC AAA71114;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site RNA #190.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 XX
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 PI WPI; 2000-086439/07.
 DR
 XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 122; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance

with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUACACAAUACUUGUUACAGAAAUC (11). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Sequence 42 BP; 11 A; 8 C; 7 G; 16 U; 0 other;
SQ

Query Match 82.1%; Score 23.8; DB 21; Length 42;
Best Local Similarity 92.6%; Pred. No. 0.35;
Matches 25; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 UAUGAUCUJUJUUGUAGCCUAGGG 27
|||
Db 4 UAAGAUCUJUJUUGUAGCCUAGGC 30

Search completed: January 30, 2004, 08:22:12
Job time : 283.667 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 06:57:47 ; Search time 575.333 Seconds
(without alignments)
2062.073 Million cell updates/sec

Title: US-09-310-844C-24
Perfect score: 29
Sequence: 1 uaugauuuuuuuuagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 20454813386 residues

Total number of hits satisfying chosen parameters: 1427288

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:*
1: gb.ba:*
2: gb.htg:*
3: gb.in:*
4: gb.om:*
5: gb.ov:*
6: gb.pat:*
7: gb.ph:*
8: gb.pl:*
9: gb.pr:*
10: gb.pro:*
11: gb.sts:*
12: gb.sy:*
13: gb.un:*
14: gb.vi:*
15: em.ba:*
16: em.fun:*
17: em.hum:*
18: em.in:*
19: em.mu:*
20: em.om:*
21: em.or:*
22: em.ov:*
23: em.pat:*
24: em.ph:*
25: em.pl:*
26: em.ro:*
27: em.sts:*
28: em.un:*
29: em.vi:*
30: em.htg.hum:*
31: em.htg.in:*
32: em.htg.other:*
33: em.htg.mus:*
34: em.htg.pln:*
35: em.htg.rat:*
36: em.htg.mam:*
37: em.htg.vrt:*
38: em.sy:*
39: em.htgc.hum:*
40: em.htgc.mus:*
41: em.htgc.other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
C 1	15.4	53.1	41	6	AX514720	AX514720 Sequence
C 2	15.4	53.1	41	6	AX520728	AX520728 Sequence
C 3	15.2	52.4	33	6	AF020509	AF020509 Sequence
C 4	15	51.7	40	6	E49126	E49126 Novel G pro
C 5	15	51.7	40	6	E50836	E50836 Novel G pro
C 6	14.8	51.0	35	6	I08597	I08597 Sequence 12
C 7	14.8	51.0	36	6	AR142180	AR142180 Sequence
C 8	14.8	51.0	43	6	AX483394	AX483394 Sequence
C 9	14.6	50.3	51	6	AX115517	AX115517 Sequence
C 10	14.6	50.3	51	10	AF328713	AF328713 Mus muscu
C 11	14.6	50.3	63	9	S63972	S63972 IGH (CDR3 r
C 12	14.6	50.3	65	6	AX484927	AX484927 Sequence
C 13	14.4	49.7	25	6	AX042583	AX042583 Sequence
C 14	14.4	49.7	25	6	AX043280	AX043280 Sequence
C 15	14.2	49.0	35	6	AX298174	AX298174 Sequence
C 16	14.2	49.0	45	6	I04390	I04390 Sequence 25
C 17	14.2	49.0	56	6	AX247478	AX247478 Sequence
C 18	14	48.3	30	6	AR256804	AR256804 Sequence
C 19	14	48.3	30	6	AR256806	AR256806 Sequence
C 20	14	48.3	30	6	AX113961	AX113961 Sequence
C 21	14	48.3	30	6	AX113963	AX113963 Sequence
C 22	14	48.3	37	6	AR003420	AR003420 Sequence
C 23	14	48.3	37	6	AX555864	AX555864 Sequence
C 24	14	48.3	37	6	AX555865	AX555865 Sequence
C 25	14	48.3	37	6	I21209	I21209 Sequence 55
C 26	14	48.3	37	6	I74476	I74476 Sequence 55
C 27	14	48.3	44	6	AR003419	AR003419 Sequence 54
C 28	14	48.3	44	6	I21208	I21208 Sequence 54
C 29	14	48.3	44	6	I74475	I74475 Sequence 54
C 30	14	48.3	60	6	AX676039	AX676039 Sequence
C 31	14	48.3	62	6	BD034932	BD034932 Sequence
C 32	13.8	47.6	25	6	AX527257	AX527257 Sequence
C 33	13.8	47.6	31	6	AX426018	AX426018 Sequence
C 34	13.8	47.6	36	6	AR142182	AR142182 Sequence
C 35	13.8	47.6	42	6	AX017119	AX017119 Sequence
C 36	13.8	47.6	42	6	AX017120	AX017120 Sequence
C 37	13.8	47.6	47	6	AR288904	AR288904 Sequence
C 38	13.8	47.6	50	6	AX157596	AX157596 Sequence
C 39	13.8	47.6	50	6	AX164867	AX164867 Sequence
C 40	13.8	47.6	50	6	AX164868	AX164868 Sequence
C 41	13.8	47.6	59	10	CRUDELNF	N27128 Chinese Ham
C 42	13.8	47.6	65	6	AX482858	AX482858 Sequence
C 43	13.6	46.9	25	6	AX610026	AX610026 Sequence
C 44	13.6	46.9	25	6	AX610027	AX610027 Sequence
C 45	13.6	46.9	31	6	AX223502	AX223502 Sequence

ALIGNMENTS

RESULT 1
AX514720/c AX514720 41 bp DNA linear PAT 05-OCT-2002
LOCUS Sequence 918 from Patent WO02052044.
DEFINITION AX514720
ACCESSION AX514720
VERSION AX514720.1 GI:23561343
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Nakamura.Y., Sekine.A., Iida.A. and Saito.S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 918 04-JUL-2002;

Pred. No. is the number of results predicted by chance to have a

```

FEATURES             Riken (JP)
source
  Location/Qualifiers
    1..41
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT          12 a 10 c 10 g 8 t 1 others
ORIGIN
Query Match
Best Local Similarity 53.1%; Score 15.4; DB 6; Length 41;
Matches 13; Conservative 6; Mismatches 6; Indels 0; Gaps 0;
QY 4 GAUUCUUUUGUAGCCCUAGGGGC 28
Db 41 GATTCACCTTTGCAAGCCCTCGGAC 17

RESULT 2
LOCUS AX520728/c 41 bp DNA linear PAT 05-OCT-2002
DEFINITION Sequence 6926 from Patent WO2052044.
ACCESSION AX520728
VERSION AX520728.1 GI:23571381
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Nakamura,Y., Sekine,A., Iida,A. and Saito,S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 6926 04-JUL-2002;
Riken (JP)
FEATURES
source
  Location/Qualifiers
    1..41
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT          12 a 10 c 10 g 8 t 1 others
ORIGIN
Query Match
Best Local Similarity 53.1%; Score 15.4; DB 6; Length 41;
Matches 13; Conservative 6; Mismatches 6; Indels 0; Gaps 0;
QY 4 GAUUCUUUUGUAGCCCUAGGGGC 28
Db 41 GATTCACCTTTGCAAGCCCTCGGAC 17

RESULT 3
LOCUS AR020509/c 33 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 5 from patent US 5789171.
ACCESSION AR020509
VERSION AR020509.1 GI:3975124
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Smeltzer,M.S
TITLE Use of cna, fnba, fnbb, and hlb, gene probes for the
JOURNAL strain-specific identification of Staphylococcus aureus
PATENT: US 5789171-A 5 04-AUG-1998;
FEATURES
source
  Location/Qualifiers
    1..33
    /organism="unknown"
BASE COUNT          12 a 8 c 7 g 6 t
ORIGIN
Query Match
Best Local Similarity 52.4%; Score 15.2; DB 6; Length 33;
Matches 13; Conservative 6; Mismatches 6; Indels 0; Gaps 0;
QY 4 GAUUCUUUUGUAGCCCUAGGGGC 28
Db 41 GATTCACCTTTGCAAGCCCTCGGAC 17

Best Local Similarity 39.3%; Pred. No. 4.6e+04;
Matches 11; Conservative 9; Mismatches 8; Indels 0; Gaps 0;
QY 2 AUGAUUUUUUUUUAAGCCCUAGGGCU 29
Db 32 ATGATTGTTTATAGTAATTTCCCGGGCT 5

RESULT 4
LOCUS E49126/c 40 bp DNA linear PAT 31-JAN-2002
DEFINITION Novel G protein-coupled receptor protein.
ACCESSION E49126
VERSION E49126.1 GI:18629263
KEYWORDS JP 2001029083-A/4.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Takasaki,A., Matsumoto,M., Sugimoto,T., Kamahara,M. and Saito,S.
TITLE Novel G protein-coupled receptor protein
JOURNAL Patent: JP 2001029083-A 4 06-FEB-2001;
YAMANOUCHI PHARMACEUT CO LTD
COMMENT OS Homo sapiens (human)
PN JP 2001029083-A/4
PD 06-FEB-2001
PF 23-JUL-1999 JP 1999209918
PI PI ATSUSHI TAKASAKI,MITSUYUKI MATSUMOTO,TAKASHI SUGIMOTO, PI
MASAZUMI KAMAHARA,
PI SATOSHI SAITO
PC C12N15/09,A61K38/00,A61K39/395,A61K39/395,A61K45/00,A61P25/04,
PC A61P25/16,
PC A61P25/18,C07K14/705,C12N5/10,C12P21/02,C12P21/08,C12Q1/69, PC
G01N33/15,
PC G01N33/50,G01N33/53,G01N33/566,C12N15/00,A61K37/02,C12N5/00 CC

FH Key Location/Qualifiers
FT source 1..40
/organism="Homo sapiens"
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT          10 a 8 c 4 g 18 t
ORIGIN
Query Match
Best Local Similarity 51.7%; Score 15; DB 6; Length 40;
Matches 11; Conservative 7; Mismatches 5; Indels 0; Gaps 0;
QY 1 UAUGAUUUUUUUUUAAGCCCUA 23
Db 35 TATGATTCTTATAGAAAGTCCAA 13

RESULT 5
LOCUS E50836/c 40 bp DNA linear PAT 31-JAN-2002
DEFINITION Novel G protein-coupled receptor.
ACCESSION E50836
VERSION E50836.1 GI:18633541
KEYWORDS JP 2001054389-A/4.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Takasaki,A., Matsumoto,M., Sugimoto,T., Kamahara,M. and Saito,S.
TITLE Novel G protein-coupled receptor
JOURNAL Patent: JP 2001054389-A 4 27-FEB-2001;

```

```

COMMENT
YAMANOUCHI PHARMACEUT CO LTD
OS Homo sapiens (human)
PN JP 2001054389-A/4
PD 27-FEB-2001
PF 17-AUG-1999 JP 1999230777
PI ATSUSHI TAKASAKI,MITSUYUKI MATSUMOTO,TAKASHI SUGIMOTO, PI
MASAZUMI KAWAHARA,
PI SATOSHI SAITO
PC C12N15/09,C07K14/705,C07K16/28,C12N1/15,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,G01N33/15,G01N33/50//C12P21/08,(C12P21/02,C12R1:91),
PC C12N15/00,
CC C12N5/00
FH Key Location/Qualifiers
FT source 1..40
FT /organism="Homo sapiens (human)".

FEATURES
source
Location/Qualifiers
1..40
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606" 18 t

BASE COUNT
10 a 8 c 4 g 18 t
ORIGIN

Query Match 51.7%; Score 15; DB 6; Length 40;
Best Local Similarity 47.8%; Pred. No. 5.7e+04;
Matches 11; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

Qy 1 UAUGAUUUUUUUUAAGCCCUA 23
Db 35 TATGATCTTATAGAAAGTCAA 13

RESULT 6
I08597/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Unkown.
Unclassified.
REFERENCE
1 (bases 1 to 35)
AUTHORS
Kaufman,R.J., Pittman,D.D. and Toole,J.J.J.
TITLE
NOVEL PROCOAGULANT PROTEINS
JOURNAL
Patent: WO 8707144-A 12-03-DEC-1987;
FEATURES
source
Location/Qualifiers
1..35
/organism="unknown"
BASE COUNT 18 a 8 c 5 g 4 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 35;
Best Local Similarity 42.3%; Pred. No. 7.1e+04;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

Qy 4 GAUUCUUUUUAAGCCCUAGGGGCU 29
Db 35 GTTTCCTTTGAAGCTTTGGGGCT 10

RESULT 7
AR142180/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Unkown.
Unkown.

REFERENCE
1 (bases 1 to 36)
AUTHORS
Seman,I.
TITLE
Method for the determination of homocysteine
JOURNAL
Patent: US 6174696-A 1 16-JAN-2001;
FEATURES
source
Location/Qualifiers
1..36
/organism="unknown"
BASE COUNT 12 a 7 c 9 g 8 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 36;
Best Local Similarity 38.5%; Pred. No. 7e+04;
Matches 10; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

Qy 1 UAUGAUUUUUUUUAAGCCCUAGGG 26
Db 33 TATCAAGCTTTTGTCCGCATATGG 8

RESULT 8
AX483394/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Candida albicans
Candida albicans
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE
1
AUTHORS
Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlser,K.L.
TITLE
Gene disruption methodologies for drug target discovery
JOURNAL
Patent: WO 02053728-A 694 11-JUL-2002;
Elitra Pharmaceuticals, Inc. (US)
FEATURES
source
Location/Qualifiers
1..43
/organism="Candida albicans"
/mol_type="genomic DNA"
/db_xref="taxon:5476"
BASE COUNT 16 a 7 c 4 g 16 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 43;
Best Local Similarity 38.9%; Pred. No. 7e+04;
Matches 7; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 1 UAUGAUUUUUUUUAAG 18
Db 23 TATGAATCTTTTGTAG 6

RESULT 9
AX115517
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS
Picoult-Newburg,I. and Pohl,M.
TITLE
Genotyping reagents, kits and methods of use thereof
JOURNAL
Patent: WO 0129262-A 640 26-APR-2001;
Orchid Biosciences, Inc. (US)
FEATURES
source
Location/Qualifiers
1..51
/organism="Homo sapiens"
/mol_type="genomic DNA"

```



```

AX042583
LOCUS AX042583 25 bp DNA linear PAT 23-NOV-2000
DEFINITION Sequence 149 from Patent WO0065088.
ACCESSION AX042583
VERSION AX042583.1 GI:11341191
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1 Ulfendahl, P.J. and Wong, K.C.
  AUTHORS
  TITLE Primers for identifying typing or classifying nucleic acids
  JOURNAL Patent: WO 0065088-A 149 02-NOV-2000;
  Amersham Pharmacia Biotech AB (SE)
FEATURES
  source
    1. .25
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="DQ41 Homozygote primer sequence"
  BASE COUNT 3 a 3 c 5 g 14 t
  ORIGIN
    Query Match 49.7%; Score 14.4; DB 6; Length 25;
    Best Local Similarity 33.3%; Pred. No. 1.1e+05;
    Matches 8; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

QY 6 UUCUUUUUGUAGCCUAGGGGU 29
Db 2 TTTTITTTTATGACTGGGGACT 25

RESULT 14
AX043280
LOCUS AX043280 25 bp DNA linear PAT 23-NOV-2000
DEFINITION Sequence 846 from Patent WO0065088.
ACCESSION AX043280
VERSION AX043280.1 GI:11341888
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1 Ulfendahl, P.J. and Wong, K.C.
  AUTHORS
  TITLE Primers for identifying typing or classifying nucleic acids
  JOURNAL Patent: WO 0065088-A 846 02-NOV-2000;
  Amersham Pharmacia Biotech AB (SE)
FEATURES
  source
    1. .25
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="DQ41 Heterozygote Primer Sequence"
  BASE COUNT 3 a 3 c 5 g 14 t
  ORIGIN
    Query Match 49.7%; Score 14.4; DB 6; Length 25;
    Best Local Similarity 33.3%; Pred. No. 1.1e+05;
    Matches 8; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

QY 6 UUCUUUUUGUAGCCUAGGGGU 29
Db 2 TTTTITTTTATGACTGGGGACT 25

RESULT 15
AX298174/c
LOCUS AX298174 35 bp DNA linear PAT 26-NOV-2001
DEFINITION Sequence 20 from Patent WO0183788.
ACCESSION AX298174
VERSION AX298174.1 GI:17128241
KEYWORDS
SOURCE synthetic construct

```

```

ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1 Heitz, T., Dhondt, S., Geoffroy, P., Legrand, M. and Gouzerh, G.
  AUTHORS
  TITLE Plant pla2 polypeptides involved in plant defence reaction,
  polynucleotides encoding said polypeptides and transformed plants
  containing them
  JOURNAL Patent: WO 0183788-A 20 08-NOV-2001;
  Rhobio (FR)
FEATURES
  source
    Location/Qualifiers
    1. .35
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="Oligonucleotide amorce NtPar3pGEX sens"
  BASE COUNT 14 a 5 c 10 g 6 t
  ORIGIN
    Query Match 49.0%; Score 14.2; DB 6; Length 35;
    Best Local Similarity 40.7%; Pred. No. 1.3e+05;
    Matches 11; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 AUGAUUUUUUUGAAGCCUAGGGGC 28
Db 27 ATCTTTTCCTTTGGTAACCTCTAGAGTC 1

Search completed: January 30, 2004, 08:51:23
Job time : 579.333 secs

```


Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0115 row: L column: 20
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 46.
Location/Qualifiers
1. 46
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0115L20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, P-"
/clone_lib="Mouse 10kb plasmid UGCM library"
/note="vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 14 a 6 c 13 g 13 t
ORIGIN
Query Match 44.8%; Score 13; DB 28; Length 46;
Best Local Similarity 50.0%; Pred. No. 1.5e+04;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 4 GAUNCUUNGUAGC 19
DB 8 GATACCTTAAGTAAGC 23
RESULT 2
BH759592 70 bp DNA linear GSS 12-MAR-2002
DEFINITION KG05236-3-prime Drosophila melanogaster P{SUPOR-P} P element insertion lines Drosophila melanogaster genomic sequence recovered from 3' end of P element, genomic survey sequence.
ACCESSION BH759592 GI:19352831
VERSION BH759592
KEYWORDS GSS.
SOURCE Drosophila melanogaster (fruit fly)
ORGANISM Drosophila melanogaster
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.
1 (bases 1 to 70)
REFERENCE Lewis,R., Hoskins,R., Liao,G., Mozdzen,N., Tsang,G., He,Y., Karpen ,G., Beilen,H., Rubin,G. and Spradling,A.
The Berkeley Drosophila Genome Project Gene Disruption Project Unpublished
CONTACT: Gerald Rubin
Berkeley Drosophila Genome Project
University of California, Berkeley
LSA Building Berkeley, CA 94720-3200, USA
Fax: 5106439947
Email: gerry@fruitfly.berkeley.edu
Sequence recovery method was inverse PCR.

Sequence orientation is forward strand relative to 5' end of P element
The P element insertion position is base 1 in the 70 bases. This insertion position refers to the first base of the 8 base target recognition sequence.
Class: transposon-tagged.
Location/Qualifiers
1. 70
/organism="Drosophila melanogaster"
/mol_type="genomic DNA"
/db_xref="taxon:7227"
/clone_lib="Drosophila melanogaster P{SUPOR-P} P element insertion lines"
/note="Inverse PCR was performed on Drosophila melanogaster strains each of which contains one or more P{SUPOR-P} P-element transposon insertion. The resultant fragment for each strain was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://www.fruitfly.org/about/methods/inverse.pcr.html."

BASE COUNT 20 a 11 c 9 g 30 t
ORIGIN
Query Match 44.1%; Score 12.8; DB 28; Length 70;
Best Local Similarity 42.9%; Pred. No. 2.1e+04;
Matches 9; Conservative 5; Mismatches 7; Indels 0; Gaps 0;
QY 5 AUNCUUNGUAGCCNANG 25
DB 15 ATACTTTATTATCCCAAG 35
RESULT 3
AA700959/c
LOCUS AA700959
DEFINITION zfb7d10.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone IMAGE:383923 3' similar to TR:P79324 P79324 RIBOSOMAL PROTEIN L15
AA700959 52 bp mRNA linear EST 19-DEC-1997
zfb7d10.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone IMAGE:383923 3' similar to TR:P79324 P79324 RIBOSOMAL PROTEIN L15
AA700959
,, mRNA sequence.
ACCESSION AA700959.1 GI:2704124
VERSION AA700959.1
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 52)
REFERENCE Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S., Krizman,D., Kucaba,T., Lacy,M., Lennon,G., Marra,M., Martin ,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F., Theising,B., White,Y., Wylie,T., Waterston,R. and Wilson,R.
WashU-NCI human EST Project Unpublished
CONTACT: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.
Trace considered overall poor quality
Possible reversed clone: similarity on wrong strand
Seq primer: -40m3 fwd. ET from Amersham
High quality sequence stop: 1.
Location/Qualifiers
1. 52
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:1292180"
/db_xref="taxon:9606"
/clone="IMAGE:383923"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares pineal_gland_N3HPG"

/note="Organ: kidney; Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP_kids was prepared, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (cloneIDs 1323912-1325831, 1471368-1472903 and 1492104-1493355). Subtraction by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 20 a 24 c 6 g 20 t
 ORIGIN
 Query Match 40.7%; Score 11.8; DB 9; Length 70;
 Best Local Similarity 47.4%; Pred. No. 7.3e+04;
 Matches 9; Conservative 4; Mismatches 6; Indels 0; Gaps 0;
 QY 5 AUNCUUNNGUAGCCCA 23
 Db 46 ATTCTTTAAGCAAGCCAGA 64

RESULT 11
 BH216023/c
 LOCUS
 DEFINITION 70 bp DNA linear GSS 08-NOV-2001
 1006039G04.2EL.y1 1006 - RescueMu Grid G Zea mays genomic, genomic survey sequence.
 ACCESSION BH216023
 VERSION BH216023.1 GI:16806681
 KEYWORDS GSS.
 SOURCE Zea mays
 ORGANISM Zea mays
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.
 1 (bases 1 to 70)

REFERENCE
 AUTHORS Walbot,V.
 TITLE Maize genomic sequences found using engineered RescueMu transposon
 JOURNAL Unpublished
 COMMENT Contact: Walbot V
 Department of Biological Sciences
 Stanford University
 855 California Ave, Palo Alto, CA 94304, USA
 Tel: 650 723 2227
 Fax: 650 725 8221
 Email: walbot@stanford.edu
 Possible ligation site of ends cut by 2 different endonucleases.
 Reverse complemented post-ligation sequence from source sequence.
 Plate: 1006039 row: 43
 Class: transposon-tagged.

FEATURES
 source
 1..70
 /organism="Zea mays"
 /mol_type="genomic DNA"
 /cultur="mixed background W23/Al88/B73"
 /db_xref="taxon:4577"
 /tissue_type="leaf"
 /dev_stage="adult"
 /lab_host="DH10B"
 /clone_lib="1006 - RescueMu Grid G"
 /note="Organ: leaf; Vector: RescueMu (engineered from pBlueScript backbone); Site 1: BamHI; Site 2: BglII; RescueMu is a 4.9 kb, modified maize mu transposon designed to allow plasmid rescue from total genomic DNA. Mu elements insert preferentially into transcription units. For more information on RescueMu, go to the web site 'www.zmdb.iastate.edu' and follow the links for 'RescueMu', 'Grid G' was grown at Stanford in 2000. DNA was extracted from leaf punches, double digested using BamHI and BglII, and ligated to form circular plasmids. DH10B cells were transformed and then screened on LB plates with ampicillin."
 BASE COUNT 20 a 16 c 18 g 16 t

ORIGIN

Query Match 40.7%; Score 11.8; DB 28; Length 70;
 Best Local Similarity 50.0%; Pred. No. 7.3e+04;
 Matches 9; Conservative 4; Mismatches 5; Indels 0; Gaps 0;
 QY 4 GAUNCUUNNGUAGCCCA 21
 Db 70 GATCTTTTATAGGAGGCC 53

RESULT 12
 U44334
 LOCUS
 DEFINITION 49 bp mRNA linear EST 03-APR-1996
 ENU44334 Aspergillus nidulans cleistothecium Emericella nidulans cDNA clone SE0762, mRNA sequence.
 ACCESSION U44334
 VERSION U44334.1 GI:1244997
 KEYWORDS EST.
 SOURCE Emericella nidulans (anamorph: Aspergillus nidulans)

ORGANISM Emericella nidulans
 Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes; Eurotiales; Trichocomaceae; Emericella.
 1 (bases 1 to 49)
 REFERENCE
 AUTHORS Lee,D., Lee,S., Hwang,H., Kim,J. and Chae,K.
 TITLE Quantitative analysis of gene expression in sexual structures of Aspergillus nidulans by sequencing of 3'-directed cDNA clones
 JOURNAL FEMS Microbiol. Lett. 138 (1), 71-76 (1996)
 MEDLINE 96236220
 PUBMED 8674973

COMMENT Contact: Keon-Sang Chae
 Chonbuk National University
 Chonju, 561-756, S. Korea
 Tel: +82-652-70-3340
 Fax: +82-652-70-3345
 Email: chae@chonbukns.chonbuk.ac.kr.

FEATURES

source
 1..49
 /organism="Emericella nidulans"
 /mol_type="mRNA"
 /strain="FGSC4"
 /db_xref="taxon:162425"
 /clone="SE0762"
 /tissue_type="cleistothecium"
 /cell_type="Hull cell"
 /dev_stage="sexual"
 /clone_lib="Aspergillus nidulans cleistothecium"
 /note="3'-directed cDNA clones; single-pass sequencing"
 BASE COUNT 11 a 13 c 10 g 15 t

ORIGIN
 Query Match 40.0%; Score 11.6; DB 14; Length 49;
 Best Local Similarity 37.5%; Pred. No. 8.4e+04;
 Matches 9; Conservative 5; Mismatches 10; Indels 0; Gaps 0;
 QY 4 GAUNCUUNNGUAGCCCA 27
 Db 21 GATCTTTTATAGGAGGCC 44

RESULT 13
 AI584456/c
 LOCUS
 DEFINITION 58 bp mRNA linear EST 07-JUN-2001
 fb9h12.x1 Zebrafish Washu MPING EST Danio rerio cDNA clone IMAGE:3719495 3' similar to SW:TRF1_SALSA P80426 SEROTRANSFERRIN I PRECURSOR ;, mRNA sequence.
 ACCESSION AI584456
 VERSION AI584456.1 GI:4570353
 KEYWORDS EST.
 SOURCE Danio rerio (zebrafish)
 ORGANISM Danio rerio
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes


```

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 32)
Chen,H., Chrast,R., Rossier,C., Morris,M.A., Lalioti,M.D. and
Antonarakis,S.E.
Cloning of 559 potential exons of genes of human chromosome 21 by
exon trapping
Genome Res. 6 (8), 747-760 (1996)
97011340
8858350
2 (bases 1 to 32)
Chen,H.M., Rossier,C., Chrast,R. and Antonarakis,S.B.
Cloning of trapped exons from human chromosome 21
Unpublished
3 (bases 1 to 32)
Antonarakis,S.E.
Direct Submission
Submitted (17-MAR-1995) Stylianos E. Antonarakis, Division of
Medical Genetics, University and Cantonal Hospital of Geneva, CMU,
1 rue Michel-Servet, 1211 Geneva, SWITZERLAND
Location/Qualifiers
1..32
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="21"
1..32
/note="trapped exon"
6 a 11 c 5 g 9 t 1 others
BASE COUNT
ORIGIN
exon
Query Match 39.3%; Score 11.4; DB 29; Length 32;
Best Local Similarity 47.1%; Pred. No. 9.6e+04;
Matches 8; Conservative 4; Mismatches 5; Indels 0; Gaps
QY 4 GAUNCUUUNNGUAGCC 20
Db 31 GATACITTCANCAAGCC 15

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 08:51:33 ; Search time 176 Seconds
(without alignments)
600.524 Million cell updates/sec

Title: US-09-310-844C-23

Perfect score: 29
Sequence: 1 mngauncuunnguagccnangn 29

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2434939 seqs, 1822278265 residues

Total number of hits satisfying chosen parameters: 1462844

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications NA:

- 1: /cgn2_6/prodata/2/pubpna/US07_PUBCOMB.seq:
- 2: /cgn2_6/prodata/2/pubpna/PCT_NEW_PUB.seq:
- 3: /cgn2_6/prodata/2/pubpna/US06_NEW_PUB.seq:
- 4: /cgn2_6/prodata/2/pubpna/US06_PUBCOMB.seq:
- 5: /cgn2_6/prodata/2/pubpna/US07_NEW_PUB.seq:
- 6: /cgn2_6/prodata/2/pubpna/PCTUS_PUBCOMB.seq:
- 7: /cgn2_6/prodata/2/pubpna/US08_NEW_PUB.seq:
- 8: /cgn2_6/prodata/2/pubpna/US08_PUBCOMB.seq:
- 9: /cgn2_6/prodata/2/pubpna/US09A_PUBCOMB.seq:
- 10: /cgn2_6/prodata/2/pubpna/US09B_PUBCOMB.seq:
- 11: /cgn2_6/prodata/2/pubpna/US09C_PUBCOMB.seq:
- 12: /cgn2_6/prodata/2/pubpna/US09_NEW_PUB.seq:
- 13: /cgn2_6/prodata/2/pubpna/US09_NEW_PUB.seq:
- 14: /cgn2_6/prodata/2/pubpna/US10A_PUBCOMB.seq:
- 15: /cgn2_6/prodata/2/pubpna/US10B_PUBCOMB.seq:
- 16: /cgn2_6/prodata/2/pubpna/US10_NEW_PUB.seq:
- 17: /cgn2_6/prodata/2/pubpna/US60_NEW_PUB.seq:
- 18: /cgn2_6/prodata/2/pubpna/US60_PUBCOMB.seq:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	12.8	44.1	68	8	US-08-781-986A-2762 Sequence 2762, Ap
2	12.4	42.8	60	13	US-09-908-975-18725 Sequence 18725, A
3	12.4	42.8	65	13	US-09-908-975-2848 Sequence 2848, Ap
4	12.2	42.1	50	12	US-10-131-827-464 Sequence 464, App
5	12.2	42.1	60	13	US-09-908-975-9828 Sequence 9828, Ap
6	12.2	42.1	60	13	US-09-908-975-12187 Sequence 12187, A
7	12.2	42.1	60	13	US-09-908-975-15109 Sequence 15109, A
8	12.2	42.1	60	13	US-09-908-975-18934 Sequence 18934, A
9	11.8	40.7	25	15	US-10-098-263B-76444 Sequence 76444, A
10	11.8	40.7	47	10	US-09-230-526A-35 Sequence 35, Appl
11	11.8	40.7	60	13	US-09-908-975-15914 Sequence 15914, A
12	11.8	40.7	60	13	US-09-908-975-17626 Sequence 17626, A
13	11.8	40.7	65	13	US-09-908-975-1254 Sequence 1254, Ap
14	11.8	40.7	65	13	US-09-908-975-30297 Sequence 30297, A
15	11.8	40.7	65	13	US-10-032-585-316 Sequence 316, App

16	11.6	40.0	24	11	US-09-964-895-27 Sequence 27, Appl
17	11.6	40.0	24	13	US-10-059-152-26 Sequence 26, Appl
C 18	11.6	40.0	31	11	US-09-848-754A-6937 Sequence 6937, Ap
C 19	11.6	40.0	31	11	US-09-848-754A-7188 Sequence 7188, Ap
C 20	11.6	40.0	31	11	US-09-848-754A-7495 Sequence 7495, Ap
C 21	11.6	40.0	31	11	US-09-740-332-6638 Sequence 6638, Ap
C 22	11.6	40.0	31	11	US-09-740-332-9154 Sequence 9154, Ap
C 23	11.6	40.0	31	13	US-09-817-879-6639 Sequence 6639, Ap
C 24	11.6	40.0	31	13	US-09-817-879-9154 Sequence 9154, Ap
C 25	11.6	40.0	31	15	US-10-163-552-1019 Sequence 1019, Ap
C 26	11.6	40.0	31	15	US-10-156-306-3281 Sequence 3281, Ap
C 27	11.6	40.0	36	9	US-09-904-599A-7 Sequence 7, Appl
C 28	11.6	40.0	38	12	US-10-388-329-15 Sequence 15, Appl
C 29	11.6	40.0	56	13	US-09-800-130A-8 Sequence 8, Appl
C 30	11.6	40.0	56	13	US-10-413-909-8 Sequence 8, Appl
C 31	11.6	40.0	60	13	US-09-908-975-5781 Sequence 5781, Ap
C 32	11.6	40.0	60	13	US-09-908-975-12753 Sequence 12753, A
C 33	11.6	40.0	60	13	US-09-908-975-14781 Sequence 14781, A
C 34	11.6	40.0	65	13	US-09-908-975-24835 Sequence 24835, A
C 35	11.6	40.0	65	13	US-09-908-975-29918 Sequence 29918, A
C 36	11.4	39.3	25	15	US-10-098-263B-5192 Sequence 5192, Ap
C 37	11.4	39.3	25	15	US-10-098-263B-5192 Sequence 5192, Ap
C 38	11.4	39.3	25	15	US-10-098-263B-94421 Sequence 94421, A
C 39	11.4	39.3	44	13	US-10-053-530-28 Sequence 28, Appl
C 40	11.4	39.3	44	15	US-10-207-655-28 Sequence 28, Appl
C 41	11.4	39.3	60	13	US-09-908-975-6202 Sequence 6202, Ap
C 42	11.4	39.3	60	13	US-09-908-975-7920 Sequence 7920, Ap
C 43	11.4	39.3	60	13	US-09-908-975-20533 Sequence 20533, A
C 44	11.4	39.3	65	13	US-09-908-975-4740 Sequence 4740, Ap
C 45	11.2	38.6	25	12	US-10-346-880-28 Sequence 28, Appl

ALIGNMENTS

RESULT 1

US-08-781-986A-2762
; Sequence 2762, Application US/08781986A
; Publication No. US20030054436A1
; GENERAL INFORMATION:
; APPLICANT: Charles Kunsch
; TITLE OF INVENTION: Staphylococcus aureus Polynucleotides and Sequences
; NUMBER OF SEQUENCES: 5255
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Human Genome Sciences, Inc.
; STREET: 9410 Key West Avenue
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
; COMPUTER: HP Vectra 486/33
; OPERATING SYSTEM: MSDOS version 6.2
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/781.986A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Benson, Bob
; REGISTRATION NUMBER: 30,446
; REFERENCE/DOCKET NUMBER: PB2488P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (301) 309-8504
; TELEFAX: (301) 309-8512
; INFORMATION FOR SEQ ID NO: 2762:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 68 base pairs
; TYPE: nucleic acid

STRANDEDNESS: double
TOPOLOGY: linear
US-08-781-986A-2762

Query Match 44.1%; Score 12.8; DB 8; Length 68;
Best Local Similarity 47.6%; Pred. No. 2.1e+03;
Matches 10; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 5 AUNCUNNGUAGCCCNANG 25
| : : : : :
Db 3 ATCCTGTCTAGCCGACG 23

RESULT 2

US-09-908-975-18725/c
; Sequence 18725, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; TITLE OF INVENTION: FAIGLER, Simchon
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18725
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-18725

Query Match 42.8%; Score 12.4; DB 13; Length 60;
Best Local Similarity 55.6%; Pred. No. 3.5e+03;
Matches 10; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 8 CUUNNGUAGCCCNANG 25
| : : : : :
Db 25 CTTCGAAAGCCCATG 8

RESULT 3

US-09-908-975-2848/c
; Sequence 2848, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; TITLE OF INVENTION: FAIGLER, Simchon
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2848
; LENGTH: 65
; TYPE: DNA

ORGANISM: Rattus norvegicus
US-09-908-975-2848

Query Match 42.8%; Score 12.4; DB 13; Length 65;
Best Local Similarity 52.9%; Pred. No. 3.6e+03;
Matches 9; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 4 GAUNCUNNGUAGCC 20
| : : : : :
Db 53 GATACCTGCAGTAAGCC 37

RESULT 4

US-10-131-827-464
; Sequence 464, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 464
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-464

Query Match 42.1%; Score 12.2; DB 12; Length 50;
Best Local Similarity 45.5%; Pred. No. 4.4e+03;
Matches 10; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 4 GAUNCUNNGUAGCCCNANG 25
| : : : : :
Db 22 GAGGCTTTCTAGGCCAAGG 43

RESULT 5

US-09-908-975-9828
; Sequence 9828, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9828
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-9828

QY
SAGCNCGCCGNNNGGAGAGCCG Z
||:|:::|
Dp
1 GATACTTTTAAAGTCC 18


```

; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 30297
; LENGTH: 65
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-908-975-30297

Query Match 40.7%; Score 11.8; DB 13; Length 65;
Best Local Similarity 50.0%; Pred.No.7.9e+03;
Matches 9; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 4 GAUNCUUUNGUAGCC 21
||:|:::|
DB 37 GATCTTCCCAAGCC 54

RESULT 15
US-10-032-585-316
; Sequence 316, Application US/10032585
; Publication No US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 316
; LENGTH: 65
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-316

Query Match 40.7%; Score 11.8; DB 13; Length 65;
Best Local Similarity 42.1%; Pred.No.7.9e+03;
Matches 8; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 5 AUNCUUUNGUAGCCNA 23
||:|:::|
DB 14 ATACTTTCAGTATACCA 32

Search completed: January 30, 2004, 13:10:22
Job time : 182 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 06:57:47 ; Search time 575.333 Seconds
(without alignments)
2062.073 Million cell updates/sec

Title: US-09-310-844c-23
Perfect score: 29
Sequence: 1 nngauncuuunnguaagccnangnn 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2988711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 1427288

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl :

- 1: gb.ba.*
- 2: gb.htg.*
- 3: gb.in.*
- 4: gb.em.*
- 5: gb.ov.*
- 6: gb.pat.*
- 7: gb.ph.*
- 8: gb.pl.*
- 9: gb.pr.*
- 10: gb.ro.*
- 11: gb.sts.*
- 12: gb.sy.*
- 13: gb.un.*
- 14: gb.vi.*
- 15: em.ba.*
- 16: em.fun.*
- 17: em.hum.*
- 18: em.int.*
- 19: em.mu.*
- 20: em.om.*
- 21: em.or.*
- 22: em.ov.*
- 23: em.pat.*
- 24: em.ph.*
- 25: em.pl.*
- 26: em.ro.*
- 27: em.sts.*
- 28: em.un.*
- 29: em.vi.*
- 30: em.htg_hum.*
- 31: em.htg_inv.*
- 32: em.htg_other.*
- 33: em.htg_mus.*
- 34: em.htg_pln.*
- 35: em.htg_rod.*
- 36: em.htg_man.*
- 37: em.htg_vrt.*
- 38: em_sy.*
- 39: em.htgo_hum.*
- 40: em.htgo_mus.*
- 41: em_htgo_other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
C 1	12.8	44.1	53	10	MDTRVNJB	X63580 M.domesticu
C 2	12.2	42.1	44	6	AX008706	AX008706 Sequence
C 3	12.2	42.1	45	6	AX008707	AX008707 Sequence
C 4	12.2	42.1	69	6	AR052906	AR052906 Sequence
C 5	12.2	42.1	69	6	AR054269	AR054269 Sequence
C 6	12.2	42.1	69	6	AR054471	AR054471 Sequence
C 7	12.2	42.1	70	6	A42881	A42881 Sequence 13
C 8	12.2	42.1	70	6	AR271415	AR271415 Sequence
C 9	12	41.4	24	6	AX291705	AX291705 Sequence
C 10	11.8	40.7	21	6	AR080204	AR080204 Sequence
C 11	11.8	40.7	21	6	AX088729	AX088729 Sequence
C 12	11.8	40.7	21	6	AX088730	AX088730 Sequence
C 13	11.8	40.7	21	6	BD023126	BD023126 Glutathio
C 14	11.8	40.7	33	10	MDTRVNJK	X63589 M.domesticu
C 15	11.8	40.7	40	10	MDTRVNJA	X63579 M.domesticu
C 16	11.8	40.7	46	10	MDTRVNJC	X63581 M.domesticu
C 17	11.8	40.7	47	6	A82690	A82690 Sequence 35
C 18	11.8	40.7	47	6	A82705	A82705 Sequence 50
C 19	11.8	40.7	51	10	MDTRVNJD	X63582 M.domesticu
C 20	11.8	40.7	65	6	AX483016	AX483016 Sequence
C 21	11.8	40.7	68	7	PT7CLS	M11570 Bacterioph
C 22	11.6	40.0	24	6	AX721991	AX721991 Sequence
C 23	11.6	40.0	31	6	AX425989	AX425989 Sequence
C 24	11.6	40.0	36	6	AR176463	AR176463 Sequence
C 25	11.6	40.0	36	6	AR176468	AR176468 Sequence
C 26	11.6	40.0	56	6	AX247478	AX247478 Sequence
C 27	11.6	40.0	57	9	S78643	S78643 IG VH3A10-I
C 28	11.6	40.0	60	12	SYNANVAA	M60029 Avian neovi
C 29	11.6	40.0	60	12	SYNANVAP	M60085 Avian neovi
C 30	11.6	40.0	61	6	AR233863	AR233863 Sequence
C 31	11.6	40.0	70	6	BD107373	BD107373 DNA conta
C 32	11.4	39.3	17	6	AX672857	AX672857 Sequence
C 33	11.4	39.3	17	6	AX728660	AX728660 Sequence
C 34	11.4	39.3	32	17	HSMC42B09	X88068 H.sapiens D
C 35	11.4	39.3	36	6	A61637	A61637 Sequence 32
C 36	11.4	39.3	40	6	AX306333	AX306333 Sequence
C 37	11.4	39.3	49	6	AX555177	AX555177 Sequence
C 38	11.4	39.3	51	6	AX204359	AX204359 Sequence
C 39	11.4	39.3	70	4	BQVMTBV	K00258 Bovine mito
C 40	11.2	38.6	20	6	AX293832	AX293832 Sequence
C 41	11.2	38.6	24	6	AX288322	AX288322 Sequence
C 42	11.2	38.6	24	6	AX289199	AX289199 Sequence
C 43	11.2	38.6	25	6	AR020995	AR020995 Sequence
C 44	11.2	38.6	25	6	AR043410	AR043410 Sequence
C 45	11.2	38.6	25	6	AR062325	AR062325 Sequence

ALIGNMENTS

RESULT 1
MDTRVNJB/c
LOCUS MDTRVNJB 53 bp mRNA linear ROD 07-MAR-1993
DEFINITION M.domesticus DBA/2 rearranged T-cell receptor (Vgamma2-N-Jgamma2).
ACCESSION X63580
VERSION X63580.1 GI:57892
KEYWORDS joining region; N-region; T-cell receptor; variable region.
SOURCE Mus musculus domesticus (western European house mouse)
ORGANISM Mus musculus domesticus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 53)
AUTHORS Roger T.R.
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 53)

LOCUS	AX008707	45 bp	DNA	linear	PAT 06-SEP-2000
DEFINITION	Sequence 21 from Patent WO9965947.				
ACCESSION	AX008707				
VERSION	AX008707.1	GI:9996218			
KEYWORDS	synthetic construct				
SOURCE	synthetic construct				
ORGANISM	artificial sequences.				
REFERENCE	1				
AUTHORS	Kenigsberg, M., Duchesne, M., Barlat, I. and Parker, F.				
TITLE	Monoclonal antibodies directed against the g3bp protein, and uses				
JOURNAL	Patent: WO 9965947-A 21 23-DEC-1999;				
	KENIGSBERG MIREILLE (FR); DUCHESNE MARC (FR); BARLAT ISABELLE (FR);				
	PARKER FABRIENNE (FR); RHONE POULENC RORER SA (FR)				
FEATURES	Location/Qualifiers				
source	1..45				
	/organism="synthetic construct"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:32630"				
	/note="polynucleotide sq44g2as"				
	9 a	16 c	7 g	13 t	
BASE COUNT					
ORIGIN					
Query Watch	42.1%; Score 12.2; DB 6; Length 45;				
Best Local Similarity	54.5%; Pred. No. 2.8e+04;				
Matches	12; Conservative				
	2; Mismatches 8; Indels 0; Gaps 0;				

Db	38	GATGCTAGTGGAAAGCCCGG	17
RESULT 4			
AR052306			
LOCUS	AR052906	69 bp	DNA
			linear
			PAT 29-SEP-1999

VERSION	AR052905.1	GI:5977768	
KEYWORDS	.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 69)		
TITLE	Mal'ty, Rde. Waal., Howard, M., Hsu, D.-H., Ishida, H., O'Garra, A., Spits, H. and Zlotnik, A.		
JOURNAL	Use of interleukin-10 (il-10) to treat endotoxin- or superantigen-induced toxicity		
FEATURES	Patent: US 5833976-A 30 10-NOV-1998;		
source	Location/Qualifiers		
	1. .69		
	/organism="unknown"		
BASE COUNT	25 a	13 c	16 g
ORIGIN			15 t

```

Query Match          42.1%; Score 12.2; DB 6; Length 69;
Best Local Similarity 43.5%; Pred. No. 2.9e+04;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

QY      5 AUNCUUNNGUAGCCCNANGNG 27
       |||::|||:|||
Db      11 ATGCCTTTAATAGCTCCAAGAG 33

RESULT 5
AR054269
LOCUS
DEFINITION Sequence 30 from patent US 5837232.
ACCESSION AR054269
VERSION AR054269.1 GI:5979846

PAT 29-SEP-1999 linear
```

ORGANISM	STATUS
COCKLE	Unknown.
ORGANISM	Unclassified.

```
REFERENCE 1 (bases 1 to 69)
AUTHORS De Waal Malefyt,R., Howard,M., Hsu,D.-H., Ishida,H., O'Garra,A.,
        Spits,H. and Zlotnik,A.
TITLE Use of an interleukin-10 antagonist to treat a B cell mediated
        autoimmune disorder
JOURNAL Patent: US 5837232-A 30 17-NOV-1998;
FEATURES Location/Qualifiers
        source
        1..69
        /organism="unknown"
BASE COUNT 25 a 13 c 16 g 15 t
ORIGIN

Query Match 42.1%; Score 12.2; DB 6; Length 69;
Best Local Similarity 43.5%; Pred. No. 2.9e+04;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

QY 5 AUNCUUUNGUAGGCCCNANG 27
   ||::||::||::||::||
Db 11 ATGCCTTTAATAAGCTCCAAGAG 33

RESULT 6
AR054471
LOCUS AR054471 69 bp DNA linear PAT 23-SEP-1999
DEFINITION Sequence 30 from patent US 5837293.
ACCESSION AR054471
VERSION AR054471.1 GI:5980048
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 69)
AUTHORS De Waal Malefyt,R., Howard,M., Hsu,D.-H., Ishida,H., O'Garra,A.,
        Spits,H. and Zlotnik,A.
TITLE Use of interleukin-10 analogs for antagonists to treat endotoxin-
        or superantigen-induced toxicity
JOURNAL Patent: US 5837293-A 30 17-NOV-1998;
FEATURES Location/Qualifiers
        source
        1..69
        /organism="unknown"
BASE COUNT 25 a 13 c 16 g 15 t
ORIGIN

Query Match 42.1%; Score 12.2; DB 6; Length 69;
Best Local Similarity 43.5%; Pred. No. 2.9e+04;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

QY 5 AUNCUUUNGUAGGCCCNANG 27
   ||::||::||::||::||
Db 11 ATGCCTTTAATAAGCTCCAAGAG 33

RESULT 7
A42881/c
LOCUS A42881 70 bp DNA linear PAT 06-MAR-1997
DEFINITION Sequence 13 from Patent WO9502701.
ACCESSION A42881
VERSION A42881.1 GI:2298330
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 70)
AUTHORS Abken,H.J., Albert,W. and Jungfer,H.
TITLE METHOD OF IDENTIFYING HUMAN AND ANIMAL CELLS CAPABLE OF UNLIMITED
        PROLIFERATION OR TUMOR FORMATION
JOURNAL Patent: WO 9502701-A 13 26-JAN-1995;
        BOEHRINGER MANNHEIM GMBH (DE)
COMMENT Other publication DE 432727 950309.
FEATURES Location/Qualifiers
        source
        1..70
        /organism="unidentified"
        /mol_type="genomic DNA"
```

```
BASE COUNT 23 a 11 c 19 g 17 t
ORIGIN

Query Match 42.1%; Score 12.2; DB 6; Length 70;
Best Local Similarity 40.9%; Pred. No. 2.9e+04;
Matches 9; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

QY 4 GAUNCUUUNGUAGGCCCNANG 25
   ||::||::||::||::||
Db 70 GATCCTTTCGGTATTCAGAAG 49

RESULT 8
AR271415/c
LOCUS AR271415 70 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 13 from patent US 6503706.
ACCESSION AR271415
VERSION AR271415.1 GI:29702833
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 70)
AUTHORS Abken,H.J., Albert,W. and Jungfer,H.
TITLE Method for identifying human and animal cells having an unlimited
        proliferation of tumor-formation potential
JOURNAL Patent: US 6503706-A 13 07-JAN-2003;
FEATURES Location/Qualifiers
        source
        1..70
        /organism="unknown"
BASE COUNT 23 a 11 c 19 g 17 t
ORIGIN

Query Match 42.1%; Score 12.2; DB 6; Length 70;
Best Local Similarity 40.9%; Pred. No. 2.9e+04;
Matches 9; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

QY 4 GAUNCUUUNGUAGGCCCNANG 25
   ||::||::||::||::||
Db 70 GATCCTTTCGGTATTCAGAAG 49

RESULT 9
AX291705/c
LOCUS AX291705 24 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 3467 from Patent WO0179548.
ACCESSION AX291705
VERSION AX291705.1 GI:17053388
KEYWORDS
SOURCE synthetic construct
        synthetic construct
        artificial sequences.
REFERENCE 1
AUTHORS Barany,F., Zirvi,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid
        sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 3467 25-OCT-2001;
        CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES Location/Qualifiers
        source
        1..24
        /organism="synthetic construct"
        /mol_type="genomic DNA"
        /db_xref="taxon:32630"
        /note="Hypothetical Probe Sequence"
BASE COUNT 6 a 5 c 8 g 5 t
ORIGIN

Query Match 41.4%; Score 12; DB 6; Length 24;
Best Local Similarity 46.7%; Pred. No. 3.5e+04;
Matches 7; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 5 AUNCUUUNGUAGGC 19
```

```

Db      23 ATCCTTTCCGTAAGC 9
      1 : |::: |::|::|
      23 ATCCTTTCCGTAAGC 9

RESULT 10
AR080204 LOCUS 21 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 10 from patent US 5968737.
ACCESSION AR080204
VERSION AR080204.1 GI:10006939
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Ali-Osman, F., Lopez-Berestein, G., Buolamwini, J.K., Antoun, G.,
Lo, H.-W., Keller, C. and Akande, O.
TITLE Method of identifying inhibitors of glutathione S-transferase (GST)
gene expression
JOURNAL Patent: US 5968737-A 10 19-OCT-1999;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
BASE COUNT 3 a 5 c 8 g 5 t
ORIGIN
Query Match 40.7%; Score 11.8; DB 6; Length 21;
Best Local Similarity 50.0%; Pred. No. 4.6e+04;
Matches 9; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 4 GAUNCUUNNGUAGGCCCC 21
|||::: |::|::|
Db 2 GAGCTTGTGAGTGAGCCC 19

RESULT 11
AX088729 LOCUS 21 bp DNA linear PAT 17-MAR-2001
DEFINITION Sequence 55 from Patent WO0114416.
ACCESSION AX088729
VERSION AX088729.1 GI:13397525
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Nepper, M.P., McClements, W.L., Jansen, K.U., Schultz, L.D., Chen, L.
and Wang, X.M.
TITLE Synthetic human papillomavirus genes
JOURNAL Patent: WO 0114416-A 55 01-MAR-2001;
Merck & Co., Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Codon-Optimized HPV16 E1 fragment"
BASE COUNT 2 a 7 c 5 t
ORIGIN
Query Match 40.7%; Score 11.8; DB 6; Length 21;
Best Local Similarity 45.0%; Pred. No. 4.6e+04;
Matches 9; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 6 UNCUNNGUAGGCCCNANG 25
|||::: |::|::|
Db 2 TCGTGTGCGTGAGCCCATG 1

RESULT 12
AX088730 LOCUS 21 bp DNA linear PAT 17-MAR-2001
DEFINITION Sequence 56 from Patent WO0114416.
ACCESSION AX088730
VERSION AX088730.1 GI:13397526
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Nepper, M.P., McClements, W.L., Jansen, K.U., Schultz, L.D., Chen, L.
and Wang, X.M.
TITLE Synthetic human papillomavirus genes
JOURNAL Patent: WO 0114416-A 56 01-MAR-2001;
Merck & Co., Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Codon-Optimized HPV16 E1 fragment"
BASE COUNT 5 a 7 c 7 g 2 t
ORIGIN
Query Match 40.7%; Score 11.8; DB 6; Length 21;
Best Local Similarity 45.0%; Pred. No. 4.6e+04;
Matches 9; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 6 UNCUNNGUAGGCCCNANG 25
|||::: |::|::|
Db 2 TCGTGTGCGTGAGCCCATG 1

RESULT 13
BD023126 LOCUS 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Glutathione S-transferase (GST) gene in cancer.
ACCESSION BD023126
VERSION BD023126.1 GI:22564349
KEYWORDS Wollinella succinogenes
SOURCE Wollinella succinogenes
ORGANISM Wollinella succinogenes
REFERENCE 1 (bases 1 to 21)
AUTHORS Aliosman, F., Berestein, G.L., Buolamwini, J.K., Antoun, G., Lo, H.W.,
Keller, C. and Akande, O.
TITLE Glutathione S-transferase (GST) gene in cancer
JOURNAL Patent: JP 2001504340-A 6 03-APR-2001;
BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM, THE UNIVERSITY OF
MISSISSIPPI
COMMENT PN JP 2001504340-A/6
PD 03-APR-2001
PF 12-NOV-1997 JP 1998522894
PR 12-NOV-1996 US 08/747536
PI FRANCIS ALIOSMAN, GABRIEL LOPEZ BERESTEIN, JOHN K BUOLAMWINI, PI
GAMIL ANTOUN,
PI HUI WEN LO, CHARLES KELLER, OLANIKE AKANDE
PC C12N15/09, A61K31/7105, A61K31/711, A61K38/00, A61K39/395 PC
/A61K39/395, A61K45/00,
PC A61K48/00, A61P35/00, A61P43/00, C07K16/40, C12N5/10, C12N9/00, PC
C12N9/10,
PC C12Q1/02, C12N15/00, C12N5/00, A61K37/02
CC Strandedness: Single;
CC Topology: Linear;
PH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1..21
/organism="Wollinella succinogenes"
/mol_type="genomic DNA"
/db_xref="taxon:844"
BASE COUNT 3 a 5 c 8 g 5 t
ORIGIN
Query Match 40.7%; Score 11.8; DB 6; Length 21;
Best Local Similarity 50.0%; Pred. No. 4.6e+04;

```



```

Matches      9;  Conservative      4;  Mismatches      5;  Indels      0;  Gaps      0;

QY      4  GAUNCUUNNGUAGGCC 21
      |||:::|:|||||
Db      2  GAGGCTTGAGTGAGGCC 19

RESULT 14
MDRVNJ/c
LOCUS      M.domesticus BALB/c rearranged T-cell receptor (Vgamma1-N-Jgamma4).
DEFINITION
ACCESSION  X63589
VERSION    X63589.1 GI:57901
KEYWORDS   joining region; N-region; T-cell receptor; variable region.
SOURCE     Mus musculus domesticus (western European house mouse)
ORGANISM   Mus musculus domesticus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  1 (bases 1 to 33)
AUTHORS    Roger, T.R.
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 33)
AUTHORS    Roger, T.
JOURNAL    Direct Submission
            Submitted (16-DEC-1991) T. Roger, Laboratoire
            d'Immunodifferentiation, Service du Pr SEMAN, Institut J.MONOD, 2,
            Place JUSSIEU, 75251 PARIS CEDEX 05, FRANCE

FEATURES   Location/Qualifiers
            source
              1..33
                /organism="Mus musculus domesticus"
                /mol_type="mRNA"
                /strain="BALB/c"
                /db_xref="taxon:10092"
                /chromosome="13"
                /clone="TKR1902 Q"
                /cell_line="TKR1902"
                /cell_type="T Lymphocyte"
                /tissue_type="Spleen"
                /clone_lib="library M13mp18"
                /dev_stage="Seed, cell expansion stage"
            misc_feature
              1..2
                /product="End of the T-cell receptor Vgamma1 gene segment"
            misc_feature
              3..7
                /product="N Sequence"
            misc_feature
              8..33
                /product="Beginning of the T cell receptor Jgamma4 gene
                segment"

BASE COUNT      8 a      6 c      10 g      9 t
ORIGIN
      1  .33
      2  /organism="Mus musculus domesticus"
      3  /mol_type="mRNA"
      4  /strain="BALB/c"
      5  /db_xref="taxon:10092"
      6  /chromosome="13"
      7  /clone="TKR1902 Q"
      8  /cell_line="TKR1902"
      9  /cell_type="T Lymphocyte"
     10  /tissue_type="Spleen"
     11  /clone_lib="library M13mp18"
     12  /dev_stage="Seed, cell expansion stage"
     13  .2
     14  /product="End of the T-cell receptor Vgamma1 gene segment"
     15  .7
     16  /product="N Sequence"
     17  .33
     18  /product="Beginning of the T cell receptor Jgamma4 gene
     19  segment"
     20  .6
     21  c      10 g      9 t
     22  .
     23  .
     24  .
     25  .
     26  .
     27  .
     28  .
     29  .
     30  .
     31  .
     32  .
     33  .

Query Match      40.7%; Score 11.8; DB 10; Length 33;
Best Local Similarity 52.6%; Pred. No. 4.8e+04;
Matches 10; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY      5  AUNCUUNNGUAGGCCNA 23
      |||:::|:|||||
Db      31  ATACCTTGCGAAGCCCGA 13

RESULT 15
MDRVNJ/c
LOCUS      M.domesticus DBA/2 rearranged T-cell receptor (Vgamma2-N-Jgamma2).
DEFINITION
ACCESSION  X63579
VERSION    X63579.1 GI:57891
KEYWORDS   joining region; N-region; T-cell receptor; variable region.
SOURCE     Mus musculus domesticus (western European house mouse)
ORGANISM   Mus musculus domesticus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  1 (bases 1 to 40)
AUTHORS    Roger, T.R.
JOURNAL    Unpublished

```

```

REFERENCE  2 (bases 1 to 40)
AUTHORS    Roger, T.
JOURNAL    Direct Submission
            Submitted (16-DEC-1991) T. Roger, Laboratoire
            d'Immunodifferentiation, Service du Pr SEMAN, Institut J.MONOD, 2,
            Place JUSSIEU, 75251 PARIS CEDEX 05, FRANCE

FEATURES   Location/Qualifiers
            source
              1..40
                /organism="Mus musculus domesticus"
                /mol_type="mRNA"
                /strain="DBA/2"
                /db_xref="taxon:10092"
                /chromosome="13"
                /clone="O3P9A"
                /cell_line="O3P9"
                /cell_type="CD4+ CD8- T Lymphocyte clone"
                /tissue_type="Spleen"
                /clone_lib="library M13mp18"
                /dev_stage="Seed, cell expansion stage"
            misc_feature
              1..5
                /product="End of the T-cell receptor Vgamma2 gene segment"
            misc_feature
              7..14
                /product="N Sequence"
            misc_feature
              15..40
                /product="Beginning of the T cell receptor Jgamma2 gene
                segment"

BASE COUNT      10 a      11 c      8 g      11 t
ORIGIN
      1  .40
      2  /organism="Mus musculus domesticus"
      3  /mol_type="mRNA"
      4  /strain="DBA/2"
      5  /db_xref="taxon:10092"
      6  /chromosome="13"
      7  /clone="O3P9A"
      8  /cell_line="O3P9"
      9  /cell_type="CD4+ CD8- T Lymphocyte clone"
     10  /tissue_type="Spleen"
     11  /clone_lib="library M13mp18"
     12  /dev_stage="Seed, cell expansion stage"
     13  .5
     14  /product="End of the T-cell receptor Vgamma2 gene segment"
     15  .14
     16  /product="N Sequence"
     17  .40
     18  /product="Beginning of the T cell receptor Jgamma2 gene
     19  segment"
     20  .10
     21  a      11 c      8 g      11 t
     22  .
     23  .
     24  .
     25  .
     26  .
     27  .
     28  .
     29  .
     30  .
     31  .
     32  .
     33  .
     34  .
     35  .
     36  .
     37  .
     38  .
     39  .
     40  .

Query Match      40.7%; Score 11.8; DB 10; Length 40;
Best Local Similarity 52.6%; Pred. No. 4.9e+04;
Matches 10; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY      5  AUNCUUNNGUAGGCCNA 23
      |||:::|:|||||
Db      38  ATACCTTGCGAAGCCCGA 20

Search completed: January 30, 2004, 08:51:19
Job time : 582.333 sec

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 30, 2004, 06:19:17 ; Search time 283.333 Seconds
(without alignments)
276.295 Million cell updates/sec

Title: US-09-310-844C-23

Perfect score: 29
Sequence: 1 nngauncuunngaagccnangn 29

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 2640686

Minimum DB seq length: 0
Maximum DB seq length: 70

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N Geneseq 19Jun03:*

1:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
25:	/SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	18	62.1	29	AAA70827	Molecular interact
2	18	62.1	29	AAA70828	Molecular interact
3	18	62.1	29	AAA70829	Molecular interact
4	18	62.1	29	AAA70830	Molecular interact
5	18	62.1	42	AAA71113	Molecular interact
6	18	62.1	42	AAA71114	Molecular interact
7	18	62.1	42	AAA71115	Molecular interact
8	18	62.1	42	AAA71116	Molecular interact

9	18	62.1	42	AAA71118	Molecular interact
10	18	62.1	42	AAA71119	Molecular interact
11	18	62.1	42	AAA71120	Molecular interact
12	18	62.1	42	AAA71121	Molecular interact
13	18	62.1	42	AAA71123	Molecular interact
14	18	62.1	42	AAA71124	Molecular interact
15	18	62.1	42	AAA71126	Molecular interact
16	18	62.1	42	AAA71127	Molecular interact
17	18	62.1	42	AAA71128	Molecular interact
18	18	62.1	42	AAA71129	Molecular interact
19	18	62.1	42	AAA71131	Molecular interact
20	18	62.1	42	AAA71132	Molecular interact
21	18	62.1	44	ABK87476	Interleukin-2 (IL-
22	18	62.1	44	AAA71112	Molecular interact
23	18	62.1	44	AAA71125	Molecular interact
24	18	62.1	44	AAA71133	Molecular interact
25	18	62.1	45	AAA70824	Molecular interact
26	18	62.1	45	AAA70825	Molecular interact
27	18	62.1	45	AAA70826	Molecular interact
28	18	62.1	46	AAA71085	Molecular interact
29	18	62.1	46	AAA71087	Molecular interact
30	18	62.1	46	AAA71089	Molecular interact
31	18	62.1	46	AAA71089	Molecular interact
32	18	62.1	46	AAA71090	Molecular interact
33	18	62.1	46	AAA71093	Molecular interact
34	18	62.1	46	AAA71094	Molecular interact
35	18	62.1	46	AAA71095	Molecular interact
36	18	62.1	46	AAA71096	Molecular interact
37	18	62.1	46	AAA71099	Molecular interact
38	18	62.1	46	AAA71100	Molecular interact
39	18	62.1	46	AAA71103	Molecular interact
40	18	62.1	46	AAA71104	Molecular interact
41	18	62.1	46	AAA71105	Molecular interact
42	18	62.1	46	AAA71106	Molecular interact
43	18	62.1	46	AAA71107	Molecular interact
44	18	62.1	46	AAA71109	Molecular interact
45	18	62.1	46	AAA71110	Molecular interact

ALIGNMENTS

RESULT 1
AAA70827
ID AAA70827 standard, RNA; 29 BP.

XX AC AAA70827;

XX 27-APR-2001 (first entry)

XX DE Molecular interaction site RNA #27.

XX KW Modulator; identification; molecular interaction; virtual library; ss.

XX OS Synthetic.

XX PN WO958947-A2.

XX PD 18-NOV-1999.

XX PF 12-MAY-1999; 99WO-US10361.

XX PR 12-MAY-1999; 98US-0076404.

XX PR 12-MAY-1999; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX PI Hofstadler S, McNeil G;

XX DR WPI; 2000-086439/07.

XX PT Identifying compounds which modulate activity of target biomolecules,

XX Claim 235; Page 235; 405pp; English.

XX This invention describes a novel method for identifying compounds which

CC modulate the activity of a target biomolecule. The method uses

CC 3-dimensional representations of the biomolecule and a library of

CC compounds and comprises (a) identifying at least one molecular

CC interaction site of the target RNA; (b) generating in silico a virtual

CC library of compounds predicted or calculated to interact with the

CC molecular interaction site; and (c) comparing 3-dimensional (3-D)

CC representations of the target RNA with members of the virtual library of

CC compounds to generate a hierarchy of the compounds ranked in accordance

CC with their respective ability to form physical interactions with the

CC molecular interaction site. The method also describes (1) RNA comprising

CC a joined sequence of at least 24 nucleotides but not more than 70

CC nucleotides and having secondary structure defined by: (a) 3 nucleotides

CC forming a first side of a first double stranded (ds) region; (b) 2

CC nucleotides forming a first side of an internal loop region; (c) 4

CC nucleotides forming a first side of a second ds region; (d) 4 or 5

CC nucleotides forming an end loop region; (e) 4 nucleotides forming a

CC second side of the second ds region; (f) 4 nucleotides forming a second

CC side of the internal loop region; and (g) 3 nucleotides forming a second

CC side of the first ds region; (2) a purified and isolated RNA fragment

CC comprising the human sequence UUUACACAUUAUCUUAUACAGAAAAUUC (II). The

CC methods and products can be used for identifying agents which modulate

CC the activity of biomolecules, particularly RNA. Such agents can be used

CC as pharmaceutical, agricultural or industrial compounds.

XX

SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;

Best Local Similarity 75.0%; Pred. No. 1.5;

Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4 GAUUCUUUNNGUAAGCCCNANGNG 27

DB 4 GAUUCUUUNNGUAAGCCCNANGNG 27

RESULT 4

AAA70830

ID AAA70830 standard; RNA; 29 BP.

XX

AC AAA70830;

XX

DT 27-APR-2001 (first entry)

XX

DE Molecular interaction site RNA #30.

XX

KW Modulator; identification; molecular interaction; virtual library; ss.

XX

OS Rattus sp.

XX

PN WO9958947-A2.

XX

PD 18-NOV-1999.

XX

PF 12-MAY-1999; 99WO-US10361.

XX

PR 12-MAY-1998; 98US-0076404.

XX

PR 12-MAY-1998; 98US-0085092.

XX

XX (ISIS-) ISIS PHARM INC.

XX

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

PI Hofstadler S, McNeil J;

XX

DR WPI; 2000-086439/07.

XX

XX Identifying compounds which modulate activity of target biomolecules,

PT used to provide compounds which can be used as pharmaceutical,

PT agricultural and industrial compounds -

XX

PS Claim 235; Page 235; 405pp; English.

XX This invention describes a novel method for identifying compounds which

CC modulate the activity of a target biomolecule. The method uses

CC 3-dimensional representations of the biomolecule and a library of

CC compounds and comprises (a) identifying at least one molecular

CC interaction site of the target RNA; (b) generating in silico a virtual

CC library of compounds predicted or calculated to interact with the

CC molecular interaction site; and (c) comparing 3-dimensional (3-D)

CC representations of the target RNA with members of the virtual library of

CC compounds to generate a hierarchy of the compounds ranked in accordance

CC with their respective ability to form physical interactions with the

CC molecular interaction site. The method also describes (1) RNA comprising

CC a joined sequence of at least 24 nucleotides but not more than 70

CC nucleotides and having secondary structure defined by: (a) 3 nucleotides

CC forming a first side of a first double stranded (ds) region; (b) 2

CC nucleotides forming a first side of an internal loop region; (c) 4

CC nucleotides forming a first side of a second ds region; (d) 4 or 5

CC nucleotides forming an end loop region; (e) 4 nucleotides forming a

CC second side of the second ds region; (f) 4 nucleotides forming a second

CC side of the internal loop region; and (g) 3 nucleotides forming a second

CC side of the first ds region; (2) a purified and isolated RNA fragment

CC comprising the human sequence UUUACACAUUAUCUUAUACAGAAAAUUC (II). The

CC methods and products can be used for identifying agents which modulate

CC the activity of biomolecules, particularly RNA. Such agents can be used

CC as pharmaceutical, agricultural or industrial compounds.

XX

SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;

Best Local Similarity 75.0%; Pred. No. 1.5;

Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4 GAUUCUUUNNGUAAGCCCNANGNG 27

DB 4 GAUUCUUUNNGUAAGCCCNANGNG 27

RESULT 5

AAA71113

ID AAA71113 standard; RNA; 42 BP.

XX

AC AAA71113;

XX

DT 27-APR-2001 (first entry)

XX

DE Molecular interaction site RNA #189.

XX

KW Modulator; identification; molecular interaction; virtual library; ss.

XX

OS Unidentified.

XX

PN WO9958947-A2.

XX

PD 18-NOV-1999.

XX

PF 12-MAY-1999; 99WO-US10361.

XX

PR 12-MAY-1998; 98US-0076404.

XX

PR 12-MAY-1998; 98US-0085092.

XX

XX (ISIS-) ISIS PHARM INC.

XX

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

PI Hofstadler S, McNeil J;

XX

DR WPI; 2000-086439/07.

XX

XX Identifying compounds which modulate activity of target biomolecules,

PT used to provide compounds which can be used as pharmaceutical,

PT agricultural and industrial compounds -

XX

XX Example 7; Figure 122; 405pp; English.

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUACUAGUUACAGAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
 Best Local Similarity 75.0%; Pred. No. 1.6;
 Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 4 GAUUCUUNNGUAGCCCNANGNG 27
 DB 7 GAUUCUUNNGUAGCCCNACGGG 30

RESULT 6
 AAA71114
 ID AAA71114 standard; RNA; 42 BP.
 XX
 AC AAA71114;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site RNA #190.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO9958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 XX
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX
 DR WPI; 2000-086439/07.
 XX
 XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 122; 405pp; English.
 XX

CC This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUACUAGUUACAGAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 11 A; 8 C; 7 G; 16 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
 Best Local Similarity 75.0%; Pred. No. 1.6;
 Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 4 GAUUCUUNNGUAGCCCNANGNG 27
 DB 7 GAUUCUUNNGUAGCCCNACGGG 30

RESULT 7
 AAA71115
 ID AAA71115 standard; RNA; 42 BP.
 XX
 AC AAA71115;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site RNA #191.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO9958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 XX
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX
 DR WPI; 2000-086439/07.
 XX
 XX Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 122; 405pp; English.
 XX
 CC This invention describes a novel method for identifying compounds which

CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAAUUAUCUAGUUAACAGAAAAC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;
 Query Match 62.1%; Score 18; DB 21; Length 42;
 Best Local Similarity 75.0%; Pred. NO. 1.6;
 Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 4 GAUNCUUUNNGUAGCCNANGNG 27
 ||||| ||||| ||||| ||||| |||||
 Db 7 GAUCUUUUUGUAGCCCAAGGG 30
 RESULT 8
 AAA71116
 ID AAA71116 standard; RNA; 42 BP.
 XX
 AC AAA71116;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site RNA #192.
 DE
 DE Modulator; identification; molecular interaction; virtual library; ss.
 KW
 KW Unidentified.
 OS
 OS WO9958947-A2.
 PN
 PN 18-NOV-1999.
 PD
 PD 12-MAY-1999; 99WO-US10361.
 PF
 PF 12-MAY-1998; 98US-0076404.
 PR
 PR 12-MAY-1998; 98US-0085092.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 PI WPI; 2000-086439/07.
 DR
 DR Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 PT
 XX Example 7; Figure 122; 405pp; English.
 PS
 PS This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of

CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAAUUAUCUAGUUAACAGAAAAC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;
 Query Match 62.1%; Score 18; DB 21; Length 42;
 Best Local Similarity 75.0%; Pred. NO. 1.6;
 Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 4 GAUNCUUUNNGUAGCCNANGNG 27
 ||||| ||||| ||||| ||||| |||||
 Db 7 GAUCUUUUUGUAGCCCAAGGG 30
 RESULT 9
 AAA71118
 ID AAA71118 standard; DNA; 42 BP.
 XX
 AC AAA71118;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site DNA #124.
 DE
 DE Modulator; identification; molecular interaction; virtual library; ss.
 KW
 KW Unidentified.
 OS
 OS WO9958947-A2.
 PN
 PN 18-NOV-1999.
 PD
 PD 12-MAY-1999; 99WO-US10361.
 PF
 PF 12-MAY-1998; 98US-0076404.
 PR
 PR 12-MAY-1998; 98US-0085092.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 PI WPI; 2000-086439/07.
 DR
 DR Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 PT
 XX Example 7; Figure 125; 405pp; English.
 PS
 PS This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of

CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the internal loop region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACAAUAUUCUAGUUUACAGAAAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 T; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
 Best Local Similarity 54.2%; Pred. No. 1.6;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 4 GAUNCUUNUGAAGCCCNANGNG 27
 ||:|:::|:|||||
 Db 7 GATTCTTTTGTAAAGCCTACGGG 30

RESULT 10
 AAA71119
 ID AAA71119 standard; DNA; 42 BP.
 XX
 AC AAA71119;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site DNA #125.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO9958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX
 DR WPI; 2000-086439/07.
 XX
 PT Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 125; 405pp; English.
 XX

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC compounds and comprises (a) identifying at least one molecular

CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the internal loop region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACAAUAUUCUAGUUUACAGAAAAAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 11 A; 8 C; 7 G; 16 T; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
 Best Local Similarity 54.2%; Pred. No. 1.6;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 4 GAUNCUUNUGAAGCCCNANGNG 27
 ||:|:::|:|||||
 Db 7 GATTCTTTTGTAAAGCCTACGGG 30

RESULT 11
 AAA71120
 ID AAA71120 standard; DNA; 42 BP.
 XX
 AC AAA71120;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Molecular interaction site DNA #126.
 XX
 KW Modulator; identification; molecular interaction; virtual library; ss.
 XX
 OS Unidentified.
 XX
 PN WO9958947-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 12-MAY-1999; 99WO-US10361.
 XX
 PR 12-MAY-1998; 98US-0076404.
 PR 12-MAY-1998; 98US-0085092.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
 PI Hofstadler S, McNeil J;
 XX
 DR WPI; 2000-086439/07.
 XX
 PT Identifying compounds which modulate activity of target biomolecules,
 PT used to provide compounds which can be used as pharmacological,
 PT agricultural and industrial compounds -
 XX
 PS Example 7; Figure 125; 405pp; English.
 XX

XX This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual

Example 7: Figure 125; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating *in silico* a virtual library of compounds predicted or calculated to interact with the

AA This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating *in silico* a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of

Identifying compounds which modulate activity of target biomolecules, used to provide compounds which can be used as pharmacological, agricultural and industrial compounds -
Example 7; Figure 126; 405pp; English.
This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance

CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUGUUACAGAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX
SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;
Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 75.0%; Pred.No. 1.6;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
CY 4 GAUUCUUUNGUAGGCCNANGNG 27
Db 7 GAUUCUUUNGUAGGCCUACGGG 30

Search completed: January 30, 2004, 08:22:12
Job time : 285.667 secs

Result No.	Score	Query Match	Length	DB	ID	Description
1	12.2	42.1	27	6	5253283-10	Patent No. 5253283
2	12.2	42.1	69	2	US-08-410-654B-30	Sequence 30, Appl
3	12.2	42.1	69	2	US-08-474-951-30	Sequence 30, Appl
4	12.2	42.1	69	2	US-08-481-560-30	Sequence 30, Appl
C 5	12.2	42.1	70	4	US-08-585-593A-13	Sequence 13, Appl
C 6	11.8	40.7	21	2	US-08-747-536-10	Sequence 10, Appl
C 7	11.6	40.0	36	4	US-08-218-369-7	Sequence 7, Appl
8	11.6	40.0	36	4	US-08-218-369-15	Sequence 15, Appl
C 9	11.6	40.0	36	5	PCT-US95-03743-7	Sequence 7, Appl
10	11.6	40.0	36	5	PCT-US95-03743-15	Sequence 15, Appl
C 11	11.6	40.0	61	4	US-09-619-213B-45	Sequence 45, Appl
C 12	11.2	38.6	25	1	US-08-741-881-28	Sequence 28, Appl
C 13	11.2	38.6	25	1	US-08-739-158-28	Sequence 28, Appl
C 14	11.2	38.6	25	3	US-08-739-167-28	Sequence 28, Appl
C 15	11.2	38.6	25	3	US-08-404-796-28	Sequence 28, Appl
C 16	11.2	38.6	25	3	US-08-931-869-28	Sequence 28, Appl
C 17	11.2	38.6	25	4	US-09-350-399-28	Sequence 28, Appl
C 18	11.2	38.6	25	4	US-09-336-140A-28	Sequence 28, Appl
19	11.2	38.6	33	1	US-08-741-881-29	Sequence 29, Appl
20	11.2	38.6	33	1	US-08-739-158-29	Sequence 29, Appl
21	11.2	38.6	33	3	US-08-739-167-29	Sequence 29, Appl
22	11.2	38.6	33	3	US-08-404-796-29	Sequence 29, Appl
23	11.2	38.6	33	3	US-08-931-869-29	Sequence 29, Appl
24	11.2	38.6	33	4	US-09-350-399-29	Sequence 29, Appl
25	11.2	38.6	33	4	US-09-336-140A-29	Sequence 29, Appl
C 26	11.2	38.6	36	2	US-08-642-045B-17	Sequence 17, Appl
C 27	11.2	38.6	36	3	US-08-852-268-17	Sequence 17, Appl

```

; COMPUTER: Macintosh
; OPERATING SYSTEM: 7.5.3
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,654B
; FILING DATE: 24-MAR-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/229,854
; FILING DATE: 19-APR-1994
; APPLICATION NUMBER: US 07/926,853
; FILING DATE: 06-AUG-1992
; APPLICATION NUMBER: US 07/742,129
; FILING DATE: 06-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: DX0221KQ1
; TELEPHONE: 908-298-2987
; TELEFAX: 908-298-5388
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 69 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
; US-08-410-654B-30

```

```

Query Match 42.1%; Score 12.2; DB 2; Length 69;
Best Local Similarity 43.5%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

```

```

QY 5 AUNCUUUNGUAGCCCNANGNG 27
| : : : :
DB 11 ATGCCTTTAATAAGCTCCAAGAG 33

```

RESULT 3

```

; US-08-474-851-30
; Sequence 30, Application US/08474851
; Patent No. 5837232
; GENERAL INFORMATION:
; APPLICANT: Rene de Waal Malefyt
; APPLICANT: Di-Hwei Hsu
; APPLICANT: Anne O'Garra
; APPLICANT: Hergen Spits
; TITLE OF INVENTION: Use of An Interleukin-10 Antagonist to Treat
; TITLE OF INVENTION: A B Cell Mediated Autoimmune Disorder
; NUMBER OF SEQUENCES: 61
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: 7.5.3
; SOFTWARE: Microsoft Word 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,851
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,654
; FILING DATE: 24-MAR-1995
; APPLICATION NUMBER: US 08/229,854
; FILING DATE: 19-APR-1994
; APPLICATION NUMBER: US 07/926,853

```

```

; FILING DATE: 06-AUG-1992
; APPLICATION NUMBER: US 07/742,129
; FILING DATE: 06-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: DX0221KQ1GD
; TELEPHONE: 908-298-2987
; TELEFAX: 908-298-5388
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 69 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
; US-08-474-851-30

```

```

Query Match 42.1%; Score 12.2; DB 2; Length 69;
Best Local Similarity 43.5%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

```

```

QY 5 AUNCUUUNGUAGCCCNANGNG 27
| : : : :
DB 11 ATGCCTTTAATAAGCTCCAAGAG 33

```

RESULT 4

```

; US-08-481-560-30
; Sequence 30, Application US/08481560
; Patent No. 5837293
; GENERAL INFORMATION:
; APPLICANT: Rene de Waal Malefyt
; APPLICANT: Di-Hwei Hsu
; APPLICANT: Anne O'Garra
; APPLICANT: Hergen Spits
; TITLE OF INVENTION: Use of Interleukin-10 to Modulate
; TITLE OF INVENTION: Inflammation or T-Cell Mediated
; NUMBER OF SEQUENCES: 61
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: 7.5.3
; SOFTWARE: Microsoft Word 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/481,560
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,654
; FILING DATE: 24-MAR-1995
; APPLICATION NUMBER: US 08/229,854
; FILING DATE: 19-APR-1994
; APPLICATION NUMBER: US 07/926,853
; FILING DATE: 06-AUG-1992
; APPLICATION NUMBER: US 07/742,129
; FILING DATE: 06-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: DX0221KQ1GCC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908-298-2987
; TELEFAX: 908-298-5388

```

INFORMATION FOR SEQ ID NO: 30:

SEQUENCE CHARACTERISTICS:
LENGTH: 69 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-481-560-30

Query Match 42.1%; Score 12.2; DB 2; Length 69;
Best Local Similarity 43.5%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

OY 5 AUNCUNUUNGUAGCCCNANGNG 27

Db 11 ATGCTTTTAATAGTCCACAGAG 33

RESULT 5

US-08-585-593A-13/C
Sequence 13, Application US/08585593A
Patent No. 6503706

GENERAL INFORMATION:

APPLICANT: ABKEN, Hinrich J.

APPLICANT: ALBERT, Winfried

APPLICANT: JUNGFER, Herbert

TITLE OF INVENTION: METHOD OF IDENTIFYING HUMAN AND ANIMAL

TITLE OF INVENTION: CELLS CAPABLE OF UNLIMITED PROLIFERATION OR TUMOR

TITLE OF INVENTION: FORMATION

NUMBER OF SEQUENCES: 66

CORRESPONDENCE ADDRESS:

ADDRESSEE: Nikaido, Marmelstein, Murray & Oram LLP

STREET: 655 Fifteenth Street N.W. Suite 330

CITY: Washington

STATE: D.C.

COUNTRY: U.S.A.

ZIP: 20005-5701

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/585,593A

FILING DATE: 16-JAN-1996

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/EP94/02307

FILING DATE: 13-JUL-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 43 23 727.4

FILING DATE: 15-JUL-1993

ATTORNEY/AGENT INFORMATION:

NAME: Murray, Robert B.

REGISTRATION NUMBER: 22,980

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)638-5000

TELEFAX: (202)638-4810

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 70 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

US-08-585-593A-13

Query Match 42.1%; Score 12.2; DB 4; Length 70;

Best Local Similarity 40.9%; Pred. No. 3.2e+02;

Matches 9; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

OY

4 GAUNCUNUUNGUAGCCCNANG 25

Db 70 GATCCTTTCGGTATTCCAGAG 49

RESULT 6

US-08-747-536-10

Sequence 10, Application US/08747536

Patent No. 5968737

GENERAL INFORMATION:

APPLICANT: Ali-Osman, Francis

APPLICANT: Lopez-Berestein, Gabriel

APPLICANT: Buolamwini, John

APPLICANT: Antoun, Gamil

APPLICANT: Lo Hui-Wen

APPLICANT: Keller, Charles

APPLICANT: Akande, Olanike

TITLE OF INVENTION: GLUTATHIONE S-TRANSFERASE (GST) GENES IN

TITLE OF INVENTION: CANCER

NUMBER OF SEQUENCES: 42

CORRESPONDENCE ADDRESS:

ADDRESSEE: Arnold, White & Durkee

STREET: P.O. Box 4433

CITY: Houston

STATE: Texas

COUNTRY: USA

ZIP: 77210

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/747,536

FILING DATE: Concurrently Herewith

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Highlander, Steven L.

REGISTRATION NUMBER: 37,642

REFERENCE/DOCKET NUMBER: UTXC:492

TELECOMMUNICATION INFORMATION:

TELEPHONE: 512/418-3000

TELEFAX: 512/474-7577

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 21 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-747-536-10

Query Match 40.7%; Score 11.8; DB 2; Length 21;

Best Local Similarity 50.0%; Pred. No. 4.2e+02;

Matches 9; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

OY 4 GAUNCUNUUNGUAGCC 21

Db 2 GAGCTTTGAGTGAGCC 19

RESULT 7

US-08-218-369-7/C

Sequence 7, Application US/08218369

Patent No. 6312699

GENERAL INFORMATION:

APPLICANT: Curriel, David T.

APPLICANT: Engler, Jeffrey A.

TITLE OF INVENTION: Ligands Added to Adenovirus Fiber

NUMBER OF SEQUENCES: 13

CORRESPONDENCE ADDRESS:

ADDRESSEE: Patrea L. Pabst

STREET: 1100 Peachtree Street, Suite 2800

CITY: Atlanta

STATE: Georgia

COUNTRY: USA

ZIP: 30309-4530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/218,369
FILING DATE: 28-MAR-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: IGI101
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 815-6508
TELEFAX: (404) 815-6555
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..36
OTHER INFORMATION: /note= "Nucleotide sequence encoding a streptavidin mimic"
US-08-218-369-7

Query Match 40.0%; Score 11.6; DB 4; Length 36;
Best Local Similarity 41.7%; Pred. No. 6.3e+02;
Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 4 GAUNCUUNNGUAGCCCNANGNG 27
|||:::|
Db 31 GAAGCTTAGTGGGGCCCATGAG 8

RESULT 8
US-08-218-369-15
Sequence 15, Application US/08218369
Patent No. 6312699
GENERAL INFORMATION:
APPLICANT: Curitel, David T.
APPLICANT: Engler, Jeffrey A.
TITLE OF INVENTION: Ligands Added to Adenovirus Fiber
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Patrea L. Pabst
STREET: 1100 Peachtree Street, Suite 2800
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30309-4530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/218,369
FILING DATE: 28-MAR-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: IGI101
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 815-6508
TELEFAX: (404) 815-6555

INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..36
OTHER INFORMATION: /note= "Nucleotides 5 through 36 are complementary to nucl
US-08-218-369-15

Query Match 40.0%; Score 11.6; DB 4; Length 36;
Best Local Similarity 41.7%; Pred. No. 6.3e+02;
Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 4 GAUNCUUNNGUAGCCCNANGNG 27
|||:::|
Db 10 GAAGCTTAGTGGGGCCCATGAG 33

RESULT 9
PCT-US95-03742-7/c
Sequence 7, Application PC/TUS9503742
GENERAL INFORMATION:
APPLICANT: The UAB Research Foundation
TITLE OF INVENTION: Ligands Added to Adenovirus Fiber
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Patrea L. Pabst
STREET: 2800 One Atlantic Center
STREET: 1201 West Peachtree Street
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03742
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: IGI101
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 873-8794
TELEFAX: (404) 873-8795
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..36
OTHER INFORMATION: /note= "Nucleotide sequence
PCT-US95-03742-7

Query Match 40.0%; Score 11.6; DB 5; Length 36;
Best Local Similarity 41.7%; Pred. No. 6.3e+02;

Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 4 GAUNCUUNNGUAGGCCNANGNG 27
|||:::|:|||||
Db 31 GAAGCTTAGGTGGGCCCATGAG 8

RESULT 10

PCT-US95-03742-15
; Sequence 15, Application PC/TUS9503742
; GENERAL INFORMATION:
; APPLICANT: The UAB Research Foundation
; TITLE OF INVENTION: Ligands Added to Adenovirus Fiber
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center
; STREET: 1201 West Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03742
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: IG101
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 873-8794
; TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..36
; OTHER INFORMATION: /note= "Nucleotides 5 through 36
; OTHER INFORMATION: are complementary to nucleotides 5 through 36 of
; OTHER INFORMATION: Sequence ID No. 7."
PCT-US95-03742-15

Query Match 40.0%; Score 11.6; DB 5; Length 36;
Best Local Similarity 41.7%; Pred. No. 6.3e+02;
Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 4 GAUNCUUNNGUAGGCCNANGNG 27
|||:::|:|||||
Db 10 GAAGCTTAGGTGGGCCCATGAG 33

RESULT 11

US-09-619-213B-45/c
; Sequence 45, Application US/09619213B
; Patent No. 6458539
; GENERAL INFORMATION:
; APPLICANT: Gold, Larry
; APPLICANT: Smith, Jonathan Drew
; APPLICANT: Koch, Tad
; APPLICANT: Golden, Mace

; TITLE OF INVENTION: Photoselection of Nucleic Acid Ligands
; FILE REFERENCE: NEX10-5
; CURRENT APPLICATION NUMBER: US/09/619,213B
; CURRENT FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 09/459,553
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: 09/093,293
; PRIOR FILING DATE: 1998-06-08
; PRIOR APPLICATION NUMBER: 08/612,895
; PRIOR FILING DATE: 1996-03-08
; PRIOR APPLICATION NUMBER: 08/123,935
; PRIOR FILING DATE: 1993-09-17
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 45
; LENGTH: 61
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; OTHER INFORMATION: Ligand
; NAME/KEY: modified base
; LOCATION: (1)..(61)
; OTHER INFORMATION: All T's are 5-bromouracil
US-09-619-213B-45

Query Match 40.0%; Score 11.6; DB 4; Length 61;
Best Local Similarity 45.8%; Pred. No. 7.1e+02;
Matches 11; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

QY 4 GAUNCUUNNGUAGGCCNANGNG 27
|||:::|:|||||
Db 42 GATACTATGACACGCCCATGTGG 19

RESULT 12

US-08-741-881-28/c
; Sequence 28, Application US/08741881
; Patent No. 5789245
; GENERAL INFORMATION:
; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.W.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSES: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/741,881
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423C6 / 1146.007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 28:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-741-881-28

Query Match 38.6%; Score 11.2; DB 1; Length 25;
Best Local Similarity 36.4%; Pred. No. 1e+03;
Matches 8; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 6 UNCUUNNGUAGCCNANGNG 27
; : : : : :
Db 24 TCCTTAGGTTAGCGGTACAAG 3

RESULT 13

US-08-739-158-28/c
; Sequence 28, Application US/08739158
; Patent No. 5814482

GENERAL INFORMATION:

; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/739,158
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 514

; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423D3 / 1146.012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-739-158-28

Query Match 38.6%; Score 11.2; DB 1; Length 25;
Best Local Similarity 36.4%; Pred. No. 1e+03;
Matches 8; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 6 UNCUUNNGUAGCCNANGNG 27
; : : : : :
Db 24 TCCTTAGGTTAGCGGTACAAG 3

RESULT 14

US-08-739-167-28/c
; Sequence 28, Application US/08739167
; Patent No. 5843723

GENERAL INFORMATION:

; APPLICANT: Dubensky Jr, Thomas W

; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.W.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/739,167
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 930049.423C7 / 1146.008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-739-167-28

Query Match 38.6%; Score 11.2; DB 2; Length 25;
Best Local Similarity 36.4%; Pred. No. 1e+03;
Matches 8; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 6 UNCUUNNGUAGCCNANGNG 27
; : : : : :
Db 24 TCCTTAGGTTAGCGGTACAAG 3

RESULT 15

US-08-404-796-28/c
; Sequence 28, Application US/08404796
; Patent No. 6015686

GENERAL INFORMATION:

; APPLICANT: Dubensky Jr, Thomas W
; APPLICANT: Polo, John M.
; APPLICANT: Ibanez, Carlos E.
; APPLICANT: Chang, Stephen M.W.
; APPLICANT: Jolly, Douglas J.
; APPLICANT: Driver, David A.
; APPLICANT: Belli, Barbara A.
; TITLE OF INVENTION: EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```

; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/404,796
; FILING DATE: 15-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,983
; REFERENCE/DOCKET NUMBER: 930049.423C5 / 1146.006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-404-796-28

```

```

Query Match      38.6%; Score 11.2; DB 3; Length 25;
Best Local Similarity 36.4%; Pred. No. 1e+03;
Matches 8; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

```

```

Qy      6  UCUUUNNGUAGCCCNANGNG 27
      :|:::|::|::|
Db     24  TCCTTAGGTAGCCGTACAAG 3

```

Search completed: January 30, 2004, 10:15:10
Job time : 55 secs

